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ABSTRACT 
 
Skeletal muscle atrophy is characterised by a loss of muscle weight and volume 
involving a reduction in muscle fibre diameter in the absence of degenerative changes 
and/or a reduction in the actual number of fibres. In humans there are a wide range of 
stimuli for skeletal muscle atrophy including bed rest, extreme training, malnutrition 
and cancer.  The underlying cellular and molecular mechanisms governing the process 
of atrophy are beginning to be elucidated.  However, there remains much to be learnt  
to allow the development of rational therapeutic interventions. 
 
A miniature neuromuscular stimulator was used to impose artificial levels of activity on 
the rat Tibialis anterior muscle in vivo.  Continuous electrical stimulation at a frequency 
of 20 Hz for 7 days resulted in a 12% (+/- 2%) decrease in muscle weight.  Foxo1 is 
known to play a central role in skeletal muscle atrophy.  Therefore transcriptional 
changes in 12 Foxo1 target genes were measured following artificial in vivo stimulation 
and compared with changes in the same genes in published  in vitro models of muscle 
atrophy. The standard in-vitro models used were treatment of C2C12 myotubes for 24 
hours with glucose free media, giving a 56% (+/- 2%) decrease in myotube diameter, 
or 24 hours treatment with 1µM dexamethasone (Dex), which we found produced no 
significant change in myotube diameter.  Marked transcriptional differences were 
observed between in vivo and in vitro atrophy models.  These differences highlighted 
the need to develop a model based on muscle inactivity that more clearly reflected 
muscle behaviour in vivo. 
 
A tetrodotoxin (TTX) nerve cuff was used to block all efferent impulse activity in the 
common peroneal nerve,  and therefore to induce progressive disuse atrophy in the 
dorsiflexors over a period of 14 days. This resulted in a maximal 51% (+/-1%) loss in 
mass of the treated Tibialis anterior muscle compared to that in the untreated control 
limb. This atrophy was achieved in the absence of any histological signs of damage or 
degeneration of the muscle fibres.  It was therefore possible to block muscle activity for 
14 days, and then reverse the blockade, allowing the same muscle fibres to recover 
without detriment over the subsequent 7 days. 
 
Microarray analysis was used to compare genome-wide transcript changes following 3, 
7 and 14 days of nerve blockade, 14 days of nerve block with 7 days of recovery, or 7 
days electrical stimulation at 20Hz.  Following quality control and normalisation of data 
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(n=4), systematic bioinformatics analysis including GO-term enrichment revealed key 
signalling pathways involved in the process of disuse atrophy.  A working hypothesis 
was developed which centres on the transcriptional control of myogenin (Myog) 
through a sensory role of the neuromuscular junction.  This involves both class II 
histone deacetylases (Hdac4/5) and the janus kinase and signal transducer and 
activator of transcription (Jak/Stat) pathway, and influences potential downstream 
Myog targets including the ubiquitin E3 ligases Trim63 and Fbxo32, as well as genes 
involved in neuromuscular junction formation.  Quantitative reverse transcription 
polymerase chain reaction (qRT-PCR) was used to confirm the temporal profiles for 
expression of key genes central to this model.  These included a 33-fold increase in 
Myog mRNA after 3 days nerve block, and a 180-fold increase in transcript for the alpha 
subunit of the nicotinic acetylcholine receptor after 14 days of nerve blockade. 
To establish whether our findings were transferable to atrophy induced by other 
mechanisms, and to examine potential chemical interventions, we returned to the 
C2C12 in vitro model.  The transcript levels of the same key genes were measured in 
myotubes following treatment with glucose-free media as well as media containing 
chemical inhibitors of the signalling pathways central to our hypothesis: the class II 
Hdac inhibitor MC1568, the Stat3 inhibitor S3I-201, and in addition to the Class I Hdac 
inhibitor MGCD0103.  Differences were again observed in the patterns of change in 
transcript levels between in vivo and in vitro treatments as well as between in vitro 
treatment groups.  The atrophy associated with glucose starvation was a 56% (+/- 2.%) 
reduction in myotube diameter relative to cells grown in normal media.  While MC1568 
and S3I-201 treatment reduced this in vitro atrophy by a small amount (to 42% +/- 4% 
and 21% +/- 6%, respectively, relative to cells grown in normal media), surprisingly 
the class I Hdac inhibitor MGCD0103 markedly blunted starvation atrophy with a 
decrease in myotube diameter of only 3% (+/- 7%). 
The discovery of therapeutic targets that could alleviate skeletal muscle atrophy is an 
exciting and potentially productive avenue of research.  Skeletal muscle atrophy has 
wide ranging causes and debilitating consequences for patients.  This project 
represents a starting point in the systematic development of drugs that could benefit 
these patients by improving quality of life and decreasing morbidity.  
v 
 
LIST OF ABBREVIATIONS 
 
Ach Acetyl Choline 
Bcl2l11 Bcl-2-interacting mediator of cell-death 
CaMKII Calcium/calmodulin-dependent protein kinase 
Ccnb1 Cyclin B 
Ccnd2 Cyclin D2 
Cdkn1b Cyclin-dependent kinase inhibitor 1B 
Chrna1 Nicotinic Acetyl Choline Receptor Subunit Alpha 1 
CSA Cross Sectional Area 
Dach2 Dachsund 2 
Dex Dexamethasone 
dNTPs Deoxynucleotide Triphosphates 
DTT Dithiothreitol 
EIF3f Eukaryotic Initiation Factor 
Fbxo32/Atrogin-1/ 
MAFbx F-Box Protein 32 
FCS Foetal Calf Serum 
Foxo Forkhead Box 01 Transcription Factor 
G6pc3 Glucose-6-phosphatase 
GO Gene Ontology 
Hdac Histone Deacetylase 
HS Horse Serum 
IGF Insulin-Like Growth Factor 
Jak Janus Kinase 
Lpl Lipoprotein Lipase 
MHC Myosin Heavy Chain 
Mitr Hdac 9 Splice Variant 
mTOR Mammalian Target of Rapamycin 
Myog Myogenin 
nAChR Nicotinic Acetyl Choline Receptor 
NCBI National Centre for Biotechnology Information 
NMJ Neuromuscular Junction 
Pdk4 Pyruvate dehydrogenase kinase 4 
PI3K Phosphatidylinositol-3-Kinase   
Plk1 Polo-like Kinase 
Polr2a RNA polymerase II polypeptide A 
qRT-PCR Quantitative Reverse Transcription Polymerase Chain Reaction 
Rn18S 18S ribosomal RNA 
SAGE Serial Analysis of Gene Expression 
Socs3 Suppressor of Cytokine Signalling 3 
Sod2 Manganese superoxide dismutase 
Stat Signal Transducer and Activator of Transcription 
TA Tibialis Anterior 
Tgfb2 Transforming growth factor β-2 
Trim63/MuRF1 Tripartite Motif Containing 63 / Muscle RING-Finger Protein 1 
TTX Tetrodotoxin 
Ub Ubiquitin 
 
vi 
 
LIST OF FIGURES 
 
Chapter 1 
 
  
Page 
1   Diagrammatic Representation of the Organisation of Skeletal 
Muscle 
 
3 
2 Diagrammatic Representation of the Neuromuscular Junction  
 
5 
3 Diagrammatic Representation of the Sarcomere and Sliding 
Filament Theory 
 
6 
4 Ubiquitin Ligases & The Proteasome 
 
9 
5 A role for Foxo Transcription Factors During Muscle Growth 
and Atrophy 
 
13 
6 The Role of Myogenin in Skeletal Muscle Atrophy 
 
15 
   
Chapter 2 
 
  
7 Schematic Representation of Nerve Cuff Assembly Showing 
The Common Peroneal Nerve In-Situ 
 
29 
8 Schematic Representation of Nerve Cuff and Stimulator 
Electrodes In-Situ 
 
31 
9 Photograph of Nerve Cuff and Stimulator Electrodes In-Situ 
 
32 
10 Segmentation of Rat TA Muscle For Analysis 
 
33 
   
Chapter 3 
 
  
11 Phase Contrast Microscopy of Cultured C2C12 Myotubes 
Subject to Atrophic Conditions 
 
50 
12 Mean Cross Sectional Area of Cultured Myotubes Decreased 
Following Treatment With Glucose-Free Media 
 
51 
13 Representative Photomicrographs of Histological Sections of 
Control and Electrically Stimulated TA Muscle 
 
52 
14 Mean Differences in TA Muscle Weight between The 
Electrically Stimulated and Unstimulated, Contralateral 
Control Limb 
 
 
53 
15 Mean Differences in TA Muscle Fibre CSA Between Electrically 
Stimulated And Unstimulated Contralateral Control 
 
54 
vii 
 
16 Specificity of Primer Sets for Foxo1 Target Genes 
 
58 
17 Comparison of Transcript Levels for Foxo1 Target Genes 
Following Atrophy Inducing Treatment in In-Vitro & In-Vivo 
Models 
 
62 
   
Chapter 4 
 
  
18 Cross Sectional Photomicrographs of Untreated and TTX 
Treated TA Muscle 
 
73 
19 Progressive Muscle Fibre Atrophy Over 2 weeks of TTX 
Treatment 
 
74 
20 Transcript Levels of Fbxo32 and Trim63 Increase In Response 
to a TTX block 
 
76 
21 Cross Sectional Photomicrographs of Untreated and TTX 
Treated TA Muscle 
 
78 
22 Nerve Block Treatment In-Vivo Induces Progressive Decrease 
in Muscle Weight and Fibre Cross Sectional Area that Can 
Recover Upon Cessation of Block 
 
80 
   
Chapter 5 
 
  
23 False Colour Representations Showing Spatial Distributions of 
Feature Intensities on Each of the 28 Arrays 
 
86 
24 Boxplots Representing Summaries of the Signal Intensity 
Distributions for Affymetrix Gene Chips 
 
87 
25 Between Array Comparisons 
 
88 
26 Unbiased Correlation Heatmap of Probe Set Expression 
Across the Whole Genome for Each Array 
 
90 
27 Principal Component Analysis of Experimental Arrays 
 
91 
28 Number of Statistically Significant Differentially Expressed 
Genes 
 
93 
29 Unsupervised Hierarchical Clustering of Top 500 Most 
Statistically Significant Differentially Expressed Genes 
 
 
96 
30 The Top 500 Most Statistically Significant Differentially 
Expressed Genes Organised Into 5 Distinct Temporal Clusters 
 
98 
31 Unsupervised Hierarchical Clustering of Top 500 Most 
Statistically Significant Differentially Expressed Genes With 
Gene Clusters Highlighted 
100 
viii 
 
 
32 A Correlation Heatmap of the Statistically Significant Genes 
Within the Go Term 'Muscle Organ Development' 
 
104 
33 A Correlation Heatmap of the Statistically Significant Genes 
Within the Go Term 'Muscle Cell Development' 
 
105 
34 Patterns of Changes in Expression Over Experimental Groups 
of Statistically Significant Genes Within the Go Term 'Cellular 
Respiration' 
 
107 
35 Patterns of Changes in Expression Over Experimental Groups 
of Statistically Significant Genes Within the Go Term 
'Neuromuscular Junction' 
 
109 
36 Mean Expression Intensity Levels of Nicotinic Acetyl Choline 
Receptor (nAChR) Subunits Over Experimental Groups 
 
110 
37 A Correlation Heatmap of the Statistically Significant Genes 
Within the Go Term ' Cytokine-Mediated Signalling Pathway' 
 
112 
38 Mean Expression Intensity Levels of Janus Kinases (Jaks) Over 
Experimental Time Period 
 
113 
39 Mean Expression Intensity Levels of Signal-Transducer and 
Activator of Transcription (Stat) 2, 3, 4, 5a, 5b and 6 Over The 
Experimental Time Period 
 
114 
40 Transcriptome Profiling Reveals Cellular Signalling Pathways 
Controlling Transcriptional Expression of Genes Integral to 
Atrophy 
 
115 
41 Specificity of Rat-Specific Primer Sets For Transcripts in 
Interest Identified by Microarray 
 
118 
42 Comparison of Gene Transcript Levels Represented by 
Microarray Expression Intensity and Quantitative Reverse 
Transcription PCR (qRT-PCR) of Hdac4, Hdac5 & Stat3 
 
121 
43 Comparison of Gene Transcript Levels Represented by 
Microarray Expression Intensity and Quantitative Reverse 
Transcription PCR (qRT-PCR) of Mitr, Socs3 & Myog 
 
123 
44 Comparison of Gene Transcript Levels Represented by 
Microarray Expression Intensity and Quantitative Reverse 
Transcription PCR (qRT-PCR) of Chrna1, Fbxo32 & Trim63 
 
125 
   
Chapter 6 
 
  
45 Chemical Inhibition of Cellular Pathways Regulating 
Myogenin and Its Targets 
 
 
133 
ix 
 
46 Phase Contrast Microscopy Showing Viable Cultured C2C12 
Myotubes Before and After Each Treatment With Each 
Chemical Inhibitor 
 
135 
47 The Response of Myotube Cross Sectional Area (CSA) to 
Glucose Starvation and Inhibition of the Hdac and Jak/Stat3 
Pathway 
 
136 
48 Specificity of Murine PCR Primer Pairs For Microarray Genes 
 
138 
49 Mean Transcript Levels of Genes of Interest following Each 
Treatment In Vitro 
 
141 
50 Mean Changes in Transcript Levels Following Treatment In 
Vitro 
 
142 
51 The Transcriptional Response of Myotubes Following Glucose 
Starvation with and without MC1568 
 
143 
52 Myogenin Transcript Levels in In Vivo and In Vitro Models of 
Atrophy 
 
145 
53 The Relationship Between Myogenin Transcript Levels and 
CSA  in Muscle (A) and Myotubes (B) 
 
146 
54 The Relationship Between Transcript Levels of Myog and The 
Ubiquitin Ligases Trim63 and Fbxo32 Both In Vitro and In 
Vivo 
 
148 
55 The Relationship Between Transcript Levels of Myog and 
Chrna1 In Vitro and In Vivo 
 
149 
56 Fold Transcript Level Changes in Myotubes Following Glucose 
Starvation with and without S3I-201 
 
151 
57 Mean Transcript Levels Following Treatment With S3I-201, 
and a combination of S31-201 and MC1568, Cultured in 
Normal and Glucose Free Media 
 
152 
58 Comparison of Transcript Changes with Glucose Starvation In 
Vitro and Muscle Block In Vivo 
153 
  
x 
 
LIST OF TABLES 
 
Chapter 2 
 
  
Page 
1 Primers for Real-Time RT-PCR (Mus musculus) 
 
39 
2 Primers for Real-Time RT-PCR (Rattus norvegicus) 
 
40 
3 Standard End-Point PCR Cycle 
 
41 
4 Standard qRT-PCR Cycle 
 
42 
5 Details of Samples Subject to Microarray Analysis 45 
   
Chapter 3 
 
  
6 Foxo1 Target Genes Involved In Metabolic Processes Included 
in Analysis 
 
56 
7 Foxo1 Target Genes Involved In Programmed Cell Death 
Included in Analysis 
 
56 
8 Foxo1 Target Genes Involved In Regulation of The Cell Cycle 
Included in Analysis 
 
57 
9 Efficiency of Amplification During qRT-PCR for Foxo Target 
Gene Pairs 
60 
   
Chapter 4 
 
  
10 Review of Osmotic Pump Efficiency 72 
   
Chapter 5 
 
  
11 Experimental Groups Compared Within Limma 
 
92 
12 The Top 10 Most Statistically Significant Differentially 
Expressed Probe Sets Over All Comparisons 
 
95 
13 The Top 10 Most Statistically Significant Enriched GO Terms 
When Comparing 3 Days Nerve  Block to the Sham Control 
 
102 
14 Efficiency of Product Amplification During qRT-PCR for Each 
Primer Set 
119 
   
Chapter 6 
 
  
15 
 
 
16 
Efficiency of Amplification During qRT-PCR for Each Primer 
Pair 
 
Gene Transcriptional Changes Across Atrophy Models 
139 
 
 
159 
  
xi 
 
APPENDICES 
 
   
Page 
1 Details of All Experimental Procedures 
 
173 
2 Subbing Slides 
 
175 
3 H&E Solutions and protocol 
 
176 
4 Electrophoresis Gels 
 
177 
5 Details of Nanodrop Readings 
 
179 
6 Sequencing Results 
 
183 
7 Primer Efficiency Curves 
 
193 
8 Validation of SYBR green reaction by melt curve analysis 196 
 
  
xii 
 
TABLE OF CONTENTS 
 
DECLARATION ...........................................................................................................................................................i 
ACKNOWLEDGEMENTS ...................................................................................................................................... ii 
ABSTRACT ................................................................................................................................................................. iii 
LIST OF ABBREVIATIONS................................................................................................................................... v 
LIST OF FIGURES ................................................................................................................................................... vi 
LIST OF TABLES .......................................................................................................................................................x 
APPENDICES ............................................................................................................................................................ xi 
Chapter 1:  Introduction ...................................................................................................................................... 1 
1.1  Motivation For The Project............................................................................................................. 2 
1.2  Skeletal Muscle Structure ................................................................................................................ 2 
1.2.1  Gross Anatomy ............................................................................................................................. 2 
1.2.2  Nervous Control of Skeletal Muscle .................................................................................. 4 
1.2.3  The Sliding Filament Theory ................................................................................................ 6 
1.2.4  The Cellular Process of Atrophy ......................................................................................... 8 
1.2.5  The Ubiqutin-Proteasome System ..................................................................................... 8 
1.3 Transcriptional Regulation of Skeletal Muscle Atrophy ................................................ 11 
1.3.1  Transcriptional Regulation................................................................................................. 11 
1.3.2 Foxo Transcription Factors ................................................................................................. 11 
1.3.3 Hdac Regulation of Myogenin and Its Role in Muscle Atrophy ......................... 14 
1.4  Experimental Models of Skeletal Muscle Atrophy ........................................................... 15 
1.4.1 In Vitro Models of Skeletal Muscle Atrophy ................................................................ 15 
1.4.2 In Vivo Models of Skeletal Muscle Atrophy.................................................................. 16 
1.4.3 Functional Atrophy: a Novel Method of Inducing Muscle Atrophy ................ 18 
1.4.4 Tetrodotoxin  (TTX) nerve block to produce muscle atrophy. ......................... 18 
1.5  The Transcriptomics of  Muscle Atrophy ............................................................................. 19 
1.5.1 Methods for Transcriptome Analysis ............................................................................. 19 
1.5.2  Transcriptome Analysis of muscle atrophy ............................................................... 20 
1.5  Summary ............................................................................................................................................... 20 
1.6  Aims ......................................................................................................................................................... 22 
Chapter 2:  Materials & Methods ................................................................................................................. 23 
2.1  C2C12 Myotube Cell Culture ....................................................................................................... 24 
2.1.1  Routine Culture of Myoblasts and Myotubes ............................................................ 24 
2.1.2  Myotube Starvation & Dexamethasone Treatment ............................................... 24 
xiii 
 
2.1.3  Myotube Treatment with Chemical Inhibitors ......................................................... 25 
2.1.4  Myotube Diameter Measurement ................................................................................... 25 
2.1.5  First Stage RNA Extraction from Cultured Myotubes ........................................... 26 
2.2  Electrical Stimulation of Tibialis Anterior (TA) Muscle in Rats ............................... 26 
2.2.1  Miniature Implantable Stimulators ................................................................................ 26 
2.2.2  Implant Procedure .................................................................................................................. 27 
2.2.3  Stimulation Protocol .............................................................................................................. 28 
2.3  Blockade of the Common Peroneal Nerve using a Nerve Cuff................................... 28 
2.3.1  Implant Contents ..................................................................................................................... 29 
2.3.2  Implant Procedure .................................................................................................................. 30 
2.3.3  Nerve Block Protocol ............................................................................................................. 33 
2.4  Muscle Tissue Processing for Extraction of RNA ............................................................. 33 
2.4.1  Terminal Procedure and Muscle Harvesting ............................................................. 33 
2.4.2  First Stage RNA Extraction from Muscle Tissue ...................................................... 34 
2.5  Histological Analysis of Frozen Sections of Muscle Tissue ......................................... 34 
2.5.1  Haematoxylin and Eosin Stain for Gross Fibre Morphology ............................. 34 
2.5.2  Fibre Cross Sectional Area Measurements ................................................................. 35 
2.6  mRNA Expression Analysis in Myotubes & Muscle Tissue ......................................... 35 
2.6.1  Second Stage RNA Extraction ............................................................................................ 36 
2.6.2  Agarose Gel Electrophoresis .............................................................................................. 36 
2.6.3  RNA Analysis using a Nanodrop ...................................................................................... 37 
2.6.4  First-Strand cDNA Synthesis ............................................................................................. 37 
2.6.5  Design of Primers for Polymerase Chain Reaction (PCR) .................................. 38 
2.6.6  End-Point PCR & Agarose Gel Electrophoresis to Test Primer Specificity 41 
2.6.7  DNA Sequencing of PCR Amplicons ............................................................................... 42 
2.6.8  Quantitative Reverse Transcription PCR (qRT-PCR) ............................................ 42 
2.6.9  Analysis of The Efficiency of the qRT-PCR Assay .................................................... 43 
2.7  Microarray Analysis ........................................................................................................................ 44 
2.7.1  Details of Samples Subject to Microarray Analysis ................................................ 44 
2.7.2  Details of Statistical and Bioinformatics Programmes Used in Microarray 
Analysis...................................................................................................................................................... 46 
Chapter 3: Comparison of Transcriptional Changes in Foxo1 Target Genes in In 
Vitro(C2C12 Myotube Culture) and In Vivo (20Hz Electrical Stimulation) Models of 
Atrophy ..................................................................................................................................................................... 47 
3.1  Introduction ........................................................................................................................................ 48 
3.2  Induction and Assessment of In Vitro Atrophy ................................................................. 49 
xiv 
 
3.2.1  Myotubes Show Little Apoptosis Following Atrophy Induction ..................... 49 
3.2.2  Myotubes Cultured in Glucose-Free Media undergo Significant Atrophy.. 50 
3.3  Induction and Assessment of In Vivo Muscle Atrophy .................................................. 51 
3.3.1  Histological Analysis Revealed Little Change in Muscle Tissue Indicative of 
Nerve Damage ........................................................................................................................................ 52 
3.3.2  Electrical Stimulation for 1 week at 20Hz Significantly Reduced TA Muscle 
Weight ........................................................................................................................................................ 53 
3.3.3  Electrical Stimulation In Vivo Decreased The Cross Sectional Area of 
Muscle Fibres .......................................................................................................................................... 54 
3.4  Transcript Changes of Foxo1 Target Genes in In Vitro & In Vivo Atrophy Models
 ............................................................................................................................................................................. 55 
3.4.1  Identification of Foxo1 Target Genes ............................................................................ 55 
3.4.2  End Point RT-PCR Validation of Primer Sets for Foxo1 Target Genes ......... 57 
3.4.3  Determination of Primer Efficiency in qRT-PCR ..................................................... 59 
3.4.4  Changes in Transcript Levels of Foxo1 Target Genes with Atrophy ............. 60 
3.5  Discussion............................................................................................................................................. 63 
3.5.1  Glucose Starvation but not Dex Treatment Induced Atrophy in C2C12 
Myotubes .................................................................................................................................................. 63 
3.5.2  Continuous Electrical Stimulation Produces Atrophy Without Damage to 
the Muscle ................................................................................................................................................ 64 
3.5.3  Transcriptional Changes Reveal Differences in the Models of Atrophy...... 65 
3.6  Summary ............................................................................................................................................... 68 
Chapter 4: Development of An In-Vivo Atrophy Model Incorporating Tetrodotoxin 
(TTX) Block of the Common Peroneal Nerve ........................................................................................ 69 
4.1 Introduction ......................................................................................................................................... 70 
4.2  Pilot Study of TTX Nerve Block Atrophy Model ................................................................ 71 
4.2.1  Efficiency of Delivery of TTX by Osmotic Pump ...................................................... 71 
4.2.2  Histological Examination of Muscle Showed Little Evidence of Nerve 
Damage ...................................................................................................................................................... 72 
4.2.3  Nerve Block Induces Progressive Muscle Atrophy ................................................ 73 
4.2.4  Transcript Levels of Trim63 and Fbxo32 Increase with Muscle Atrophy . 75 
4.3  Full Scale In-Vivo TTX Nerve Block Study ............................................................................ 77 
4.3.1  Histological Analysis of Muscle Revealed Little Evidence of Nerve Damage
 ........................................................................................................................................................................ 77 
4.3.2  Evidence of Muscle Atrophy In Full TTX Nerve Block Study ............................ 79 
4.4  Discussion............................................................................................................................................. 80 
4.4.1  TTX Nerve Block Induces Progressive, Recoverable Atrophy .......................... 81 
xv 
 
4.4.2  Summary ...................................................................................................................................... 82 
Chapter 5: Microarray Analysis of In Vivo Skeletal Muscle Atrophy Via Nerve block and 
Electrical Stimulation ........................................................................................................................................ 83 
5.1 Introduction ......................................................................................................................................... 84 
5.2  Normalisation & Quality Control of Microarray Data .................................................... 84 
5.2.1  Spatial Distribution of Feature Intensities ................................................................. 85 
5.2.2  Inter Array Intensity Distributions ................................................................................ 86 
5.2.3  Between Array Comparisons ............................................................................................. 87 
5.3  Preliminary Data Analysis Confirms Clustering of Experimental Groups .......... 89 
5.3.1  Chip Correlation Heatmap .................................................................................................. 89 
5.3.2  Principal Component Analysis .......................................................................................... 90 
5.4  Differential Expression  Analysis Reveals Atrophy to be a Dynamic Process ... 92 
5.4.1  Number of Differentially Expressed Probe Sets Between Experimental 
Groups ........................................................................................................................................................ 93 
5.4.2  Analysis of  the Top 500 Most Statistically Significant Differentially 
Expressed Genes ................................................................................................................................... 94 
5.4.3  Genes Cluster Into Dynamic Groups .............................................................................. 96 
5.5  Gene Ontology Terms Analysis ................................................................................................101 
5.5.1  Method Validation .................................................................................................................103 
5.5.2  The Role of The Neuromuscular Junction in In Vivo Muscle Atrophy ........108 
5.5.3  The Role of Cytokine Signalling in In Vivo Muscle Atrophy .............................111 
5.5.4  Modelling Atrophy Signalling Pathways From Transcriptome Profiling .114 
5.6  Confirmation of Transcriptional Changes in the Myogenin Pathway Using qRT-
PCR ..................................................................................................................................................................117 
5.6.1  End Point RT-PCR Validation of Primer Sets for Microarray Genes ...........117 
5.6.2  Determination of Primer Efficiency in qRT-PCR ...................................................118 
5.6.3  Comparative Transcript Changes Determined by Microarray and qRT-PCR 
analyses ...................................................................................................................................................119 
5.7  Discussion...........................................................................................................................................126 
5.7.1  Preliminary Analysis Reveals Nerve Block Atrophy to be a Dynamic 
Process with Transcript Levels Recovering Upon Cessation of Block ....................126 
5.7.2  Microarray Analysis Distinguishes In Vivo Models of Atrophy .....................127 
5.7.3  Myogenin May Play a Key Role in Nerve Block Atrophy ...................................128 
5.7.4  Summary ....................................................................................................................................130 
Chapter 6: Chemical Inhibition of In Vitro Muscle Atrophy and Comparisons With The In 
Vivo Models ...........................................................................................................................................................131 
6.1  Chapter Introduction ....................................................................................................................132 
xvi 
 
6.2  Atrophy Measurement Following Glucose Starvation of Myotubes.....................134 
6.2.1  Phase Contrast Microscopy of Chemically Treated Myotubes Shows 
Healthy Cultures .................................................................................................................................134 
6.2.2  The Effects of Chemical Inhibition on Atrophy Induced by Glucose 
Starvation ...............................................................................................................................................135 
6.3  Transcriptional Changes of Cellular Pathway Genes ...................................................137 
6.3.1  End Point RT-PCR Validation of Murine Primer Pairs .......................................138 
6.3.2  Determination of Primer Efficiency in qRT-PCR ...................................................139 
6.3.3  Overview of Transcriptional Changes.........................................................................140 
6.3.4  Does Glucose Starvation in Myotubes Utilise Hdac4 or Stat3 Regulation of 
Myogenin? ..............................................................................................................................................142 
6.3.5  The Class II Hdac Inhibitor MC1568 Significantly Reduces Atrophy in 
Myotubes Cultured in Glucose-Free Media ...........................................................................143 
6.3.6  The Class I Hdac Inhibitor MGCD0103 Inhibits Atrophy Through Altered 
Myogenin Expression .......................................................................................................................144 
6.3.7 Comparisons of The Effects of S3I-201 on Atrophy and Combination 
Therapy with MC1568 .....................................................................................................................150 
6.3.8  The Differential transcriptional response to In Vitro Glucose Starvation 
and In Vivo Nerve Block ..................................................................................................................152 
6.4  Discussion...........................................................................................................................................154 
6.4.1  A Potential Role for Class I or II Hdacs in Control of Myotube Size.............154 
6.4.2  Further Evidence for The Role of Myog in Muscle Atrophy ............................156 
6.4.3  Does the Jak/Stat pathway play a role in Atrophy? .............................................158 
6.4.4  Myotube Starvation & Nerve Block Atrophy Utilise Different Cellular 
Pathways .................................................................................................................................................158 
6.4.5  Summary ....................................................................................................................................159 
Chapter 7: Thesis Conclusions and Further Work............................................................................161 
REFERENCES .......................................................................................................................................................165 
APPENDICES ........................................................................................................................................................173 
 
  
1 
 
 
 
 
 
 
Chapter 1:  Introduction 
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1.1  Motivation For The Project 
 
Progressive muscle wasting or muscle atrophy is a debilitating and life-threatening 
disorder.  It is a pathological aspect of many diseases including cancer, diabetes, 
chronic obstructive pulmonary disease (COPD), and AIDS and is a natural consequence 
of the inactivity associated with ageing, when it is known as sarcopenia (Holecek, 
2012).  Loss of muscle mass in elderly patients may affect quality of life by increasing 
risk of falling and fractures, as well as the risk of surgical complications (Aversa et al., 
2011).  Weight loss in cancer cachexia patients causes reduced mobility and quality of 
life.  Studies suggest that in patients with nonresectable pancreatric cancer, a  25-30% 
loss of body weight has been reported upon death (Tisdale, 2009).  Critical illness 
requiring care in the intensive care unit (ICU) and prolonged ventilatory support is 
associated with muscle wasting as a combined result of the underlying condition, bed 
rest, muscle inactivity and mechanical ventilation (Callahan and Supinski, 2009, Khan 
et al., 2008).  Patients in intensive care can lose about 2% of their muscle mass per 24 
hours and some patients lose up to 50% of their total muscle mass during their stay in 
the ICU (Khan et al., 2008).  Some critically ill patients develop acute quadriplegic 
myopathy caused by a specific and pronounced depletion of muscle myosin (Larsson et 
al., 2000). 
The underlying cellular and molecular mechanisms governing the process of atrophy 
are beginning to be elucidated.  However, there remains much to learn before these 
mechanisms are clarified sufficiently to allow the development of rational therapeutic 
interventions.  The discovery of therapeutic targets that could alleviate skeletal muscle 
atrophy is an exciting and potentially productive avenue of research.  This project 
represents a starting point in the systematic development of drugs that could benefit 
these patients by improving quality of life and decreasing morbidity. 
 
1.2  Skeletal Muscle Structure 
1.2.1  Gross Anatomy 
 
Skeletal muscle is a form of striated muscle capable of contractions, generally within a 
limited range.  If a larger range of movement is required it is achieved through the 
amplification provided by the lever systems of the skeleton, which muscles attach to via 
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bundles of collagen fibres known as tendons.  Skeletal muscle is under control of the 
somatic nervous system, implying voluntary control.  However, this is an inadequate 
term as many of the movements in which it participates, such as breathing and 
swallowing, are not usually under conscious control.  Muscles vary considerably in size, 
shape and arrangement of fibres depending on the function for which it is required.  An 
individual muscle is made up of many individual cells known as muscle fibres 
(myofibres), which are bundled together into fascicles, each surrounded by a layer of 
connective tissue called the perimysium.  Many fascicles combined make up a muscle, 
and a connective sheath called the epimysium surrounds the muscle and provides a 
pathway for blood vessels and nerves (Figure 1) (Salmons, 1995). 
 
 
Figure 1  Diagrammatic Representation of the Organisation of Skeletal Muscle 
Skeletal Muscle is composed of numerous myofibres that are bundled together into 
fascicles surrounded by the perimysium 
 
 
The myofibres are composed of myofibrils, which are cylindrical structures of about 
1μm in diameter. These are the dominant ultra-structural feature of an electron 
micrograph and give the striated appearance of skeletal muscle. The myofibrils are 
mainly composed of the proteins actin and myosin.  Primarily these form thin (actin) 
and thick (myosin) filaments, which overlap to some extent when the muscle is at rest.   
These filaments repeat along the length of the myofibril in sections known as 
sarcomeres, which form the basic functional unit of the muscle fibre.  Muscles contract 
by ATP-driven conformational changes in the myosin head. 
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The nuclei of mammalian myofibres are entirely postmitotic and cannot replace 
themselves (Charge and Rudnicki, 2004, Moss and Leblond, 1971, Snow, 1978); 
consequently the contribution of another, precursor cell type is required for growth 
and injury-induced regeneration (Collins and Partridge, 2005).  Satellite cells form a 
small population of quiescent muscle precursor cells which reside beneath the basal 
lamina of each myofibre (Charge and Rudnicki, 2004, Mauro, 1961).  In response to 
muscle injury, satelite cells are activated, proliferate and differentiate, at which time 
they fuse together to repair or replace damaged myofibres (Charge and Rudnicki, 
2004). 
 
1.2.2  Nervous Control of Skeletal Muscle 
 
Every skeletal muscle is supplied by one or more nerves.  Muscle nerves are frequently 
referred to as motor nerves, but they contain both motor and sensory components.  The 
major motor component consists of the large, myelinated axons that supply the muscle 
fibres; these α-efferents, or α-motor axons are among the fastest-conducting nerve 
fibres in the body (Finsterer et al., 2011).  Within muscles, nerves follow the connective 
sheaths, coursing in the epimysial and perimysial septa before entering the fine 
endomysial tissue around the muscle fibres.  A specialised synpase, the neuromuscular 
junction, is formed where the terminal branch of an α-motor axon contacts the muscle 
fibre (Deschenes, 2011).  The axon terminal gives off several short, curling branches 
over an elliptical area, the motor end plate (Salmons, 1995).  The arrival of an action 
potential at the motor end plate causes acetylcholine (ACh) to be exocytosed from 
synaptic vesicles into the synaptic cleft that separates the nerve ending from the 
sarcolemma (figure 2). 
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Figure 2  Diagrammatic Representation of the Neuromuscular Junction 
Acetylcholine exocytosed from the neuron moves over the synaptic cleft to bind to 
acetylcholine (Ach) receptors, increasing sarcolemma permeability, and hence 
conductance. 
 
 
The ACh is rapidly bound by nicotinic acetylcholine receptors, or nAChRs on muscle.  
These receptors are made up of five subunits, arranged symmetrically around a central 
pore (Purves, 2008, Deschenes, 2011).  Each subunit comprises four transmembrane 
domains with both the N- and C-terminus located extracellularly.  In vertebrates, 
nicotinic receptors are broadly classified into two subtypes based on their primary 
sites of expression: muscle-type nicotinic receptors and neuronal-type nicotinic 
receptors. In the muscle-type receptors, found at the neuromuscular junction, receptors 
are either the embryonic form, composed of α1, β1, δ, and γ subunits in a 2:1:1:1 ratio, 
or the adult form composed of α1, β1, δ, and ε subunits in a 2:1:1:1 ratio (Purves, 
2008).  Binding of ACh to these receptors triggers an almost instantaneous increase in 
the permeability, and hence conductance, of the postsynaptic membrane.  This 
generates the end-plate potential, a local depolarisation, which is normally several 
times larger than is needed to initiate an action potential in the surrounding 
sarcolemma.  This ensures that excitation is passed with high security to the muscle so 
that, except under conditions of extreme fatigue, a muscle action potential is generated 
for each nerve impulse.  The action potential propagates along the length of the muscle 
fibre and spreads into its interior along the T-tubules, initiating contraction (Salmons, 
1995). 
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1.2.3  The Sliding Filament Theory 
 
The sarcomere consists of a central bidirectional thick filament (myosin) flanked by 
two actin filaments, orientated in opposite directions (figure 3). 
 
 
Figure 3  Diagrammatic Representation of the Sarcomere and Sliding Filament 
Theory 
Upon contraction from the relaxed state (A) the thin and thick filaments slide over each 
other to shorten the I band and overall sarcomere length (B). 
 
Myosin is the principal contractile protein in muscle.  It is a heterohexamer with a 
molecular size of about 520 kilodaltons (kD) (Rayment et al., 1993), and is composed of 
two myosin heavy chains (MHCs), the carboxy-terminal portions of which associate to 
form an α-helical coiled-coil rod or 'myosin tail' (Schiaffino and Reggiani, 1994).  The 
myosin tail accounts for the self association of myosin at low ionic strength and forms 
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the backbone of the thick filaments (Rayment et al., 1993).  The amino portions of the 
MHCs are separated to form two elongated, globular domains known as the 'myosin 
heads', which act as an actin-based molecular motor to convert chemical energy 
released from the hydrolysis of adenosine tri phosphate (ATP) into mechanical force 
(Weiss et al., 1999).  At the head-tail junction each MHC associates with two myosin 
light chains (MLCs). 
Following the binding of ACh to the nAChRs the resulting action potential spreads 
through the muscle fibres network of T-tubules, depolarizing the inner portion of the 
muscle fibre.  The depolarization activates L-type voltage-dependent calcium channels 
(dihydropyridine receptors) in the T tubule membrane, which are in close proximity to 
calcium-release channels (ryanodine receptors) in the adjacent sarcoplasmic reticulum.  
Activated voltage-gated calcium channels physically interact with calcium-release 
channels to activate them, causing the sarcoplasmic reticulum to release calcium.  The 
calcium binds to the troponin C present on the actin-containing thin filaments of the 
myofibrils (Gillis et al., 2007). The troponin then allosterically modulates the 
tropomyosin. Under normal circumstances, the tropomyosin sterically obstructs 
binding sites for myosin on the thin filament; once calcium binds to the troponin C and 
causes an allosteric change in the troponin protein, troponin T allows tropomyosin to 
move, unblocking the binding sites (Gillis et al., 2007).  Myosin has ADP and inorganic 
phosphate bound to its nucleotide binding pocket, and is in a ready state to bind to the 
newly uncovered binding sites on the thin filament, which is very tightly coupled to the 
release of inorganic phosphate. Myosin is now bound to actin in the strong binding 
state. The release of ADP and inorganic phosphate are tightly coupled to the power 
stroke, which is a conformational change in the myosin head.  Actin acts as a cofactor in 
the release of inorganic phosphate, expediting the release. This will pull the Z-bands 
towards each other, thus shortening the sarcomere and the I-band (figure 3 panel B). 
ATP binds myosin, allowing it to release actin and be in the weak binding state (a lack 
of ATP makes this step impossible, resulting in the rigor state characteristic of rigor 
mortis). The myosin then hydrolyzes the ATP and uses the energy to move into the 
'cocked back' conformation. ATP binds to myosin as long as it is available and calcium 
is present on the thin filament (Gillis et al., 2007).  While the above steps are occurring, 
calcium is actively pumped back into the sarcoplasmic reticulum. When calcium is no 
longer present on the thin filament, the tropomyosin changes conformation back to its 
previous state so as to block the binding sites again. The myosin ceases binding to the 
thin filament, and the contractions cease (Salmons, 1995). When a muscle fibre 
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contracts, all sarcomeres contract simultaneously because of the spread of excitation 
along the plasma membrane and the t-tubukes, so that force is transmitted to the fibre 
ends. 
 
1.2.4  The Cellular Process of Atrophy 
 
Under normal physiological conditions, muscle mass is maintained at a relatively 
constant level by a balance between protein synthesis and protein degradation. This 
balance is highly important in situations where for example more power is needed 
from the muscle (hypertrophy) or in periods when food sources are limited and protein 
breakdown is required to produce energy (atrophy).  When this balance is perturbed so 
that protein breakdown rates exceed the rates of protein synthesis, loss of muscle mass 
occurs.  Muscle mass or muscle atrophy involves a reduction in muscle fibre diameter 
in the absence of degenerative changes or a reduction in the actual number of fibres.  It 
can be caused by reduced protein synthesis, increased protein breakdown or a 
combination of these changes, the balance of which is probably determined by the 
cause of the atrophy (Aversa et al., 2011).  The regulation of protein synthesis is 
complex, but reduced anabolic signalling through the PI3K/Akt pathway with altered 
downstream signalling through mTOR, GSK-3β, and Foxo is an important factor in 
muscle wasting that at least in part accounts for reduced protein synthesis (Glass, 
2010).  Proteolytic pathways involved in the degradation of proteins in atrophying 
muscle include the ubiquitin-proteasome pathway. 
 
1.2.5  The Ubiqutin-Proteasome System 
 
The ubiquitin  proteosome pathway and specific ubiquitin pathway enzymes have been 
directly implicated in the progression of muscle atrophy (Eddins et al., 2011, Sandri et 
al., 2004, Stitt et al., 2004).  Ubiquitin is a small 76-residue protein that is highly 
conserved among all living organisms (Hershko and Ciechanover, 1998, Eldridge and 
O'Brien, 2010).  Ubiquitin is used as a post-translational lysine modification on proteins 
affecting stability, activity and/or localisation of the target protein (Hershko and 
Ciechanover, 1998, Pickart, 2001, Pickart and Eddins, 2004, Sun and Chen, 2004).  The 
co-ordinated action of three enzymes (E1, E2 and E3) facilitate the conjugation of the c-
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terminal glycine of ubiquitin to the ε-amino group of a specific lysine on the target 
protein (Eldridge and O'Brien, 2010) (figure 4). Ubiquitin (Ub) and ubiquitin-like 
proteins are activated for transfer by the E1 ubiquitin-activating enzyme. Activated 
ubiquitin is then transferred in thioester linkage from the active-site cysteine of E1 to 
the active-site cysteine of an E2 ubiquitin-conjugating enzyme. The E2Ub thioester next 
interacts with an E3 ubiquitin ligase, which effects transfer of Ub from E2Ub to a lysine 
residue of a substrate. Monoubiquitinated, the substrate can either dissociate from the 
E3 or can acquire additional Ub modifications in the form of multiple single 
attachments. 
 
 
 
Figure 4   Ubiquitin Ligases & The Proteasome 
Ubiquitin (Ub) and ubiquitin-like proteins are activated for transfer by the E1 
ubiquitin-activating enzyme.  The E2Ub thioester interacts with an E3 ubiquitin ligase, 
which effects transfer of Ub from E2Ub to a lysine residue of a substrate (1). 
Monoubiquitinated substrate can either dissociate from E3 or additional ubiquitins can 
be attached (2).  The substrate protein may be moved to the 26S proteasome for 
degradation into short oligopeptides and releases free ubiquitin (3). 
 
In addition to the conjugation of a ubiquitin (monoubiquitylation) to a target substrate 
protein, additional ubiquitins can be attached to one of the seven lysines on each 
ubiquitin (polyubiquitination)  (Hershko and Ciechanover, 1998, Sun and Chen, 2004).  
This affords an extraordinary amount of signalling diversity for proteins that are 
modified by ubiquitin.  Of these seven lysines on ubiquitin, lysine 48 is the modification 
that has been the most studied (K48-linked polyubiquitination) (Eddins et al., 2007).  
This modification generally targets the substrate protein to the 26S proteasome for 
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degradation.  The 26S proteasome hydrolyses the polypeptide into short oligopeptides 
and releases free ubiquitin (figure 4) (Eddins et al., 2007).   
Targeting of ubiquitin to a substrate protein's lysine is accomplished by an E3 ubiquitin 
ligase.  E3's provide the majority of substrate recognition and selectivity.  There are 
over 600 E3 ligases that target cellular proteins (Deshaies and Joazeiro, 2009).  Each E3 
ligase has very specific protein substrates.  There are two major classes of E3s; RING 
E3s and HECT domain containing E3s (Deshaies and Joazeiro, 2009, Scheffner and 
Staub, 2007).  The two major E3 ligases that have been implicated in skeletal muscle 
atrophy are Trim63, also known as MuRF1 and Fbxo32, also known as Atrogin-1 or 
MAFbx.  Trim63 is upregulated in at least 13 different models of atrophy (Clarke et al., 
2007) and has been shown to be the E3 required for the degradation of myosin heavy 
and light chain proteins (Clarke et al., 2007, Cohen et al., 2009).  Clarke et al 
demonstrated a physical interaction in vitro between Trim63 and MHC by immune 
precipitation of epitope-tagged Trim63 protein, which co-immunoprecipitated MHC 
protein.  The study went on to show that the loss of MHC induced by the treatment of 
cultured myotubes with the cachectic glucocorticoid dexamethasone (dex) was blocked 
by siRNA-mediated depletion of Trim63.  Furthermore, MHC was found to be spared in 
Trim63-/- mice in comparison to wild-type mice under dex-induced atrophy conditions 
(Clarke et al., 2007).  Fbxo32 has been implicated in muscle atrophy and was originally 
thought to also degrade myofibrillar proteins (Bodine et al., 2001).  However, more 
recent studies have suggested that the role of Fbxo32 is to regulate protein synthesis 
via the degradation of alternative substrates, the transcription factor MyoD (Tintignac 
et al., 2005) and the eukaryotic initiation factor EIF3f (Lagirand-Cantaloube et al., 
2008).   
The activation and proliferation of satellite cells, followed by their differentiation and 
fusion with myotubes, is believed to be essential for hypertrophy of adult skeletal 
muscle (Hawke and Garry, 2001, Rosenblatt et al., 1994) and MyoD has been shown to 
be upregulated prior to satellite cell proliferation (Charge and Rudnicki, 2004).  EIF3f is 
a regulatory subunit that plays a major role in muscle hypertrophy through its actions 
in the insulin-like growth factor (IGF)/ mammalian target of rapamycin (mTOR) 
pathway (Csibi et al., 2010). 
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1.3 Transcriptional Regulation of Skeletal Muscle Atrophy 
1.3.1  Transcriptional Regulation  
 
One of the mechanisms by which skeletal muscle changes in response to the demands 
placed upon it, i.e. increased activity or decreased nutrient supply, is through the 
regulation of gene transcription.  Transcriptional regulation controls when, and how 
much RNA is produced by RNA polymerase.  There are several regulatory mechanisms, 
including a role for transcription factors, which position RNA polymerase at the start of 
a protein-coding sequence of DNA and then release the polymerase to transcribe 
mRNA.  Transcription factors can be regulated pre- or post-transcription. 
Foxo and Myogenin are transcription factors that have been implicated in skeletal 
muscle atrophy, through their role in the upregulation of genes encoding the E3 
ubiquitin ligases Trim63 and Fbxo32.  Whilst it is the activation of Foxo which 
determines its activity, control of myogenin activity occurs through transcriptional 
expression. Myogenin has been shown to be indirectly regulated by the action of 
Histone deacetylases (Hdacs).  Histones are proteins found in eukaryotic cell nuclei that 
package and order the DNA into structural units called nucleosomes. They are the chief 
protein components of chromatin, acting as spools around which DNA winds.  
Acetylation of histones decreases their affinity for DNA (Hong et al. 1993), resulting in a 
change in nucleosomal conformation (Norton et al. 1989) and  thus an increase the 
accessibility of transcriptional regulatory proteins to chromatin templates (Lee et al. 
1993; Vettese-Dadey et al. 1996).  Hdacs are a class of enzymes that remove acetyl 
groups on a histone, returning them to their original conformation and thus lending 
them to reduce transcription (Choudhary et al., 2009).   
 
1.3.2 Foxo Transcription Factors 
 
In differentiated myotube cultures both dex treatment and calorific restriction  have 
been reported to induce atrophy, accompanied by increased expression of Fbxo32 and 
Trim63 (Sandri et al., 2004, Stitt et al., 2004).  This was antagonised by simultaneous 
treatment with IGF-1, that acts through the phosphatidylinositol 3-kinase (PI3K)/Akt 
signalling pathway (Sandri et al., 2004, Stitt et al., 2004).  These studies demonstrated a 
novel role for Akt as, in addition to stimulating skeletal muscle hypertrophy (Rommel 
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et al., 2001), Akt stimulation could dominantly inhibit the induction of atrophy 
signalling.  This link between IGF, Fbxo32 and Trim63 was confirmed in vivo.  Lee et al 
showed that the expression levels of the E3 ubiquitin ligases, measured by northern 
blotting, increased the atrophy induced by diabetes in the rat.  Here too, IGF-1 blocked 
the transcriptional upregulation of E3 ligases (Lee et al., 2004).  Stitt et al showed that 
activation of the PI3K/Akt pathway using C2C12 lines that stably expressed 
constitutively active forms of PI3K or Akt, was sufficient to block dex-induced 
upregulation of Fbxo32 and Trim63 (Stitt et al., 2004).  The mechanism by which Akt 
inhibited the expression of these E3s was demonstrated to involve the Forkhead (Foxo) 
family of transcription factors (Sandri et al., 2004, Stitt et al., 2004).   
Foxo transcription factors were first discovered more than 10 years ago in Drosophila 
and are characterized by a shared 100 amino acid DNA-binding motif, termed the 
“winged helix” or “forkhead” domain (Tzivion et al., 2011). Conserved forkhead 
domains have been identified in eukaryotic organisms from yeast to humans. The 
human genome contains more than 40 FOX genes, the Foxo family members; Foxo1, 
Foxo3 and Foxo4 are all expressed in skeletal muscle (Furuyama et al., 2002). The 
forkhead transcription factors have been shown to play diverse roles in development, 
metabolism, immunology, cancer, and cell-cycle control (Tuteja and Kaestner, 2007).  
Sandri et al demonstrated a role for Foxo during calorific restriction and dex-induced 
atrophy in myotubes.  Foxo transcription factors, particularly Foxo1, are excluded from 
the nucleus when phosphorylated by Akt, resulting in an association with 14-3-3 
sequestered proteins (Van Der Heide et al., 2004, Tzivion et al., 2011).  Upon 
dephosphorylation they are translocated to the nucleus, where activation of Foxo 
transcription factors was shown to be required for upregulation of Fbxo32 and Trim63 
(figure 5).  
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Figure 5  A role for Foxo Transcription Factors During Muscle Growth and 
Atrophy  
In normal growth conditions IGF-1 activates its receptor, resulting in the activation of 
downstream targets and the consequent phosphorylation of Foxo. Foxo associates with 
the 14-3-3 proteins and is sequestered in the cytoplasm (Panel A).  During atrophic 
conditions IGF-1 does not bind to the cellular receptors and therefore neither the 
receptor, or its downstream, targets are activated.  As a consequence of the inactive 
signalling cascade Foxo remains unphosphorylated causing it to dissociate from the 14-
3-3 proteins and translocate to the nucleus where it activates transcription of Trim63 
and Fbxo32 (Panel B). 
 
These findings have subsequently been confirmed in vivo.  Transgenic over-expression 
of Foxo1 resulted in an atrophic phenotype in mouse; showing smaller muscle mass, 
reduced muscle fibre cross sectional area and impaired skeletal muscle function (Kamei 
et al., 2003).  Senf et al demonstrated using a limb casting model of inactivity  in rat that 
expression of a dominant-negative Foxo3a in rat soleus muscle, introduced by injection 
and electroporation, was able to block muscle fibre atrophy by over 40% (Senf et al., 
2010). 
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1.3.3 Hdac Regulation of Myogenin and Its Role in Muscle Atrophy 
 
Myogenin (Myog) is a basic helix-loop-helix (bHLH) transcription factor essential for 
skeletal muscle development.  Transgenic mice homozygous for a targeted mutation in 
the Myog gene survive foetal development but die immediately after birth and show a 
severe reduction in the mass of all skeletal muscle (Hasty et al., 1993).  During normal 
development, Myog expression is downregulated in skeletal muscle postnatally, but can 
be reinduced in response to denervation in mouse (Macpherson et al., 2011, Tang et al., 
2009).   Curiously, in view of its role in development, Myog has also been shown to bind 
the promotor regions of the Fbxo32 and Trim63 genes (Moresi et al., 2010),  activating 
their expression (Macpherson et al., 2011, Moresi et al., 2010), and linking Myog as 
having an important role in the control of muscle atrophy.  Consequently, control of 
Myog expression is highly relevant when looking at the mechanisms behind skeletal 
muscle atrophy.   
Hdacs have been shown to play an important role in the regulation of Myog expression.  
Hdacs are classified into four classes (I, IIa & b, III and IV) depending on sequence 
identity and domain organization.  The class II Hdacs (HDAC4, 5, 6, 7, 9, and 10) are 
able to shuttle in and out of the nucleus depending on their phosphorylation state (de 
Ruijter et al., 2003).  Hdac inhibitors, a class of compounds that interfere with the 
function of Hdacs have recently been used in studies which have shown an important 
role for Hdacs in the regulation of Myog, and ultimately in muscle atrophy.  The class IIa 
Hdacs, Hdac4 and Hdac5, which act as transcriptional repressors (Haberland et al., 
2009, McKinsey et al., 2000, Potthoff et al., 2007), are upregulated in skeletal muscle 
upon denervation and repress the expression of Dach2 and Mitr,  two negative 
regulators of Myog (Cohen et al., 2007, Tang et al., 2009) (figure 6).   
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Figure 6  The Role of Myogenin in Skeletal Muscle Atrophy 
Hdac4 and Hdac5 repress the expression of Dach2 and Mitr; the negative regulators of 
myogenin.  Myogenin expression increases which promotes the expression of Fbxo32, 
Trim63 and acetylcholine receptors. 
 
1.4  Experimental Models of Skeletal Muscle Atrophy 
 
Muscle wasting is a pathological condition of many diseases ranging from cancer to 
AIDS and is also a natural consequence of muscle inactivity and age-related sarcopenia.  
Experimental models used to investigate muscle atrophy are equally wide ranging, and 
the relationship between the model used and the resulting data should be taken into 
account when making comparisons between studies. 
 
1.4.1 In Vitro Models of Skeletal Muscle Atrophy 
 
Myoblast cultures provide important and convenient mechanistic models of the 
signalling and molecular pathways potentially employed by skeletal muscle in vivo to 
regulate hypertrophy and atrophy.  These myoblast models use either primary skeletal 
muscle cells derived from human or animal biopsies or, more frequently, established 
cell lines such as the mouse C2C12 or rat L6 myoblast cells (Sharples and Stewart, 
2011).  Myoblast cell lines may be cultured to allow differentiation into multinucleate 
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myotubes.  Calorific restriction of myotubes or treatment with a corticosteroid, such as 
dexamethasone, can induce atrophy in cultured myotubes and are commonly used in 
studies of muscle atrophy (Sandri et al., 2004, Stitt et al., 2004).  While these models are 
relatively simple to establish and have been very useful in beginning to unravel the 
mechanisms underlying skeletal muscle atrophy, there are several disadvantages of in 
vitro muscle cultures when compared with in vivo models. The limitations of an in vitro 
model include reduced differentiation capacity with passage, an inability to sustain 
myotubes for extended periods in culture and the environment of two-dimensional 
monolayer that lacks biomimicity, thus making direct comparisons with muscle in vivo 
difficult (Sharples and Stewart, 2011).  Thus while these models can continue to be 
useful in highlighting some of the mechanisms involved, the study of the in vivo 
response is vital in directing research towards a therapeutic target for muscle atrophy. 
This thesis contains data from both types of model, highlighting some of the 
weaknesses of work bases in vitro, and some of the complexities that arise when 
dealing with the neuromuscular system as a whole. 
 
1.4.2 In Vivo Models of Skeletal Muscle Atrophy 
 
There are several in vivo animal models which adopt different methods of inducing 
atrophy, reflecting specific clinical causes of muscle wasting.  Animal models of disease 
where muscle atrophy is one of the symptoms include induction of diabetes by 
selective destruction of the insulin-producing B-cells of the pancreas with a single, 
rapid injection of streptozotocin (STZ), a glucose moiety with a very reactive 
nitrosourea group from the mould Streptomyces guiseus (Wei et al., 2003).  Cancer 
studies include several genetically engineered rodent models which were recently 
reviewed in detail by Holecek et al (Holecek, 2012), an example of which would be the 
Lewis lung carcinoma murine model described by Busquets et al in 2004 (Busquets et 
al., 2004).  However, these models have the added symptoms of the disease itself, which 
may complicate the investigation of muscle atrophy specifically.  Furthermore, the idea 
that systemic inflammation may be the primary cause of  muscle wasting in ageing 
populations, and that muscle wasting is not entirely attributable to disuse, is an 
indication of the complexity of numerous factors that contribute to muscle wasting in 
different conditions leading to atrophy (Degens and Alway, 2006). Gaining an 
understanding of the molecular and cellular pathways that govern muscle atrophy 
without the interference of a diseased state is fundamental in understanding the 
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process of muscle wasting without confounding pathology.  In order to achieve this goal 
models of muscle disuse atrophy have been developed.  These include denervation, 
joint immobilisation and tail suspension.   
Denervation studies either cut (van der Meer et al., 2011) or remove a section of the 
motor nerve supplying the muscle to be studied (Tang and Goldman, 2006), or crush 
the nerve so that it becomes damaged (Gigo-Benato et al., 2010).  The advantage of this 
technique is the ability to compare denervated and innervated (contralateral) hindlimb 
muscles.  Recent studies have shown a rapid onset of muscle atrophy in both young and 
old rats after just 1-2 weeks of denervation (van der Meer et al., 2011). However there 
are several disadvantages including the debate as to whether the lack of neurotrophic 
factors plays a role in the atrophy process as well as the lack of neuronal impulses 
(Midrio, 2006).  Furthermore, this model provides a very limited option to look at the 
recovery from atrophy.  Reinnervation is possible following a crush injury but requires 
a period of remodelling of axons and endplates (Varejao et al., 2004). Analysis of 
recovery is vital to see whether the pathways that lead to muscle atrophy are 
reversible, a key factor when considering the clinical implications.  
Hindlimb suspension, where elastic tail casts are used to suspend the hindlimbs of the 
animal from the cage is another in vivo model which is used commonly in studies of 
atrophy.  This technique unloads the muscles but does not restrict the movement of the 
limbs themselves.  Consequently it has been suggested that this model is more suited to 
studies on microgravity during spaceflight than on muscle disuse (Holecek, 2012).  
Indeed, direct comparisons of the hindlimb suspension model have concluded that for 
certain muscles of the hindlimb the model shows no evidence of muscle disuse (Michel 
and Gardiner, 1990).   
Joint immobilisation, such as limb casting, where the muscles of the limb are not 
prevented from contracting, but the limb is unable to move,  has been shown to cause 
systemic stress responses and alterations, which may interfere with changes induced 
on the muscle by immobilisation (Holecek, 2012).  The technique of limb 
immobilisation has also been used in human studies, where volunteers had one leg 
immobilised using a standard knee brace for up to 14 days (Yasuda et al., 2005).  This 
approach may bypass the problems of translating findings from animal models but also 
has the added problems of increased ethical considerations and the availability of 
volunteer subjects. The issue of inter-individual variability also becomes more 
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important when looking at human studies, where it is difficult to control other 
components, such as diet and sleep patterns, which may contribute to the results. 
 
1.4.3 Functional Atrophy: a Novel Method of Inducing Muscle Atrophy 
 
The use of miniature implantable stimulators to alter the activity pattern in a muscle 
has been used to study changes in the contractile properties of skeletal muscle, such as 
muscle fibre types (Jarvis et al., 1996), as well as changes in mitochondrial biogenesis 
and metabolism (McMullen et al., 2011). Continuous electrical stimulation of the 
Tibialis anterior muscle  was found to decrease muscle mass first in rabbit (Jarvis and 
Salmons, 1991, Mayne et al., 1991) and later in rat (Jarvis et al., 1996).  The 
mechanisms behind this change in muscle size were not fully investigated as both 
studies focussed primarily on muscle fibre type, but a significant decrease in muscle 
weight was observed nonetheless.  A study by Joplin and Salmons showed that 
increased muscle activity resulted in an increase in protein synthesis (Joplin et al., 
1987). However, in certain types of activity, such as those mimicking endurance-type 
training, the level of protein degradation increases even further, resulting in muscle 
atrophy. This is ultimately the principle behind the model of functional atrophy, where 
one could perhaps say ‘over use’ of the muscle is the driving force behind the change in 
muscle size.  However, whilst it is possible to use electrical stimulation of muscle to 
induce atrophy in vivo, whereby the change in muscle size is clearly an adaptive 
response to extreme activity, the physiological state of the muscle does not reflect the 
conditions that are linked with muscle wasting in diseased states, and is completely 
different from a disuse atrophy state.  
 
1.4.4 Tetrodotoxin  (TTX) nerve block to produce muscle atrophy. 
 
A model employing the use of tetrodotoxin (TTX) to block action potentials in nerves is 
an interesting alternative to the other models of disuse atrophy, such as denervation or 
limb casting. TTX works by binding to the voltage-gated, fast sodium channels in nerve 
cell membranes, essentially preventing any affected nerve cells from firing by blocking 
the channels used in the process.  The binding site of this toxin is located at the pore 
opening of the voltage-gated Na+ channel (Hwang and Noguchi, 2007).  Such a toxin has 
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great potential for use in a muscle atrophy study as the ability to block specific nerve 
activity means that a particular muscle can be targeted and studied following a period 
of complete inactivity. Furthermore, as the toxin is reversible and does not 
permanently damage the nerve there is still the potential for neurotrophism.    Studies 
that have used nerve block with TTX in rat models to look for changes in the contractile 
properties of muscle (Buffelli et al., 1997) or fibre type changes (Dupont Salter et al., 
2003) have reported a decrease in muscle weight with this treatment.  Thus TTX nerve 
block can be said to be an effective and clinically relevant model for muscle atrophy. 
However, there is currently no study which has focussed on the molecular and cellular 
signalling pathways which are involved in muscle atrophy using an in vivo TTX nerve 
block. 
 
1.5  The Transcriptomics of  Muscle Atrophy 
 
There are several methods in place with which differential expression of a large 
number of genes can be identified and analysed.  Analysis of the transcriptome is an 
exciting new tool with which the signalling pathways and molecular mechanisms 
controlling skeletal muscle atrophy can be further explored and delineated.  
 
1.5.1 Methods for Transcriptome Analysis 
 
Current high-throughput profiling technologies have enabled a more in depth approach 
to investigating interactions between multiple components within a signalling pathway. 
The more common methods used in studying muscle atrophy are serial analysis of gene 
expression (SAGE) and DNA microarray. SAGE allows the quantitative and 
simultaneous analysis of a large number of transcripts by producing a snapshot of the 
messenger RNA (mRNA) population in a sample of interest in the form of small tags 
that correspond to fragments of those transcripts.  The SAGE technique does not 
require specific probes for transcripts and thus provides the potential for identifying 
novel changes in gene expression. The alternative approach employs the use of 
Affymetrix GeneChip microarray analysis, a technique that was originally developed by 
Maskos et al (Maskos and Southern, 1992).  A DNA microarray is a collection of 
microscopic DNA probes attached to a solid surface that are used to measure the 
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expression levels of large numbers of genes.  Probe-target hybridization is usually 
detected and quantified by detection of fluorophore-, silver-, or chemiluminescence-
labelled targets to determine relative abundance of nucleic acid sequences in the target. 
The latter technique has been established for longer and thus there is a greater body of 
data available for comparison when considering muscle atrophy.  
 
1.5.2  Transcriptome Analysis of muscle atrophy 
 
Transcriptome analysis of the response of muscle to various models of muscle atrophy 
has been much improved with recent technological advances.  SAGE analysis was used 
by St-Amand et al to investigate gene expression changes following 12 days of limb 
immobilisation in rat (St-Amand et al., 2001).  More recent analyses have used 
Affymetrix GeneChips for microarray analysis. For example, several studies have 
looked at the transcriptional response to hind limb unloading  following 12 hours (Bey 
et al., 2003),  21 days (Stein et al., 2002) or over a time course (Stevenson et al., 2003).  
There have also been studies combining many different data sets (meta-analysis) to 
look for common molecular signals over several different types of atrophy (Calura et al., 
2008). We have used a combination of a the clinically accurate in vivo model of atrophy 
with the complex and accurate technology of Affymetrix GeneChip microarray analysis. 
The data presented here is key to understanding in greater detail the molecular 
mechanisms underlying the atrophy process, and the recovery from disuse atrophy to 
the normal active state. 
 
1.5  Summary 
 
The molecular mechanisms that lead to muscle atrophy have been studied using a 
variety of techniques in vitro and in vivo.   In vitro myoblast cultures provide key 
mechanistic models of the signalling and molecular pathways potentially employed by 
skeletal muscle in vivo to regulate atrophy.  However, the limitations of such models, 
such as the inaccurate physiological conditions, have led to the development of in vivo 
models which can look at the molecular response to atrophy at the level of muscle 
tissue as opposed to the cellular level.   
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The importance of looking at the in vivo response is vital in directing research towards 
a therapeutic target for muscle atrophy.  There are currently several in vivo animal 
models which adopt different methods of inducing atrophy, reflecting specific clinical 
causes of muscle wasting.  These include denervation, joint immobilisation and tail 
suspension.  While each of these techniques has its place in the study of muscle 
atrophy, there are disadvantages associated with each model. 
The development of a new model of atrophy, referred to as ‘functional atrophy’, where 
electrical stimulation of muscle results in a decrease in muscle size was a promising 
advancement in the field.  With very little evidence of muscle damage, and the ability of 
the animal to continue using the muscle in the usual manner, this model of atrophy can 
provide more accurate information about the muscular response to atrophy and not the 
response to damage or unloading, However, clinical cases of atrophy are generally the 
result of disuse of a muscle rather than the continuous or over use that produces 
functional atrophy, much like the response of endurance training in athletes. 
Consequently, it has become apparent that a more clinically relevant in vivo model of 
atrophy was required. Such a model would enable direct comparisons between use and 
disuse atrophy to look for common pathways in both that would have the potential for 
therapeutic and enhancement targets. 
The use of TTX to block nerve action, resulting in muscle disuse is an exciting avenue in 
the search for a more clinically and physiologically relevant model of muscle atrophy. 
The advantages associated with the in vivo models over the in vitro models, as well as 
the accuracy of the treatment to the muscle suggests that this model could be the future 
to beginning to elucidate the molecular mechanisms involved. 
The most suitable and effective way of analysing the response in this model is to make  
a genome wide analysis of the transcriptional output of the muscle.  Analysis of 
numerous transcripts may highlight potential pathways involved in the process of 
muscle atrophy, providing possible areas to focus on for therapeutic targets to either 
prevent muscle atrophy or induce hypertrophy. Our studies have highlighted a central 
role for the Foxo transcription factors and Myog, a transcription factor known to 
regulate genes involved in the control of muscle size.  A better understanding of the 
expression of these transcription factors in muscle atrophy, as well as the signalling 
pathways in which they are involved, may begin to elucidate the mechanisms governing 
muscle size. 
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1.6  Aims 
 
The aims of this thesis were to investigate the cellular and molecular mechanisms that 
govern skeletal muscle atrophy.  Specifically, 
 
 To compare changes in transcripts associated with muscle atrophy using in 
vitro models of skeletal muscle atrophy with an in vivo model of functional 
atrophy induced by electrical stimulation. 
 To establish an in vivo model of atrophy that better represented the 
physiological state in disuse atrophy.  An in vivo model using a TTX nerve block 
would be developed to induce progressive muscle atrophy, sampling at 3, 7 and 
14 days without detriment to the muscle. In further groups, the nerve block 
would then be removed and the muscle allowed to recover for 7 days. 
 In order to gain a better understanding of the cellular and molecular basis of 
atrophy and with the aim of generating a hypothesis of the pathways involved, 
the muscle from this model would be analysed, and compared with the 
electrical stimulation model of functional atrophy using DNA microarray.  
Following systematic and rigorous statistical analysis of the data, comparisons 
of transcriptional changes would be made between the two in vivo models of 
atrophy and the temporal effects of the nerve blockade and recovery to original 
active state. 
 The final aim was to determine whether these findings were transferable to 
models of atrophy currently in use in the literature, and to examine potential 
chemical interventions.  To accomplish this aim we would return to the C2C12 
in vitro model.  Chemical inhibitors of the signalling pathways identified by 
microarray analysis would be used and the degree of atrophy following 
chemical treatment, as well as the associated transcriptional changes would be 
measured to assess the effect of these inhibitors and the pathways they affect. 
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Chapter 2:  Materials & Methods 
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2.1  C2C12 Myotube Cell Culture 
 
C2C12 is a mouse myoblast cell line. C2C12 cells were originally obtained by Yaffe and 
Saxel through serial passage of myoblasts cultured from the thigh muscle of C3H mice 
after a crush injury (Yaffe and Saxel, 1977). Given the correct conditions, they are 
capable of differentiation into myotubes from the fusion of myoblasts into multi-
nucleated cells.  In this latter form they were used in this study as an in-vitro model of 
mature muscle cells. 
 
2.1.1  Routine Culture of Myoblasts and Myotubes 
 
C2C12 mouse myoblasts (gifted by Dr Vasilaki, The University of Liverpool) were 
cultured on BD Falcon 10 cm petri dishes (Scientific Lab Supplies Ltd, Hessle, UK) in 
Dulbecco's Modified Eagle Medium (Gibco, Paisley, UK) (DMEM) supplemented with 
10% Foetal Calf Serum (FCS) and antibiotics (50U/ml penicillin and 50µg/ml 
streptomycin) at 37°C, 5% CO2 until the cells reached 80% confluence.  The medium 
was then replaced with DMEM supplemented with 2% horse serum (Gibco, Paisley, UK) 
(HS) and antibiotics and incubated for seven days, replenishing the media at three or 
four days, to induce myotube formation before any experimental treatments were 
started. 
 
2.1.2  Myotube Starvation & Dexamethasone Treatment 
 
Cultured myotubes obtained by methods outlined in 2.1.1 were treated by replacing the 
culture media with DMEM supplemented with 2% HS and antibiotics (Normal Media 
Control); DMEM, no glucose (Gibco, Paisley, UK) supplemented with 2% HS and 
antibiotics (Glucose Free Media); or DMEM supplemented with 2% HS, antibiotics and 
1µM Dexamethasone (Sigma, Dorset, UK) (Dex Treated Media) and incubated for 24 
hours at 37°C, 5% CO2. 
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2.1.3  Myotube Treatment with Chemical Inhibitors 
 
Each treatment group contained cultured myotubes obtained by methods outlined in 
2.1.1.  Each was treated by replacing the culture media with either DMEM 
supplemented with 2% HS and antibiotics or DMEM, no glucose supplemented with 2% 
HS and antibiotics.  In some groups chemical inhibitors were added to the 
supplemented media, which replaced the culture media for 24 hours incubation at 
37°C, 5% CO2.    4 groups were treated with (a) the histone deacetylase (Hdac) Class I 
inhibitor MGCD0103 (Selleck, Houston, USA) at 10µM, (b) the Hdac class II inhibitor 
MC1568 (Selleck) at 10µM (c) the Signal Transducer and Activator of Transcription 
(Stat3) inhibitor S3I-201 (Selleck) at 50µM or (d) a combination of MC1568 and S3I-
201.  Concentrations were used as advised by Selleck and to ensure these were suitable 
for treatment of the cultured myotubes a CellTiter 96® Aqueous Non-Radioactive Cell 
Proliferation Assay (Promega, Southampton, UK) was performed as per manufacturer’s 
instructions. 
 
2.1.4  Myotube Diameter Measurement 
 
An Olympus IMT-2 microscope was used to capture phase contrast photomicrographs 
of myotubes in culture using an Olympus c5050 digital camera.  Photomicrographs 
were taken of five random fields over each plate before and after treatment.  Using 
ImageJ 1.45i (http://rsbweb.nih.gov/ij/) each photograph was overlaid with an 8x8 
grid.  Running from top left to bottom right, at the first 10 points for which the grid 
intersections fell in a myotube its minimum diameter was measured using the the 
ImageJ software.  The precise magnification of each section was determined using a 
stage graticule, photographed with the same settings, where each bar represents 100 
μm.  This allowed cross sectional areas to be calculated from precise diameter 
measurements. 
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2.1.5  First Stage RNA Extraction from Cultured Myotubes 
 
The treatment media, described in 2.1.2 and 2.1.3 was removed following 24 hours 
incubation.  The myotube cells were then washed twice with sterile 1X phosphate 
buffered saline (PBS).  The cells were then lysed with 1 ml  Tri Reagent (Sigma) and 
dislodged from the plate surface using a cell lifter.  This suspension was then 
transferred to a 1.5 ml microcentrifuge tube and centrifuged at 14,000g for 10 minutes 
at 4°C.  The supernatant was removed and transferred to a fresh 1.5 ml microcentrifuge 
tube.  This crude extract was then processed as outlined in section 2.6.1. 
 
2.2  Electrical Stimulation of Tibialis Anterior (TA) Muscle in Rats 
 
Electrical stimulation of rat skeletal muscle by means of a miniature implantable 
stimulator was used to impose an atrophy inducing pattern of activity upon that 
muscle.  In all studies the experimental subjects were male Wistar rats weighing 
between 350-450g.  The Tibialis anterior (TA) muscle of the anterior compartment of 
the lower limb was chosen for stimulation because the common peroneal nerve, which 
supplies this muscle is largely motor in function; thus stimulation could be applied with 
little or no adverse sensory effects.  Furthermore, the TA muscle acts to dorsiflex the 
foot at the ankle joint and thus activation of this muscle will have little effect on the 
normal movement of the animal.  In all studies the left TA muscle was stimulated and 
the contralateral TA was used as an internal unstimulated control. 
 
2.2.1  Miniature Implantable Stimulators 
 
The stimulator was developed by Dr Jonathan Jarvis and Prof. Stanley Salmons (Jarvis 
and Salmons, 1991).  It was used to deliver stimulation at a fixed frequency of 20Hz and 
could be switched on or off remotely by a defined sequence of light-flashes through the 
skin.  The components of the stimulator were mounted by hand onto printed circuits 
and protected in a coating of biocompatible silicone rubber.  A Dacron™ mesh extended 
from the silicone rubber to facilitate suturing in-vivo and help to prevent migration of 
the stimulators.  Electrodes were PVC-insulated and made from multi-stranded 
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stainless steel, ending in uninsulated loops which could be sutured to the underlying 
muscle. 
 
2.2.2  Implant Procedure 
 
An anaesthetist was required to monitor animals for all implant procedures.  The 
anaesthesia was adjusted accordingly to ensure a deep anaesthetic state throughout the 
procedure.  All rats were anaesthetised by inhalation of isofluorane in conjunction with 
pure oxygen and nitrous oxide.  Once anaesthetised, a subcutaneous injection of 
antibiotic (5mg/kg Baytril®) and an intramuscular injection of a semi-synthetic opioid 
Buprenorphine (0.05mg/Kg Temgesic) into the quadriceps femoris muscle of the right 
hind limb were administered.  All implants were carried out under strict aseptic 
conditions using autoclaved instruments.  The sterilised miniature implantable 
stimulator was submerged in sterile saline and inserted into the abdominal cavity via 
an incision through the skin and abdominal muscles of the flank on the left side of the 
animal.  The stimulator was then sutured to the abdominal wall by way of the Dacron™ 
mesh.  The electrodes were then tunnelled subcutaneously to the left hind limb.  The 
abdominal muscles were closed using a running suture.  Exposure of the common 
peroneal nerve, just proximal to the knee joint, was achieved by making a small, 
transverse incision in the biceps femoris muscle in the posterior compartment of the 
thigh.  The electrodes were passed under the nerve using a 21 gauge needle and 
sutured in place with an attachment to the aponeurosis of the gastrocnemius muscle 
lying beneath.  The electrodes were thus close to the nerve without actually being in 
contact.  The biceps femoris muscle was then closed using a running stitch 
supplemented with several single interrupted stitches at two or three points along the 
line of the wound.  External sutures were then used to close the skin.  Prolene (Ethicon 
Ltd, Gargrave, UK) was used for all suturing, size 5-0 internally and externally.  Animals 
were allowed to recover from the implant procedure for seven days before initiating 
stimulation, at which point both the muscle and skin had begun to heal and the effects 
of the anaesthetic had worn off. 
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2.2.3  Stimulation Protocol 
 
The miniature implantable stimulators were pre-programmed to produce a stimulation 
pattern at a continuous frequency of 20 Hz for a period of 7 days.  Stimulators were 
switched on remotely using a stroboscope to transmit a sequence of light pulses 
through the skin.  Bi-directional communication by way of a sequence of flashes 
emitted from the stimulator indicated the stimulator had received the instructions.  The 
stimulator could also be switched off when required with a single flash from the 
stroboscope.    Rats undergoing stimulation were checked daily by palpating the front 
of the lower hind limb to ensure the frequency was correct.  If signs of discomfort were 
evident or there was stimulation in the posterior compartment of the hind limb, known 
as co-contraction, stimulation was reduced in amplitude or terminated immediately.  
Full details of all implant experiments can be found in appendix 1. 
 
2.3  Blockade of the Common Peroneal Nerve using a Nerve Cuff 
 
A tetrodotoxin (TTX) nerve cuff was used to confer total blockade of all impulse activity 
reaching the muscle and induce progressive muscle atrophy over a period of 14 days.  
This atrophy was achieved in the absence of any histological signs of damage or 
degeneration to the muscle tissue.  It was therefore possible to block muscle activity for 
14 days, and then reverse the blockade, allowing the muscle to recover without 
detriment over the subsequent 7 days.  TTX was delivered to a nerve cuff on the 
common peroneal nerve via an osmotic pump which was implanted sub-cutaneously.  
The common peroneal nerve was chosen because it is largely motor in function; thus 
nerve block could be applied with little or no adverse sensory effects.  Furthermore, the 
muscles of the anterior compartment of the lower limb which are supplied by the 
common peroneal nerve, act to dorsiflex the foot at the ankle joint and thus blockade of 
these muscle had little effect on the normal movement of the animal.  In all studies the 
experimental subjects were male Wistar rats weighing between 350-450g. 
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2.3.1  Implant Contents 
 
The implant consists of a mini-osmotic pump which delivers TTX via a delivery tube to 
a nerve cuff which surrounds the common peroneal nerve at a rate of 0.5 μl/hour.  The 
cuff allows the nerve to be bathed in TTX, which blocks action potentials in nerves by 
binding to the voltage-gated, fast sodium channels in nerve cell membranes. 
The implanted system was prepared under sterile conditions.  The mini-osmotic pumps 
(Alzet, Model 2002) were filled with calculated volumes of TTX solution (350 g/ml in 
sterile 0.9% saline) using a  1 ml syringe and blunt-tipped, 27 gauge filling tube to at 
least 90% potential volume to prevent unpredictable pumping rate fluctuations.  This 
was confirmed by weighing the pump before and after filling.  Attached to the flow 
moderator of the pump was a delivery-tube-and-nerve-cuff assembly (Figure 7), made 
in-house as a modification of the design used by Michel and Gardiner (Michel and 
Gardiner, 1990). 
 
 
Figure 7  Schematic Representation of Nerve Cuff Assembly Showing The 
Common Peroneal Nerve In-Situ 
Delivery tube and nerve cuff made from silastic tubing allows a continuous flow of TTX 
solution from the osmotic pump to surround the nerve. 
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The delivery tube was made from silastic tubing (Dow Corning) with outside diameter 
of 0.047 inches and internal diameter of 0.025 inches.  The nerve cuff was made using 
silastic tubing with outside diameter 0.125 inches and internal diameter 0.078 inches 
with a slit made along the wall of the tubing, which allowed the cuff to be placed around 
the nerve.  The delivery tube ran from the flow moderator of the osmotic pump to be 
attached using room temperature vulcanising (RTV) silicone rubber (Dow Corning) 
perpendicular to the nerve cuff.  To ensure an uninterrupted flow from the pump, 
through the tubing and into the nerve cuff a 19 gauge needle was pushed through the 
wall of the nerve cuff and the tube threaded over this needle until it touched the outer 
surface of the nerve cuff.  The RTV silicone rubber was then applied to the outside of 
the joint and allowed to set before removal of the needle.  Once the osmotic pump was 
filled and attached to the delivery-tube-and-nerve-cuff assembly the whole implant was 
placed in sterile 0.9% saline and left overnight to prime the pump and allow the TTX 
solution to run through the delivery tube ready to be implanted. 
 
2.3.2  Implant Procedure 
 
The nerve cuff assembly was implanted along with the electrical stimulator described 
in 2.2.2.  The stimulator was included to allow the nerve block to be checked.  If the 
action of the nerve was fully blocked the electrical stimulator was unable to cause the 
TA muscle to contract.  Figure 8 shows the schematic representation of the implant in-
situ.   
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Figure 8  Schematic Representation of Nerve Cuff and Stimulator Electrodes In-
Situ 
The first electrode was tunnelled underneath the common peroneal nerve and sutured 
at either side to the underlying Gastrocnemius muscle.  The second was sutured into the 
Gastrocnemius muscle near to the first electrode.  The nerve cuff was placed around the 
nerve, downstream of the electrodes. 
 
 
The nerve cuff in-situ is also shown in the photographs in figure 9 below. 
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Figure 9  Photograph of Nerve Cuff and Stimulator Electrodes In-Situ 
A. Photograph Showing Nerve Cuff In-Situ Prior to Closure of Wound.  B. shows the 
same image with diagrammatic representation of constituent parts of the implant and 
nerve. The nerve cuff and delivery tube are represented in blue, electrodes in green and 
the common peroneal nerve in white. 
 
An incision was made between the scapulae of the animal’s back once the electrodes 
had been stitched into place in the hindlimb.  The mini osmotic pump was positioned 
under the skin caudal to the incision on the back of the animal.  The delivery tube was 
then tunnelled subcutaneously to the left lower limb.  The common peroneal nerve was 
freed from the surrounding tissues taking great care not to stretch or touch the actual 
nerve as much as possible.  The nerve cuff was then placed around the nerve and held 
in place by a suture at either end which ran around the cuff and into the underlying 
gastrocnemius muscle.  A third suture was placed around the delivery cuff and into the 
biceps femoris approximately one centimetre from the nerve cuff ensuring not to 
restrict the diameter of the tube.  As outlined in 2.2.2, the biceps femoris muscle was 
then closed using a running stitch aided with several single interrupted stitches at 
various points along the line of the wound.  External sutures were then used to close 
the skin.  Prolene (Ethicon Ltd.) was used for all suturing, size 5-0 internally and 
externally.   
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2.3.3  Nerve Block Protocol 
 
The nerve block was effective as soon as the nerve cuff assembly was surgically 
implanted.  The nerve block was left in place for 3, 7 and 14 days from the time of 
implant.  Each day the animals were checked to ensure the nerve block was in place 
using the electrical stimulators.  If signs of discomfort were evident or the block was 
not in place the experiment was terminated immediately.  Another experimental group 
were subjected to 14 days of nerve block followed by 7 days of recovery.  This was 
made possible as the pumps were known to deliver the TTX solution at a rate of 0.5μl 
per hour.  Therefore if the pumps were filled with exactly 168 μl TTX solution this 
would run out after 14 days.  The nerve block was checked at day 14 and its absence 
was confirmed on day 15 by turning on the electrical stimulators and palpating the 
contraction of the TA muscle in the anterior compartment of the left hind limb.  Full 
details of all implant experiments can be found in appendix 1. 
 
2.4  Muscle Tissue Processing for Extraction of RNA 
2.4.1  Terminal Procedure and Muscle Harvesting 
 
Rats were terminated by exposure to increasing concentrations of CO2 followed by 
cervical dislocation, in accordance with Schedule 1 of the Animals (Scientific 
Procedures) Act 1986.  Muscles were harvested using baked instruments and cut into 
sections on a sterile petri-dish using a sterile scalpel blade as shown in figure 10. 
 
Figure 10  Segmentation of Rat TA Muscle For Analysis 
Muscles were separated into samples to be analysed using histology (H), RNA 
extraction for qRT-PCR (R), RNA extraction for microarray analysis (M) and analysis of 
protein content (P) 
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The sections removed for RNA, microarray and protein analysis were approximately 
100mg each.  The samples were snap frozen in liquid nitrogen and stored at -80 °C. The 
remaining muscle from the proximal end of the muscle belly, for histological analysis, 
was mounted onto cork and frozen in melting isopentane above liquid nitrogen to 
prevent the formation of ice crystals.  The samples were then stored at -80 °C. 
 
2.4.2  First Stage RNA Extraction from Muscle Tissue 
 
In order to prevent degradation of RNA by RNAses the instruments used for RNA 
extraction were baked overnight in an oven at 200°C.  Frozen muscle samples 
(approximately 100 mg) were smashed under liquid nitrogen in the baked pestle and 
mortar and homogenised in 1 ml Tri Reagent (Sigma).  Following centrifugation at 
14,000g for 10 minutes at 4°C, the aqueous supernatant was removed, placed into a 
fresh 1.5 ml microcentrifuge tube and processed as outlined in 2.6.1. 
 
2.5  Histological Analysis of Frozen Sections of Muscle Tissue 
 
Examination of histological sections of both stimulated and unstimulated muscle tissue 
allowed evidence of nerve damage to be quantified as well as the measurement of fibre 
cross sectional area (CSA).  A block of TA muscle was mounted onto a cork disc and 
immediately frozen in isopentane and snap frozen in liquid nitrogen.  Samples were 
stored at -80°C.  Serial sections (10 μm) were cut using a cryostat (Bright Instrument 
Company Ltd., Huntingdon, UK) and mounted onto subbed, glass slides (see appendix 
2).  The matched stimulated and unstimulated sections from each animal were placed 
on the same slide so that both were processed in parallel.  Slides of sectioned muscle 
were stored at -80°C for future analysis by histological techniques. 
 
2.5.1  Haematoxylin and Eosin Stain for Gross Fibre Morphology 
 
Haematoxylin and eosin (H&E) staining was used to assess the general morphology of 
muscle fibres and look for signs of nerve damage following electrical stimulation and 
nerve block via the TTX nerve cuff (see appendix 3 for details of solutions used).  H&E 
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staining causes muscle fibres to appear pink and nuclei blue.  Before staining, sections 
were removed from the -80°C freezer and left for 30 minutes to adjust to room 
temperature.  Sections were then dipped in tap water to rehydrate.  Sections were then 
placed in Haematoxylin solution for 3 minutes before washing in warm, running tap 
water for 3 minutes.  The sections were then placed in eosin for 1 minute before being 
dipped in running tap water for 10 seconds.  The sections were then dehydrated 
through ascending grades of alcohol (50%, 70%, 90% and 100%), cleared in xylene and 
finally mounted in Di-N-Butyl phthalate in xylene (DPX)(BDH, Lutterworth, UK). 
 
2.5.2  Fibre Cross Sectional Area Measurements 
 
Using a Leitz Diaplan microscope photomicrographs were taken of histological sections 
of muscle tissue stained with H&E (outlined in 2.5.1).  Images were captured using an 
Olympus c5050 digital camera.  Photomicrographs were taken of five random fields 
over each section.  Using ImageJ 1.45i (http://rsbweb.nih.gov/ij/) each photograph 
was overlaid with an 8x8 grid.  Running from top left to bottom right, the first 10 points 
for which the grid intersections fell in a muscle fibre its diameter was measured using 
the ImageJ software.  The precise magnification of each section was determined using a 
stage graticule, where each bar represents 100 μm.  This allowed cross sectional areas 
to be calculated from precise diameter measurements. 
 
2.6  mRNA Expression Analysis in Myotubes & Muscle Tissue 
 
RNA was extracted from frozen muscle tissue, reverse transcribed into cDNA and the 
transcript levels of chosen genes were analysed using qRT-PCR.  First stage extraction 
for myotubes (2.1.4) and frozen muscle tissue (2.4.2) produced an aqueous 
supernatant containing RNA which could be further treated in a common protocol as 
outlined below. 
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2.6.1  Second Stage RNA Extraction 
 
0.2 mL chloroform (Sigma) was added to the aqueous supernatant containing RNA 
produced in 2.1.4 or 2.4.2.  Each sample was shaken vigorously for 15 seconds and left 
to stand at room temperature for 15 minutes.  The samples were then centrifuged at 
14,000g at 4°C for 15 minutes.  This separated the samples into three phases; an upper 
aqueous phase which contained the RNA, an inter-phase which contained the DNA, and 
an organic phase containing protein.  The supernatant aqueous phase was transferred 
into a fresh 1.5 ml microcentrifuge tube and 0.5 ml isopropanol (Sigma) was added 
before each sample was left to stand at room temperature for 10 minutes.  Samples 
were then centrifuged at 14,000g at 4 °C for 10 minutes.  The supernatant was removed 
and the RNA pellet washed with 1 ml of 75% ethanol.  Once the ethanol was removed, 
the RNA pellets were left to dry for 5 minutes at room temperature and then re-
suspended in 50 μl diethylpyrocarbonate (DEPC) treated water (Sigma).  RNA samples 
were stored at -80 °C. 
 
2.6.2  Agarose Gel Electrophoresis 
 
Agarose gel electrophoresis was used to assess the quality of RNA extracted in 2.6.1 
and also to assess primer specificity (2.6.6).  To produce a 1.5% gel; 1.5 g of agarose 
(Invitrogen, Paisley, UK) was dissolved in 100 ml of 0.5X tris-borate EDTA buffer (TBE) 
(Sigma) in double distilled water.  10 μl of 10 mg/ml ethidium bromide  (Sigma) was 
added so that fragments could be visualised under ultra violet (UV) light.  The gel was 
poured into a casting tray, which was fitted with well-forming combs and left to 
polymerise for 45 minutes.  Once cooled, approximately 900 ml 0.5X TBE was added to 
the gel tank, ensuring the gel was well covered and the well-forming combs were 
removed.  5 μl RNA was mixed with 5 μl RNAse-free water and 2 μl of 6X DNA loading 
dye (30% glycerol, 0.05% bromophenol blue and 0.05% xylene cyanol) and loaded into 
a well.  5 μl of hyperladder IV DNA size marker (Bioline) was loaded into one well per 
gel so that the sizes of the RNA products could be determined.  Following 
electrophoresis at 100 mV for 1.5 hours, the gel was visualised under UV light.  A digital 
image was taken using the geneflash syngene bioimaging system (Syngene, Cambridge, 
UK).  The prominence of 18S and 28S ribosomal RNA (18S rNA and 28S rRNA) bands 
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and lack of lower molecular weight smears indicated the quality (and yield) of RNA (see 
Appendix 4). 
 
2.6.3  RNA Analysis using a Nanodrop 
 
A precise estimation of the concentration and purity of the RNA extracted in 2.6.1 was 
made using a NanoDrop micro-volume spectrophotometer (Thermo Scientific, 
Loughborough, UK).  The concentration was determined by measuring UV light 
absorbance at 260 nm of 1.5 μl of undiluted RNA.  The ratio of absorbance at 260 nm v 
280 nm was used to assess the purity of RNA with respect to protein contamination, 
since proteins absorb maximally at 280 nm.  A ratio of 2.0 indicated high purity (for full 
Nanodrop results for each sample see Appendix 5). 
 
2.6.4  First-Strand cDNA Synthesis 
 
Based on the concentration determined in 2.6.3, 1 μg of total RNA was used for first 
strand cDNA synthesis in a 21 μl reaction;  RNAse free water was added to 1 μg RNA to 
make a final volume of 12 μl.  Following the addition of 1 μl oligo dT primer 
(Invitrogen) the samples were incubated at 70°C for 10 minutes.  The samples were 
then snap cooled on ice to aid binding of the primer.  A reaction mix consisting of 4μl of 
5X buffer, 2 μl of dithiothreitol (DTT) and 1 μl of deoxynucleotide triphosphates 
(dNTPs) (Invitrogen) were added per RNA sample and incubated at 42°C for two 
minutes.  1μl of Superscript II Reverse Transcriptase (Invitrogen) was then added and 
the reaction mix incubated for a further 50 minutes at 42°C.  The reaction was then 
inhibited by heating the mixtures to 70°C for 15 minutes.  Each cDNA sample was 
stored at -80°C.  For a control RNA sample prepared from both rat and mouse muscle 
tissue, a parallel reaction was performed which contained all the reaction components 
except the reverse transcriptase enzyme (RT-).  Consequently the mRNA is not reverse 
transcribed into cDNA.  These RT- samples were used as negative controls to confirm 
amplicons for each primer pair were derived from cDNA. 
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2.6.5  Design of Primers for Polymerase Chain Reaction (PCR) 
 
Forward and reverse primers were designed to amplify the genes detailed in tables 1 
and 2.  Primers were designed using reference mRNA sequences for Mus musculus and 
Rattus norvegicus, which were available through the National Centre for Biotechnology 
Information (NCBI) database.  Forward and reverse primers were designed to anneal to 
separate exons so that any amplification of contaminating genomic DNA could be 
distinguished from amplification of cDNA.  All primers were 20 or 21bp in length, to 
ensure adequate specificity.  Where possible the GC content of primers was 50-55%.  
Amplicons were designed to range from 112-297bp in length to ensure optimum 
amplification of the products during the PCR reaction.  The software programme 
'netprimer' (www.premierbiosoft.com/netprimer) was used to predict the efficiency of 
the primers.  This estimated the probability of secondary structure formation produced 
by the inter-molecular on intra-molecular interactions such as self-priming and the 
formation of primer dimers or hairpins.  Primers were synthesised by Invitrogen and 
resuspended as a 100 μM stock in Sigma-Water (Sigma). 
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Table 1  Primers for Real-Time RT-PCR (Mus musculus) 
Rn18s; 18S ribosomal RNA, Polr2a; polymerase (RNA) II (DNA directed) polypeptide A, 
G6pc3; glucose 6 phosphatase catalytic 3, Pdk4; pyruvate dehydrogenase kinase 
isoenzyme 4, Lpl; lipoprotein lipase, Bcl2l11; BCL2-like 11 (apoptosis facilitator), 
Tgfb2; transforming growth factor beta 2, Sod2; superoxide dismutase 2 mitochondrial, 
Ccnd2; cyclin D2, Ccnb1; cyclin B1, Plk1; polo-like kinase 1, Cdkn1b; cyclin-dependent 
kinase inhibitor 1B, Trim63; tripartite motif-containing 63, Fbxo32; F-box protein 32, 
Myog; myogenin, Stat3; signal transducer and activator of transcription 3, Hdac4; 
histone deacetylase 4, Hdac5; histone deacetylase 5, Mitr; a histone deacetylase 9 splice 
variant, Dach2; dachshund 2, Chrna1; nicotinic cholinergic receptor nicotinic (alpha 
polypeptide 1), Socs3; suppressor of cytokine signaling 3, Foxo1; forkhead box O1. 
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Table 2  Primers for Real-Time RT-PCR (Rattus norvegicus) 
Rn18s; 18S ribosomal RNA, Polr2a; polymerase (RNA) II (DNA directed) polypeptide A, 
G6pc3; glucose 6 phosphatase catalytic 3, Pdk4; pyruvate dehydrogenase kinase 
isoenzyme 4, Lpl; lipoprotein lipase, Bcl2l11; BCL2-like 11 (apoptosis facilitator), 
Tgfb2; transforming growth factor beta 2, Sod2; superoxide dismutase 2 mitochondrial, 
Ccnd2; cyclin D2, Ccnb1; cyclin B1, Plk1; polo-like kinase 1, Cdkn1b; cyclin-dependent 
kinase inhibitor 1B, Trim63; tripartite motif-containing 63, Fbxo32; F-box protein 32, 
Myog; myogenin, Stat3; signal transducer and activator of transcription 3, Hdac4; 
histone deacetylase 4, Hdac5; histone deacetylase 5, Mitr; a histone deacetylase 9 splice 
variant, Dach2; dachshund 2, Chrna1; nicotinic cholinergic receptor nicotinic (alpha 
polypeptide 1), Socs3; suppressor of cytokine signaling 3. 
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2.6.6  End-Point PCR & Agarose Gel Electrophoresis to Test Primer Specificity 
 
Primer specificity was assessed using cDNA extracted from control TA muscle and 
cultured myotubes treated with normal media, using end-point RT-PCR with HotStar 
Taq Master Mix (Qiagen, Crawley, UK).  The reaction for each primer pair was made up 
of  3 μl cDNA, 15 μl Hotstar Taq Master Mix, 1.5 μl each of 20 μM forward and reverse 
primers and 9 μl RNAse-free water totalling 30 μl. A negative control was performed in 
parallel using RT- control samples for each primer pair.  End-point PCR reactions were 
set up in 0.5 ml microcentrifuge tubes and performed using a Px2 thermocycler 
(Thermo).  The efficacy of primer sets at temperatures ranging from 55-65°C was 
assessed using a gradient annealing temperature programme to find an optimum 
annealing temperature (shown in tables 1 and 2).  The standard PCR cycle used for all 
primer pairs is indicated in table 3 below. 
 
 
Temperature (°C) Time of Stage Action Number of Cycles 
95 10 Minutes Hotstart 1 
94 30 Seconds Denaturation 
40 55-65 30 Seconds Annealing 
72 1 Minute Extension 
72 10 Minutes Polishing 1 
 
Table 3  Standard End-Point PCR Cycle  
 
Agarose gel electrophoresis was used to assess the specificity of each primer set.  A 2% 
gel was produced as outlined in 2.6.2, using 2 g of agarose instead of 1.5 g.  10 μl of the 
PCR reaction was mixed with 2 μl of 6X DNA loading dye (30% glycerol, 0.05% 
bromophenol blue and 0.05% xylene cyanol) and loaded into a well.  5 μl of 
hyperladder IV DNA size marker (Bioline) was loaded into one well per gel so that the 
sizes of the PCR amplicons could be determined.  Following electrophoresis at 100 mV 
for 1.5 hours, the gel was visualised under UV light.  A digital image was taken using the 
geneflash syngene bioimaging system (Syngene).  The prominence of a clear band at the 
expected size indicated that the primer set worked efficiently at that temperature.  All 
primer sets had an optimum annealing temperature of 61°C. 
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2.6.7  DNA Sequencing of PCR Amplicons 
 
All sequencing was performed by Eurofins MWG Operon on 20 ng unpurified PCR 
product produced in 2.6.6 using the cycle sequencing technology (dideoxy chain 
termination / cycle sequencing) on ABI 3730XL sequencing machines.  Analysis of the 
returned sequence was performed using the NCBI basic local alignment tool (BLAST) 
program (www.ncbi.nlm.nih.gov/BLAST) by means of a basic search against a 
nucleotide database for Mus musculus or Rattus norvegicus.  Sequencing data for primer 
sets can be found in appendix 6.  Due to low concentrations of some of the transcripts, 
sequencing was not successful for all the targeted transcripts. 
 
2.6.8  Quantitative Reverse Transcription PCR (qRT-PCR) 
 
qRT-PCR was used to quantitatively assess the transcript levels for genes of interest in 
RNA extracted from cultured myotubes and TA muscle tissue to evaluate changes in 
mRNA in response to a given treatment.  The standard three-step reaction using an iQ5 
Thermocycler (BioRad)  is outlined in table 4 below. 
 
 
Temperature (°C) Time of Stage Action Number of Cycles 
95 3 Minutes Hotstart 1 
94 30 Seconds Denaturation 
40 61 30 Seconds Annealing 
72 30 Seconds Extension 
 
Table 4  Standard qRT-PCR Cycle 
 
Fluorescence levels were measured after each of the 40 PCR cycles.  The reaction 
contained 3 μl cDNA, 3.96 μl RNAse-free water, 7.5 μl 2X SYBR Green Supermix 
(BioRad, Hemel Hempstead, UK) and 0.27 μl each of 20 μM forward and reverse primer 
totalling 15 μl.  Reactions were carried out in triplicate on a 96-well plate and a 
negative control containing no cDNA was run with each primer set to assess the 
presence of contamination.  Analysis was carried out by comparison of the cycle 
threshold (CT) values for genes in untreated and treated samples.  The CT refers to the 
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cycle at which the fluorescence generated within the reaction exceeds a defined 
threshold and is thus related to the amount of starting template.  The combined mean 
amplification of the Rn18s and Polr2a reference genes was used as a reference against 
which all data for genes of interest was normalised.  These genes were chosen as a 
result of unpublished data by Dr Lauren Fisher, The University of Liverpool, showing 
that neither reference genes significantly change with electrical stimulation in muscle 
(Fisher, 2010).  A melt curve analysis of the amplicons at every 1° for 36 cycles was 
used to look for primer dimer formation and amplification of other non-specific double-
stranded products, as SYBR green binds non-specifically to all double stranded 
products.  The relative expression for genes of interest was determined by the 2-ΔCT 
method, where differences between the mean reference gene CT value and the target 
gene CT value in each sample was quantified individually.  Further analysis was by the 
2-ΔΔCT method, where the expression differences between two samples was represented 
as a fold-change. 
 
2.6.9  Analysis of The Efficiency of the qRT-PCR Assay 
 
The need for efficiency analysis of a SYBR green based qRT-PCR assay is related to the 
fact that real-time quantification is based on the relationship between the starting 
template amount and the CT value obtained during amplification.  Three-step qRT-PCR 
reactions were performed as outlined in 2.6.8.  Standard curves for all primer sets were 
generated using a 2-fold serial dilution of a control template cDNA with dilution factor 
plotted against the mean CT value obtained during amplification.  The standard curves 
for each primer set can be found in appendix 7.  These curves were then used to assess 
the efficiency of amplification.  Amplification efficiency (E) was calculated from the 
gradient of the standard curve using the following formula: 
E = 2-1/slope 
in order to express amplification efficiency as a percentage the following equation was 
used: 
%E = (E-1) x 100 
An amplification efficiency of 90-105% indicated a robust, reproducible assay.  The R2 
value, which is a statistical measure of how well a regression line approximates real 
data points, was used to assess confidence of the amplification efficiency calculated 
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from the gradient of the standard curve.  An R2 value of 1.0 indicates a perfect fit, values 
of over 0.95 were deemed acceptable. 
 
2.7  Microarray Analysis 
 
Microarray analysis was used to compare genome-wide transcript changes following 3, 
7 and 14 days of nerve blockade, in addition to 14 days of nerve block with 7 days of 
recovery, or 7 days electrical stimulation at 20Hz.  Using the GeneChip® Rat Genome 
230 2.0 Array (Affymetrix, High Wycombe, UK) over 30,000 transcripts and variants 
from over 28,000 well-substantiated rat genes were measured.  Frozen muscle 
samples, detailed in 2.7.1, harvested by methods outlined in 2.4.1, were sent as part of 
our collaboration with Pfizer Inc. to AROS Applied Biotechnology (Aarhus, Denmark) 
who carried out all RNA extraction, cDNA synthesis, chip hybridisation and 
fluorescence measurements.  The data, in CEL file format was returned for subsequent 
analysis. 
 
2.7.1  Details of Samples Subject to Microarray Analysis 
 
Frozen muscle tissue samples were sent to AROS Applied Biotechnology for processing 
as detailed in table 5 below. 
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Table 5  Details of Samples Subject to Microarray Analysis 
Pilot study (Chip IDs beginning with A958) chips consisted of the untreated 
contralateral control TA muscle samples (A1236-02,05,07,08) and the treated samples 
(A1236-01,06,03,04).  The untreated control samples (marked with *) were only 
included in the quality control stages of the microarray analysis and were excluded 
from subsequent analysis.  Chips beginning with A1236 represent TA samples from the 
treated limbs of the animals indicated by number. 
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Untreated and treated muscle samples from a pilot study of four animals, two having 
the nerve bock in place for 7 days and two for 14 days, was initially sent for processing.  
These samples are indicated with the AROS Chip ID beginning with A958.  The data was 
stored and analysed with the main study indicated by AROS Chip ID beginning with 
A1236.  In the main study the treated muscle samples from each animal was analysed.  
The experimental groups included in the main study included a sham operated control 
group as well as animals treated with 3, 7 and 14 days of of nerve blockade, in addition 
to 14 days of nerve block with 7 days of recovery, or 7 days electrical stimulation at 
20Hz.  The untreated control samples from the pilot study (marked with *) were only 
included in the quality control stages of the microarray analysis and were excluded 
from subsequent analysis.   
 
2.7.2  Details of Statistical and Bioinformatics Programmes Used in Microarray Analysis 
 
All Statistical analysis of microarray data was carried out using the software  R: A 
Language and Environment for Statistical Computing. version 2.13.1 (©2011, www.R-
project.org).  This is an open source programme developed by the R Development Core 
Team at the R Foundation for Statistical Computing, Vienna.  Packages utilised within R 
included the Bioconductor project (Gentleman et al., 2004), which provides tools for 
the analysis and comprehension of high-throughput genomic data by using the R 
statistical programming language, and is open source and open development.  These 
tools included: affy (Gautier et al., 2004); an extensible, interactive environment for 
data analysis and exploration of Affymetrix oligonucleotide array probe level data.  
Limma  (Smyth, 2004); is a package for the analysis of gene expression microarray data, 
especially the use of linear models for analysing designed experiments and the 
assessment of differential expression.  GOstats (Falcon and Gentleman, 2007) ; has 
extensive facilities for testing the association of Gene Ontology (GO) (Ashburner et al., 
2000) terms to genes in a gene list. 
Training for use of all statistical and bioinformatics software was undertaken under the 
supervision of Alex Gutteridge through the collaboration with Pfizer Inc. 
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Chapter 3: Comparison of Transcriptional Changes in Foxo1 Target 
Genes in In Vitro(C2C12 Myotube Culture) and In Vivo (20Hz 
Electrical Stimulation) Models of Atrophy 
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3.1  Introduction 
 
Muscle atrophy is characterised by a loss of muscle weight and volume that involves a 
reduction in muscle fibre diameter in the absence of degenerative changes and/or a 
reduction in the actual number of fibres by apoptosis or necrosis (Glass, 2010).  
Atrophy of individual fibres may be due to either a reduction in protein synthesis, 
enhanced proteolysis, or both (Glass, 2010). A greater understanding of the molecular 
mechanisms that govern muscle atrophy is required in order to direct research 
towards a therapeutic target. 
Increased ubiquitin-proteasome dependent proteolysis plays a key role on the control 
of muscle mass (Eddins et al., 2011, Sandri et al., 2004, Stitt et al., 2004).  Myotube cell 
culture models of atrophy have shown that important atrophy-related ubiquitin ligases, 
Fbxo32 & Trim63, are induced following treatment with the corticosteroid 
Dexamethasone (Dex) (Sandri et al., 2004, Stitt et al., 2004) and during calorific 
restriction (Sandri et al., 2004),  and that their expression is controlled by transcription 
factors of the foxo family (Sandri et al., 2004, Stitt et al., 2004).  Foxo1, in particular has 
been implicated to have a central role in the control of muscle mass (Kamei et al., 
2003). 
There are currently numerous experimental models used to investigate muscle atrophy 
both in vitro and in vivo. To date, comparisons between these models in terms of the 
data produced have not been made, to determine whether it is viable to use different 
methods interchangeably. In order to compare the modes of action of different models 
of atrophy the transcriptional changes of known targets of Foxo1 transcription factors, 
identified from the literature (3.4.1), were measured following atrophy-inducing 
treatments (3.4).  The models of atrophy to be compared included incubation of 
myotube cell cultures for 24 hours with media lacking glucose (calorific restriction) or 
media treated with Dex (3.2).  These models would also be compared to the in vivo 
functional atrophy model involving the use of a miniature neuromuscular stimulator to 
impose artificially increased levels of activity on the rat Tibialis  anterior muscle (3.3).  
The aim of this chapter is to compare and contrast these models and to better 
understand the similarities or differences in the molecular mechanisms underlying the 
atrophy produced. Thus the questions to be addressed here are to determine whether 
Foxo target genes other than the E3 ligases are induced during atrophy, and to compare 
the transcriptional responses of Foxo1 target genes, and other key genes linked with 
atrophy, to look for common or divergent models of atrophy. 
49 
 
3.2  Induction and Assessment of In Vitro Atrophy 
 
C2C12 mouse myoblasts were cultured to induce myotube formation as outlined in 
2.1.1.  Myotubes were subject to three experimental conditions, replacing the culture 
media with either DMEM supplemented with 2% HS (Normal Media Control), glucose-
free DMEM supplemented with 2% HS (Glucose Free Media) or DMEM supplemented 
with 2% HS and 1µM Dex (Dex Treated Media).  Six plates were included in each group 
and incubated for 24 hours at 37°C, 5% CO2. 
The myotubes were visually assessed (3.2.1), the degree of atrophy determined by 
measuring changes in myotube cross sectional area (3.2.2) and RNA extracted to assess 
expression of foxo1 target genes (3.4). 
 
3.2.1  Myotubes Show Little Apoptosis Following Atrophy Induction 
 
Phase contrast microscopy was used to observe myotube cultures before and after 
treatment to ensure that cultures remained viable.  Induction of apoptosis would result 
in abnormal numbers of free floating cells as well as aggregates of single cells.  Figure 
11 shows representative photomicrographs of the cell cultures, showing intact 
myotubes with little evidence of apoptosis at the time of harvest. 
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Figure 11  Phase Contrast Microscopy of Cultured C2C12 Myotubes Subject to 
Atrophic Conditions 
Representative photomicrographs of control myotube cultures (A) and cultures before 
and after treatment with glucose-free media (B) and Dex (C).  There was little evidence 
of apoptosis in all cultures. 
 
 
3.2.2  Myotubes Cultured in Glucose-Free Media undergo Significant Atrophy 
 
The cross sectional area (CSA) of the cultured C2C12 myotubes were measured before 
and after atrophic treatments, in order to measure the degree of atrophy produced by 
each treatment.  The full method is provided in section 2.1.3.  
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Figure 12  Mean Cross Sectional Area of Cultured Myotubes Decreased Following 
Treatment With Glucose-Free Media 
Treatment of cultured C2C12 myotubes for 24 hours growth in normal media, glucose 
free media, or media containing 1μM Dex.  CSAs were taken from photomicrographs of 
cells in culture.  Glucose starvation resulted in a 56 % decrease in CSA. (n=6, 
*p<0.000001). Error bars indicate standard error of the mean (SEM). 
 
Growth for 24 hours in glucose-free media produced a 56.36% decrease in mean CSA 
relative to that before the change of media (Figure 12), which was shown to be 
statistically significant following a t-test (p<0.000001).  No significant change in mean 
CSA was found in control samples, cultured in normal media or in samples cultured in 
media containing Dex.  The absence of atrophy on treatment with Dex was unexpected 
and is discussed in detail in 3.5.1. 
 
3.3  Induction and Assessment of In Vivo Muscle Atrophy 
 
Miniature neuromuscular stimulators were used to impose 20 Hz continuous electrical 
stimulation on the rat Tibilais anterior muscle for 7 days in vivo (n=6).  Methods are 
outlined in 2.2.  The degree of atrophy, determined by changes in muscle weight (3.3.2) 
and fibre CSA (3.3.3), was measured following stimulation.  It is recognised in the 
literature that denervation of muscle due to damage to the motor axons also produces 
atrophy (Carlson, 2008), and in fact muscle denervation is used as a model of atrophy.  
In order to assess whether the electrical stimulation of muscle was able to produce 
atrophy that was not associated with nerve damage, histological analysis of muscle 
tissue was performed to look for evidence of nerve damage. 
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3.3.1  Histological Analysis Revealed Little Change in Muscle Tissue Indicative of Nerve 
Damage 
 
It is possible to ascertain whether a nerve has been damaged through analysis of the 
fibres in the muscle that it supplies. Histological sections of stimulated and 
unstimulated, contralateral control muscle tissue were analysed to assess whether 
changes in muscle fibres were indicative of nerve damage.  Frozen sections (10µm) 
were stained with Haematoxylin and eosin (See 2.5.1), which distinguishes between 
muscle fibres and nuclei.  Any accidental nerve damage leading to denervation of the 
muscle would appear in the sections as the migration of nuclei from the periphery of 
the muscle fibres into the interior of the fibre (figure 13, panel C), as areas of small, 
non-uniformly shaped fibres, or the infiltration of inflammatory cells.  Sections from 
muscles taken from each of the 6 animals, both stimulated and control, were assessed.  
Very little evidence of nerve damage was observed in any of the histological sections, 
with most sections containing no denervated fibres, in line with previous findings in rat 
(Jarvis et al., 1996).  Figure 13 shows representative examples of the histological 
sections of the stimulated and control muscles samples.   
 
 
 
Figure 13  Representative Photomicrographs of Histological Sections of Control 
and Electrically Stimulated TA Muscle 
Haematoxylin and eosin stain on sectioned muscle tissue (10μm) in control muscle and  
muscle that had electrical stimulation imposed on it for 1 week continuously at a 
frequency of 20Hz (A, B). An example of a single denervated muscle fibre is shown in 
panel C where nuclei are seen to infiltrate the fibre. Very few denervated fibres were 
observed in the experimental sections. 
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3.3.2  Electrical Stimulation for 1 week at 20Hz Significantly Reduced TA Muscle Weight 
 
In order to assess the level of muscle atrophy produced by continuous electrical 
stimulation the weights of the control and stimulated TA muscles were measured 
immediately following harvesting, as outlined in section 2.4.1.  Figure 14 shows the 
mean weight of the TA muscle from the untreated contralateral control limb and the 
limb that had been continuously electrically stimulated for 7 days, at a frequency of 20 
Hz.  The muscle weights are expressed as a percentage of the whole animal body weight 
to normalise the measurements to differing animal sizes. Electrical stimulation 
produced a 12.64% decrease in muscle weight when compared to the unstimulated 
contra-lateral control.  This was shown to be statistically significant following a paired 
Ttest (p=0.016). 
 
 
 
 
 
Figure 14  Mean Differences in TA Muscle Weight between The Electrically 
Stimulated and Unstimulated, Contralateral Control Limb 
Muscle weight is expressed as a percentage of whole body weight to normalise 
measurements to differing animal sizes.  Electrical stimulation was imposed at 20Hz 
continuously for 7 days and produced a significant 12.64% difference in electrically 
stimulated TA weight when compared to the unstimulated contralateral control. (n=6, 
*=p<0.05 following a paired Ttest).  Error bars indicate SEM. 
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3.3.3  Electrical Stimulation In Vivo Decreased The Cross Sectional Area of Muscle 
Fibres 
 
The CSA of fibres were measured from Haematoxylin and Eosin stained muscle sections 
as outlined in 2.5.2.  Electrical stimulation produced a 17.18% decrease in mean fibre 
cross sectional area (Figure 15).  This decrease was not found to be statistically 
significant following a paired t-test, with a p value of 0.153.  However, when the 
individual animals are considered, five out of the six animals showed a decrease in fibre 
CSA ranging from 9 to a 46%.  Only one animal showed an increase in fibre CSA (Rat 
1759 - 21% increase). This large range in changes in CSA with an outlying result would 
account for the relatively high standard error and non significance of the result.   
 
 
 
Figure 15  Mean Differences in TA Muscle Fibre CSA Between Electrically 
Stimulated And Unstimulated Contralateral Control  
Fibre CSAs were taken from photomicrographs of Haematoxylin and eosin stained 
muscle sections (10μm).  Electrical stimulation was imposed at 20Hz continuously for 7 
days and produced a 17% difference in the mean values in electrically stimulated TA 
weight compared to the unstimulated contralateral control (n=6, p=0.153 following a 
paired Ttest). Error bars indicate SEM. 
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3.4  Transcript Changes of Foxo1 Target Genes in In Vitro & In Vivo Atrophy Models 
 
In order to compare and contrast the molecular mechanisms involved in the in vitro 
and in vivo models of muscle atrophy, and to look for similarities or differences in their 
modes of action, the transcriptional changes of known Foxo1 target genes were 
measured following treatment in vitro and in vivo using qRT-PCR.  
 
3.4.1  Identification of Foxo1 Target Genes 
 
Having tested the two in vitro and one in vivo model of muscle cell atrophy, we wished 
to compare the transcriptional response of genes that have in common Foxo1 target 
sequences, knowing from previous literature that Foxo has been implicated as an 
important modulator in atrophy. A literature search was undertaken to identify Foxo1 
target genes that are directly activated by this transcription factor. Ten genes were 
identified from studies where evidence for activation or direct binding of these genes 
by the Foxo1 transcription factor was reported.  Details of the ten genes, a brief 
description of their function and the evidence for Foxo1 activation or binding are 
shown in tables 6, 7 and 8.  The ten genes were separated into three biological 
processes; Metabolic Process (table 6), Programmed Cell Death (table 7) and 
Regulation of Cell Cycle (table 8).  Fbxo32 and Trim63 were also included for analysis, 
as studies have shown these to be under the control of Foxo1 during muscle atrophy 
(Stitt et al., 2004). 
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METABOLIC PROCESS 
Target Gene Gene Function Evidence of 
Activation or 
Binding 
Reference 
Glucose-6-
phosphatase 
(G6pc3) 
 
Catalyses the hydrolysis of 
glucose-6-phosphatase to 
glucose, which is the terminal 
step of both gluconeogenesis and 
glycogen breakdown. 
Labelled DNA 
probe binding 
Assay. 
(Ayala et al., 
1999) 
Pyruvate 
dehydrogenase 
kinase 4 
(Pdk4) 
 
Kinase enzyme which acts to 
inactivate the enzyme pyruvate 
dehydrogenase, so participates in 
the regulation of the pyruvate 
dehydrogenase complex.  This 
complex acts to convert pyruvate 
into acetyl-coA. and so the 
downregulation of the complex 
allows more pyruvate to be 
available for gluconeogenesis. 
Luciferase 
Reporter Gene 
Assay 
(Furuyama et 
al., 2003) 
Lipoprotein 
Lipase 
(Lpl) 
 
Hydrolyzes lipids in lipoproteins, 
such as those found in very low-
density lipoproteins into three 
free fatty acids and one glycerol 
molecule. 
Up-regulation 
of expression 
(Kamei et al., 
2003) 
 
Table 6  Foxo1 Target Genes Involved In Metabolic Processes Included in Analysis 
 
PROGRAMMED CELL DEATH 
Target Gene Gene Function Evidence of 
Activation or 
Binding 
 Reference 
Bcl-2-
interacting 
mediator of cell-
death (Bcl2l11) 
Forms hetero- or homodimers 
and act as anti- or pro-apoptotic 
regulators that are involved in a 
wide variety of cellular activities.  
Electrophoretic 
Mobility Shift 
Assay (EMSA) 
(Gilley et al., 
2003) 
Transforming 
growth factor β-
2 
(Tgfb2) 
Known to inhibit cell proliferation 
and induce apoptosis in many cell 
types. 
Transient 
Reporter Gene 
Assays 
(Samatar et 
al., 2002) 
Manganese 
superoxide 
dismutase 
(Sod2) 
Transforms toxic superoxide, a 
byproduct of mitochondrial 
electron transport chain, into 
hydrogen peroxide and diatomic 
oxygen. This increase in 
protection from reactive oxygen 
species antagonizes apoptosis 
caused by glucose deprivation. 
Chromatin 
Immuno-
precipitation 
(ChIP) 
(Adachi et al., 
2007) 
 
Table 7  Foxo1 Target Genes Involved In Programmed Cell Death Included in 
Analysis 
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REGULATION OF CELL CYCLE 
Target Gene Gene Function Evidence of 
Binding 
 Reference 
Cyclin D2 
(Ccnd2) 
 
Forms a complex with and 
functions as a regulatory subunit 
of Cdk4 or Cdk6, whose activtiy is 
required for cell cycle G1/S 
transition. 
Chromatin 
Immuno-
precipitation 
(ChIP) 
(Park et al., 
2005) 
Cyclin B 
(Ccnb1) 
 
Cyclin B is a mitotic cyclin. The 
amount of cyclin B (which binds to 
Cdk1) and the activity of the cyclin 
B-Cdk complex rise through the 
cell cycle until mitosis completes, 
where they fall abruptly due to 
degradation. 
Chromatin 
Immuno-
precipitation 
(ChIP) 
(Alvarez et al., 
2001) 
Polo-like 
Kinase 
(Plk1) 
 
Plk1 modulates the ubiquitination 
of cyclin B, targeting it for 
degradation without affecting 
prior ubiquitination of anaphase 
inhibitors. 
Chromatin 
Immuno-
precipitation 
(ChIP) 
(Alvarez et al., 
2001) 
Cyclin-
dependent 
kinase 
inhibitor 1B 
(Cdkn1b) 
 
p27Kip1 is a cdk inhibitor that 
associates with G1 cyclin/cdk 
complexes and inhibits their 
enzymatic activity leading to an 
arrest in the G1 phase of the cell 
cycle. 
Chromatin 
Immuno-
precipitation 
(ChIP) 
(Adachi et al., 
2007) 
 
Table 8  Foxo1 Target Genes Involved In Regulation of The Cell Cycle Included in 
Analysis 
 
 
3.4.2  End Point RT-PCR Validation of Primer Sets for Foxo1 Target Genes 
 
Forward and reverse primers were designed for the selected Foxo1 target genes to 
enable analysis of mRNA transcripts by end-point RT-PCR and qRT-PCR in murine 
C2C12 myotubes and rat muscle.  All primer pairs were tested using a gradient 
annealing temperature programme to find the optimum annealing temperature for 
each individual primer pair (data not shown).  RT-PCR followed by 2% agarose gel 
electrophoresis (outlined in 2.6.6) confirmed that all primer pairs amplified a PCR 
product of the correct size at an annealing temperature of 61 °C (figure 16 A).  An RT- 
template was tested with each primer pair and confirmed no amplification from 
genomic DNA by the primer sets (figure 16 B). 
All PCR products were sequenced (method outlined in 2.6.7).  The resulting sequences 
were subject to a BLAST search, which showed that the sequence derived for each PCR 
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product was specific to their target gene, further confirming primer specificity 
(sequencing data is compiled in appendix 6). 
 
 
 
Figure 16  Specificity of Primer Sets for Foxo1 Target Genes  
End-point RT-PCR Followed by 2% agarose gel electrophoresis shows single bands of 
the correct size for each of the primer pairs in mouse and rat (A).  An RT- template was 
tested with each primer set to look for amplification of genomic DNA (B) and was 
negative in each case.  A molecular weight hyperladder was run on each gel, whose 
band positions for 100-400 base pairs (bp) are shown. 
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3.4.3  Determination of Primer Efficiency in qRT-PCR 
 
The amplification efficiency of all primer sets for Foxo1 target genes was assessed 
using qRT-PCR.  As quantification is based on the relationship between the initial 
amount of template and the cycle threshold (Ct) value obtained during amplification, 
two criteria must be met to allow accurate and reproducible quantification of 
transcripts.  Firstly, the amplification efficiency of the primer pairs must be determined 
to ensure that the template doubles with each cycle of the reaction, which is vital for 
the accurate analyses of the data.  Secondly, amplification of a single product and not of 
any contaminating products or the formation of primer dimers was determined using a 
melt curve analysis since SYBR green binds non-specifically to double stranded DNA.  2-
fold serial dilutions of a cDNA template were used to generate standard curves (method 
outlined in 2.6.9).  Using the equation of the linear regression line, together with the 
coefficient of determination (R2) the efficiency of the primers was calculated.  The 
standard curves generated for each of the primer pairs can be found in appendix 7.  The 
efficiency of all the primer sets was between 90 and 110%, as recommended for use in 
qRT-PCR by BioRad.  The calculated efficiency for each primer set is shown in table 9. 
Primer dimer formation or co-amplification of non-specific products was assessed by 
melt-curve analysis, where these would appear as additional peaks.  Melt curve analysis 
showed no evidence of non-specific amplification by any of the primer sets.  Melt 
curves for each of the primer sets can be found in appendix 8. 
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Table 9 Efficiency of Amplification During qRT-PCR for Foxo Target Gene Pairs  
2-fold serial dilutions of a template cDNA (from control, untreated tissue) were used to 
generate a standard curve for each primer set.  Amplification efficiency was calculated 
from the gradient of the linear regression line of these curves.  For subsequent analysis 
an optimum efficiency of between 90 and 105% was required, and achieved for all 
primer pairs. 
 
3.4.4  Changes in Transcript Levels of Foxo1 Target Genes with Atrophy 
 
In order to compare the glucose starvation in vitro and functional atrophy in vivo 
models of atrophy, qRT-PCR was used to measure the transcript levels of Foxo1 target 
genes before and after treatment.  The patterns of change in these transcripts would 
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give insight into whether the different methods of producing atrophy shared similar 
modes of action.  Foxo1 target genes were chosen as this transcription factor has been 
shown to play a central role in skeletal muscle atrophy.  Figure 17 shows the changes in 
transcript levels for each of the target genes following each atrophy inducing treatment.  
Relative transcript abundance was calculated using the 2-ΔΔCT method.  The mean 
amplification of Rn18s and Polr2a was used as a reference against which all the results 
were normalised.  Differences between the mean CT value of the two reference genes 
and the target gene CT value was quantified in each sample.  The difference between 
two samples was then calculated as a fold-change.  Genes were grouped according to 
their biological processes defined by associated Gene Ontology Terms; Metabolic 
Process (A), Programmed Cell Death (B), Regulation of Cell Cycle (C) and Ubiquitin-
Protein Ligase Activity (D). 
Changes in transcript within treatment groups were consistent, reflected in figure 17 
by small standard errors, even with large changes e.g. Ccnb1, Plk1.  Treatment with Dex 
gave relatively small changes in transcript level when compared to glucose starvation 
and electrical stimulation.  Even when changes were found to be significant the changes 
were less than 2-fold, with the exception of Fbxo32, which was still only 2.6-fold 
increase with Dex treatment.  These relatively small changes are consistent with the 
fact that Dex treatment gave no significant change in myotube CSA as seen in figure 12.   
Transcript changes show a large degree of variation between glucose starvation and 
electrical stimulation.  In only four of the 12 genes the transcripts change in the same 
direction with each treatment; Lpl, Bcl2l11, Sod2 and Fbxo32.  Furthermore, whilst the 
direction of change is the same, the degree of change is different.  In the case of Lpl, 
glucose starvation gave less than a 3-fold increase in transcript level, whereas electrical 
simulation produced an almost 6-fold increase.  This degree of variation in transcript 
level change is evident in each of the four groups of genes.  In particular in the 
regulation of cell cycle group (figure 17, panel C).  Here Ccnb1 shows an almost 6.5-fold 
decrease in transcript level on treatment with glucose-free media, but a 3.5-fold 
increase with electrical stimulation.  Also, Plk1 shows around a 7.5-fold decrease in 
transcript level with treatment with glucose starvation but around a 3.5-fold increase 
with electrical stimulation.  The differences in transcript changes with glucose 
starvation and electrical stimulation and possible explanations for them are discussed 
in detail in 3.5.3. 
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Figure 17  Comparison of Transcript Levels for Foxo1 Target Genes Following 
Atrophy Inducing Treatment in In-Vitro & In-Vivo Models 
Mean fold changes following treatment are shown for transcripts measured using qRT-
PCR and normalised to the mean of two housekeeping genes (Rn18s and Polr2a).  In-
vitro atrophy of C2C12 myotubes was induced by starvation via glucose free media for 
24 hours (Blue) or treatment with 1μM dexamethasone for 24 hours (Red).  Graphs 
show fold changes in transcripts relative to the control group cultured for 24 hours in 
normal media.  In-vivo results relate to TA muscle tissue which was electrically 
stimulated at 20Hz continuously for 7 days (Green).  Graphs shows fold changes 
relative to the unstimulated, contralateral control TA.  Genes were grouped according 
to their biological processes defined by associated Gene Ontology Terms; Metabolic 
Process (A), Programmed Cell Death (B), Regulation of Cell Cycle (C) and Ubiquitin-
Protein Ligase Activity (D). Each treatment group contains an n number of 6, with error 
bars indicating standard error.  Statistically significant fold changes (p<0.05 following 
ANOVA statistical test) are indicated by *. Error bars indicate SEM. 
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3.5  Discussion 
 
In vivo and In vitro models of atrophy were established; Incubation of myotube cell 
cultures for 24 hours with glucose-free media and 24 hours with 1μM Dexamethasone 
(Dex), as well as 7 days of continuous electrical stimulation at a frequency of 20Hz on 
the rat Tibialis anterior muscle in vivo.  The transcriptional profile of Foxo1 target genes 
following treatment in vitro and in vivo were measured in order to compare the effects 
of the different models and determine whether the models show signs of convergence. 
 
3.5.1  Glucose Starvation but not Dex Treatment Induced Atrophy in C2C12 Myotubes 
 
Incubation for 24 hours in glucose-free media produced a significant 56% decrease in 
mean CSA in C2C12 myotubes (figure 12).  This model was adapted from the study 
conducted by Sandri et al in which they 'starved' myotube cultures by replacing the 
culture media with PBS for 6 hours (Sandri et al., 2004).  They noted a 60% decrease in 
myotube diameter following treatment.  This approach was tested in a pilot study but 
the level of apoptosis present following treatment, made evident by large numbers of 
free-floating and single cells, might have interfered with any results produced by this 
model.  'Starvation' of myotubes by removal of growth media and replacement with 
PBS for 6 hours has been repeated in studies subsequently (Lagirand-Cantaloube et al., 
2009), showing atrophy induction without mention of apoptosis.  Atrophy has also 
been observed in studies  that have used serum starvation of myotubes to investigate 
insulin signalling (Giraud et al., 2007).  Others have used a model where the 
differentiation media is not replenished (Stevenson et al., 2005) leading to a 53% 
reduction in diameter.  Surprisingly, the removal of only glucose from cultured 
myotubes with the aim of studying muscle atrophy has not been studied before now.  
The induction of atrophy in myotubes using this model is a novel finding.  Interestingly, 
other studies have also shown that high glucose culture media stimulated protein 
degradation through the ubiquitin–proteasome pathway and also inhibited protein 
synthesis (Russell et al., 2009) suggesting that the levels of extracellular glucose may 
play a central role in the balance of protein synthesis and degradation within the 
muscle fibre. 
In contrast, treatment with 1μM Dex for 24 hours gave no significant reduction in 
myotube CSA (figure 12).  This is in contrast findings from other studies; Sandri et al 
observed a 40% decrease in myotube diameter following the same treatment (Sandri et 
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al., 2004).  However other studies have used increasing concentrations of Dex for 24 
hours and confirmed our finding that there was no significant decrease in myotube 
diameter with 1μM Dex (Stitt et al., 2004) and that significant decreases in myotube 
CSA were apparent following treatment with 10μM and above (Stitt et al., 2004).  This 
suggests that in this study the concentration of Dex used was not high enough to induce 
atrophy, and if repeated a concentration of 10 or even 100μM may be more suitable 
and would be more likely to induce atrophy.  As a result of this the transcriptional 
changes seen with treatment of 1μM Dex were negligible (figure 17) and not be 
discussed further. 
 
3.5.2  Continuous Electrical Stimulation Produces Atrophy Without Damage to the 
Muscle 
 
Very little evidence of nerve damage was observed in any of the Haematoxylin and 
eosin stained histological sections following stimulation (figure 13).  Continuous 
electrical stimulation at a frequency of 20Hz for 7 days produced a significant 12.64% 
decrease in muscle weight when compared to the unstimulated contra-lateral control 
(figure 14).  When the CSA of muscle fibres was analysed a difference of 17.18% in the 
mean values was found between the stimulated and control muscles (figure 15).  
Previous studies have shown that stimulation at 20Hz revealed no damage to muscle 
after 9 and up to 61 days (Jarvis et al., 1996).  This study also showed that this 
stimulation pattern produced atrophy of the Tibialis anterior muscle with a 51% mean 
reduction in weight following 55-61 days of stimulation.  The conclusion from this 
study stated that there was a switch in muscle fibre type with continuous electrical 
stimulation from fast to slow.  This switch in fibre type has been shown subsequently in 
unpublished data produced by Dr. Lauren Fisher (Fisher, 2010), and apparent as early 
as only one week of stimulation.  Slow twitch fibres are inherently smaller in cross 
section (Jarvis et al., 1996) and the switch of some fibres from fast to slow may go some 
way to explain the change in size of the muscle as a whole.  However, Jarvis et al also 
showed a decrease in mean fibre CSA in the fast twitch fibres following stimulation.  
One explanation for this change in size may be to facilitate diffusion of oxygen and 
nutrients, whose demand increases with electrical stimulation (Eisenberg et al., 1984, 
Hepple et al., 2000).  This theory was further strengthened by the observation of 
increased capillary density, with many fibres deeply indented by capillaries (Joplin et 
al., 1987, Shen et al., 2009).  The idea of the muscle adapting due to functional demands 
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during electrical stimulation prompted the phrase 'functional atrophy'.  To the best of 
our knowledge, the use of electrical stimulation with the aim of producing and studying 
skeletal muscle atrophy is a novel model. 
 
3.5.3  Transcriptional Changes Reveal Differences in the Models of Atrophy 
 
While it was observed that treatment with glucose-free media in vitro and 20Hz 
continuous electrical stimulation of skeletal muscle in vivo both induce atrophy, the 
differences in the changes in key transcripts suggested that the mechanisms behind 
these modes of atrophy are different (figure 17).  This was not completely unexpected 
as the in vitro model employed a calorie restricting state on immature muscle cells 
whereas the electrical stimulation model employed an increase in contractile activity in 
an animal model, where the diet was non-restricted.  Although for the muscle itself the 
great increase in activity must lend to greatly increase the demand and usage of fuel, 
and thus potentially cause a relative ‘starvation’. Additionally, the maturation state of 
the cells involved in each of the models i.e. in vitro cells being immature multinucleate 
precursors of muscle fibres where as in vivo the muscle fibres are fully mature and form 
part of a larger tissue with a mixed population of cells, may go some way to explaining 
the differences observed in the transcript changes with each treatment. 
A marked difference was observed in transcripts which were functionally involved in 
the regulation of cell cycle.  Transcript levels of each of the four genes (Ccnd2, Ccnb1, 
Plk1 and Cdkn1b) showed no significant change following treatment with Dex for 24 
hours.  This is most likely a reflection of the concentration of Dex used to treat the 
myotubes, discussed in 3.5.1.  However treatment of myotubes with glucose-free media 
and electrical stimulation of skeletal muscle in rat produced very different results, in 
particular with Ccnb1 and Plk1.  Glucose starvation produced a significant 6.5- and 7.5-
fold decrease in transcript levels of Ccnb1 and Plk1 respectively.  However electrical 
stimulation produced an opposing 3.5-fold increase in the transcript levels of these 
genes following treatment.  Cyclin B1 (Ccnb1) is a regulatory protein involved in 
mitosis and contributes to the switch-like all or none behaviour of the cell in deciding 
to commit to mitosis.  Once activated, Ccnb1 promotes several of the events of early 
mitosis.  Before mitosis almost all Ccnb1 in the cell is located in the cytoplasm, but in 
late prophase it relocates to the nucleus following phosphorylation (Hagting et al., 
1999).  Phosphorylation also prevents export from the nucleus by blocking the nuclear 
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export signal (Yang et al., 2001).  Ccnb1 is phosphorylated by Polo kinase (Plk1) 
(Hagting et al., 1999).   
 
Ccnd2 transcript levels showed no significant change following any of the treatments in 
vitro or in vivo. However, Cdkn1b showed a significant 2-fold increase with glucose 
starvation compared to no significant increase with electrical stimulation.  Cdkn1b 
(also known as p27kip1) encodes a protein which belongs to the Cip/Kip family of cyclin 
dependent kinase (Cdk) inhibitor proteins. The encoded protein binds to and prevents 
the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controls the cell 
cycle progression at G1. It is often referred to as a cell cycle inhibitor protein because 
its major function is to stop or slow down the cell division cycle (Polyak et al., 1994).   
 
The transcriptional changes in these genes following glucose starvation indicate a 
down regulation of mitosis.  This cell cycle arrest has been observed in other studies 
involving starving myotubes by non replacement of differentiation media (Stevenson et 
al., 2005).  Mitotic figures are rarely seen in muscle fibers in vivo, because myonuclei 
are postmitotic and unable to proliferate (Lash et al., 1957, Collins and Partridge, 
2005).  However, satellite cells have long been recognized as reserve myoblasts and a 
source of new myonuclei during growth and regeneration (Moss and Leblond, 1971, 
Collins and Partridge, 2005).  Studies have shown that the number of myonuclei 
decreases upon denervation in vivo (Schmalbruch and Lewis, 2000).  This may be due 
to the reduction in protein synthesis associated with muscle atrophy. Indeed it has 
been noted previously that protein synthesis does increase with continuous electrical 
stimulation, even though there must be a more than compensatory increase in protein 
degradation, since the total mass of the muscle declines (Joplin et al., 1987).  This 
increase in protein synthesis may be due to the fibre type switch discussed in 3.5.2.  
This increase in protein synthesis requires an increase in ribosomal RNA, which 
already accounts for 80% of all RNA present in the muscle.  This would be facilitated by 
an increase in myonuclei number, which has been observed with continuous electrical 
stimulation in previous studies (Joplin et al., 1987). 
The transcripts for genes involved in metabolic processes were also likely to give 
different changes in transcript following treatments as the metabolic demands placed 
upon the cells in each model were almost opposite.  An in vitro environment where the 
muscle cells have not began to contract and the model then involves starving the cells 
was bound to have opposing metabolic effects to those in a model where the cells form 
67 
 
part of mature muscle fibre and are being activated to contract above and beyond 
normal physiological levels.   This increase in the metabolic demands was reflected  in 
an increase in the transcript levels of each of the three genes involved in metabolic 
processes following electrical stimulation, including those involved in carbohydrate 
(G6pc3) and in particular lipid (Lpl) metabolism, where Lpl showed an almost 6-fold 
increase.  This increase in fatty acid oxidation has been demonstrated in previous 
studies following continuous electrical stimulation for 7 days (Bonen et al., 1999).    
However, Lpl was the only transcript from the metabolic process group to increase 
with glucose starvation of cultured myotubes.  This may have been due to the lack of 
available glucose and so the cells look for alternative fuel sources.  The reduction in 
transcript level of G6pc3 is further evidence to support this observation.  Indeed, other 
studies have shown an increase in fatty acid oxidation in myotubes following 
starvation, which is mediated by AMPK; a protein known to maintain the energy 
balance in cells (Carling, 2004). 
The transcript levels of the E3 ubiquitin ligases Trim63 and Fbxo32 both increase 
following 20Hz stimulation, suggesting they play a part in the protein breakdown 
associated with the functional changes involved in this model.  This observation that 
Trim63 and Fbxo32 increase in expression following continuous electrical stimulation 
is a novel finding.  There have been studies using electrical stimulation to try and 
counteract the effects of denervation (Russo et al., 2010).  These reported a blunting of 
the over expression of Trim63 and Fbxo32, which is normally present with denervation 
when electrical stimulation is added.  However the stimulation pattern used in that 
study was different from the pattern we used (20Hz continuously for 7 days).  The 
electrical stimulation sessions were applied daily for 6 days, beginning 24 h after 
denervation, and produced 200 maximal contractions of the TA muscle. These maximal 
contractions were divided into four sets of 50 contractions, with a duration of 3.2 min 
per set and 10 min rest (without ES) between sets.  This pattern was chosen to 
minimise muscle fatigue and may explain the differences seen in the changes in 
expression of Trim63 and Fbxo32.   
Following glucose starvation of myotubes Fbxo32 transcript levels increase but not 
Trim63.  This is in agreement with other studies where an increase in Fbxo32 is 
reported following starvation of myotubes (Sandri et al., 2004).  Although studies have 
shown that Trim63 expression increases with Dex treatment of myotubes (Stitt et al., 
2004), there is no evidence in the literature that it is involved in the atrophy process 
induced via starvation. The control of Trim63 and Fbxo32 expression may involve 
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Myog and the Hdac dependent pathway as shown in figure 6, and the effectors of Myog 
may differ between the in vitro and in vivo models of atrophy in response to different 
physiological conditions. 
 
3.6  Summary 
 
 
The data has shown that two very different methods can produce atrophy in muscle, 
one which is based on calorific restriction (treatment with glucose free media) and one 
which involves artificially increased activity (electrical stimulation).  The 
transcriptional profiling of tissue taken from both these models suggests that the 
mechanisms by which the atrophy is induced may be different, based on the differential 
response of key target genes linked to atrophy pathways. 
 
However, neither model accurately reflects the physiological state of clinical muscle 
atrophy, where the most common cause is inactivity of muscle. Thus it was concluded 
from these findings that a model based on muscle inactivity was required in order to 
gain a greater insight into the mechanisms behind muscle atrophy in a more clinically 
relevant state. 
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Chapter 4: Development of An In-Vivo Atrophy Model Incorporating 
Tetrodotoxin (TTX) Block of the Common Peroneal Nerve  
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4.1 Introduction 
 
In chapter 3, glucose starvation of C2C12 myotubes and electrical stimulation of 
skeletal muscle were used to induce atrophy.  There was evidence that these two 
models produced atrophy via contrasting cellular mechanisms, despite some 
concordant transcriptional changes in foxo1 target genes.  Although calorific restriction 
and imposed electrical stimulation have both been shown to induce atrophy neither is 
representative of a physiological state of inactivity in muscle.  As discussed in 1.4.1 in 
vitro models of atrophy provide excellent models to highlight some of the mechanisms 
involved.  However, the study of the in vivo response is vital in directing research 
towards a therapeutic target for muscle atrophy.  In vivo models that represent specific 
physiological states such as functional atrophy via electrical stimulation or atrophy 
associated with specific disease states such as rodent models of cancer cachexia 
(Busquets et al., 2004) are limited in translating their findings across other clinical 
causes of atrophy.  However an in vivo model of muscle inactivity, which can be used to 
investigate the molecular mechanisms of atrophy independent of a specific disease 
state, could give a clearer picture of the normal processes involved in the changes in 
muscle size.  The mechanisms involved may translate over a larger range of atrophy 
models, and move us closer to the development of rational therapeutic interventions. 
Other studies have adopted in vivo models of disuse atrophy including denervation 
(Tang and Goldman, 2006), hindlimb suspension (Stevenson et al., 2003) or joint 
immobilisation (Yasuda et al., 2005).  However, each of these models has drawbacks.  
Denervation may still impact on muscle through neurotrophic factors released with 
nerve damage (Midrio, 2006), and is limited in its capacity to investigate recovery from 
atrophy.  Hindlimb suspension involves unloading of the muscle without restriction of 
activity and it has been suggested that this model may be better suited to study muscle 
changes with microgravity during spaceflight (Holecek, 2012).  Joint immobilisation, 
such as limb casting has been shown to cause systemic stress responses, which may 
interfere with changes induced on the muscle by immobilisation (Holecek, 2012).  
The aim of this chapter was to set up an in vivo model of atrophy which avoids these 
drawbacks.  A tetrodotoxin (TTX) nerve block model would not damage the nerve while 
completely blocking muscle activity and without imposing undue stress upon the 
animal.  The block could also be time-limited in order to study recovery from atrophy.  
Once established, tissue samples collected from this experiment could be analysed in 
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order to elucidate the cellular and molecular changes involved in inactivity induced 
atrophy. 
 
4.2  Pilot Study of TTX Nerve Block Atrophy Model 
 
A pilot study was designed in order to verify the TTX experimental model, and 
established that muscle atrophy was evident in the absence of muscle damage and 
without detriment to the animal. The pilot study consisted of 4 animals, which had a 
nerve block in place for 7 days (n=2) or 14 days (n=2).  The nerve cuffs were assembled 
in-house.  Full details of the nerve cuff implant, surgical procedures and the protocol 
used can be found in section 2.3. 
 
4.2.1  Efficiency of Delivery of TTX by Osmotic Pump 
 
As this model relies on the continuous delivery of TTX to the nerve cuff, initial tests 
were carried out to ascertain whether the mini osmotic pump was functioning at the 
correct flow rate.  This was achieved by calculating the amount of TTX that was ejected 
from the pump over the experimental period.  Table 10 details the efficiency of each of 
the four pumps used in the pilot study.  The volume of TTX contained in the pump at 
day 0 was calculated by weighing the empty and full pump prior to implantation.  Upon 
cessation of the nerve blockade the pumps were removed from the animal.  The 
remaining liquid was then removed from the pump via a 1 ml syringe and blunt-tipped, 
27 gauge needle and weighed.  Comparing the volume at day 0 and the volume at 
termination gave the volume of liquid ejected from the pump during the experimental 
period.  From this, the flow rate could be calculated (μl/hour).  The desired flow rate 
was 0.5 μl/hour, the actual flow rates were between 0.48 and 0.51 μl/hour, which was 
acceptable.  The flow rates were monitored for each of the pumps used in any 
subsequent implants. 
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Table 10  Review of Osmotic Pump Efficiency 
Calculated flow rate for osmotic pumps over experimental period. Volumes at day 0 
were calculated by weighing the empty and full pump.  Volumes at termination show 
remaining weight of TTX solution after the pump had been removed from the animal.  
 
 
4.2.2  Histological Examination of Muscle Showed Little Evidence of Nerve Damage 
 
Analysis of histological sections of both treated and untreated muscle tissue allowed 
evidence of nerve damage to be quantified.  Frozen sections were stained with 
Haematoxylin and eosin (See 2.5.1), which distinguishes muscle fibres and nuclei.  
Evidence of nerve damage would appear in the sections as the migration of nuclei from 
the periphery of the fibre into the interior of the fibre (as shown in figure 13, panel C) 
as well as areas of small, non-uniformly shaped fibres or the infiltration of 
inflammatory cells.  Figure 18 shows histological sections from each of the four pilot 
study animals.  Very little evidence of nerve damage was observed in any of the 
histological sections with most sections containing no denervated fibres, meaning that 
our methods of implantation caused no significant damage to the muscle fibres. 
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Figure 18  Cross Sectional Photomicrographs of Untreated and TTX Treated TA 
Muscle 
Haematoxylin and eosin stain on sectioned muscle tissue (10μm) from rats 1 and 2, 
where the TTX block was in place for 1 week and rats 3 and 4 where the TTX block was 
in place for 2 weeks. No significant morphological changes indicative of nerve damage 
were evident in fibres from muscle subjected to nerve block by TTX. 
 
 
4.2.3  Nerve Block Induces Progressive Muscle Atrophy 
 
In order to assess the degree of muscle atrophy induced during the TTX nerve block, 
the  changes in weight and cross sectional area were measured in treated muscles and 
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compared to control.  TA muscles were weighed immediately after harvesting.  Figure 
19 A shows the weight of both the untreated control and treated muscles of the four 
pilot study animals.  The differences in muscle weight between treated and contra-
lateral control limbs are also expressed as a percentage in Figure 19 B.   
 
 
Figure 19  Progressive Muscle Fibre Atrophy Over 2 weeks of TTX Treatment 
Graphs show changes in TA muscle weight following TTX nerve block for 1 week (blue) 
and 2 weeks (red). A; Individual muscle weights of control (C) and treated (T) TA 
muscles.  Panel B; Percentage difference in weight, comparing untreated and treated TA 
muscles in each animal.  Panel C; Individual Mean CSA of control (C) and treated (T) TA 
muscles. Panel D; Percentage difference in cross sectional area (CSA) of muscle fibres 
comparing untreated and treated TA muscles.  Fibre Cross Sectional Areas (CSA) were 
calculated by measuring the diameter of fibres from photomicrographs of 
Haematoxylin and eosin stained muscle sections (10μm). Panel E; Individual muscle 
weights normalised to animal body weight.  
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Following 7 days of nerve block, a decrease of 28.1% and 27.3% was observed in rats 1 
and 2 respectively.  Following 14 days a greater reduction in muscle weight was 
observed, with a decrease of 52.85 and 47.84% in rats 3 and 4 respectively.  From these 
values it can be seen that TTX nerve block induced a progressive muscle atrophy over 
the experimental time period.  Figure 19, panel A shows that the contra-lateral control 
TA muscles in rats 3 and 4 were larger than the equivalent in rats 1 and 2. Therefore to 
try to normalise these values, muscle weights were normalised to whole body weight to 
ensure that these differences would not result in misleading data (figure 19 E). 
Expression of the muscle weights as a percentage of whole body weight showed that in 
rats that were blocked for 7 days, the treated TA muscles were 0.13 and 0.14% of 
whole body weight, whereas the treated muscles in rats that were blocked for 14 days 
were both 0.11% of whole body weight.  This suggests a progressive decrease in muscle 
weight regardless of the differences in the weight of the control TA muscles, and 
therefore a progressive increase in muscle atrophy after a further 7 days of the TTX 
nerve block .   
Cross sectional areas (CSA) of fibres were also measured from Haematoxylin and eosin 
stained muscle sections as outlined in 2.5.2, (figure 19 D).  The values are expressed as 
a percentage difference between treated and contra-lateral control muscles.  All four 
animals showed a decrease in fibre CSA following nerve block, ranging from 27.3% to 
53.9%.  The progression in the degree of atrophy is less clear when looking at fibre CSA 
compared with muscle weights, as the inter-individual variation is greater.  However, 
the mean percentage decrease in CSA for the two animals blocked for 7 days was 
35.2%, compared with 43.9% following 14 days block, suggestive of a progression in 
muscle atrophy after a further 7 days of nerve block. 
 
4.2.4  Transcript Levels of Trim63 and Fbxo32 Increase with Muscle Atrophy 
 
As the aim of the subsequent nerve block study was to analyse the transcriptomic 
response to muscle inactivity, it was important to ascertain whether the nerve block 
model induced changes in transcript levels of known atrophy genes.  The transcript 
levels of two ubiquitin E3 ligases (Fbxo32 and Trim63), which are known to be 
fundamental in the process of skeletal muscle atrophy, were measured using qRT-PCR 
using the methods outlined in 2.6.8. The results (shown in figure 20) are displayed 
using the 2-ΔCT method, where differences between the mean reference genes CT values 
and the target gene CT value was quantified individually for each muscle sample. 
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Figure 20  Transcript Levels of Fbxo32 and Trim63 Increase In Response to a TTX 
block 
Transcript levels of Fbxo32 (A) and Trim63 (B) in individual TA muscle samples, 
measured using qRT-PCR and normalised to the mean of two housekeeping genes 
(Rn18s and Polr2a).  Bars indicate untreated control TA levels (C) and levels following 
treatment with TTX (T) for 1 week (blue) or 2 weeks (red). 
 
The transcript levels of Fbxo32 (figure 20 A) increase markedly following 7 days of 
nerve block (mean 14-fold over control muscle).  However, after 14 days of block 
Fbxo32 levels fall back to around 2-fold that of control.  Transcript levels of Trim63 
(figure 20 B) showed greater variation between individuals than those of Fbxo32.  An 
increase in Trim63 was evident after both 7 and 14 days nerve block, with some 
indication this may also reduce during the second week. This was surprising as muscle 
weight and morphology (4.2.3) suggested that the degree of atrophy is progressive 
during the second week of block.  However, figure 20 shows that the transcript levels of 
the two ubiquitin ligases does not increase progressively over the two weeks.  This 
result did confirm that nerve block altered transcript levels and also hinted at temporal 
differences in those changes.  Furthermore, it demonstrates that transcriptional 
responses are not a simple transition from a control pattern to an atrophy pattern but 
rather a dynamic process that requires sampling at more than one time point. 
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4.3  Full Scale In-Vivo TTX Nerve Block Study 
 
Following the successful pilot study in which progressive muscle atrophy was induced 
by TTX nerve block over the experimental time period without damage or degeneration 
of the muscle fibres, the experimental numbers and time periods were increased.  The 
subsequent study consisted of animals where the nerve block was in place for 3, 7 or 14 
days (n=6). The study also included a TTX nerve block for 14 days following which the 
block was reversed, allowing the muscle to recover without detriment over the 
subsequent 7 days. 
 
4.3.1  Histological Analysis of Muscle Revealed Little Evidence of Nerve Damage 
 
Analysis of histological sections of both treated and untreated muscle tissue allowed 
evidence of nerve damage to be quantified.  Frozen sections were stained with 
Haematoxylin and eosin (See 2.5.1) to assess evidence of nerve damage (as described in 
4.2.2).  Figure 18 shows representative histological sections for each of the full scale 
experimental groups.  Very little evidence of nerve damage was observed in any of the 
histological sections with most sections containing no denervated fibres, confirming 
that our methods of implantation caused no significant damage to the muscle fibres in 
this larger study. 
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Figure 21  Cross Sectional Photomicrographs of Untreated and TTX Treated TA 
Muscle 
Haematoxylin and eosin stain on sections of untreated and treated TA muscle tissue 
(10μm) from sham control (A), 3 days nerve block (B), 7 days nerve block (C), 14 days 
nerve block (D) and 14 days nerve block with 7 days recovery (E).  No significant 
morphological changes indicative of nerve damage were evident in fibres from muscle 
subjected to nerve block by TTX. 
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4.3.2  Evidence of Muscle Atrophy In Full TTX Nerve Block Study 
 
The degree of muscle atrophy was measured by changes in muscle weight and cross 
sectional area.  Mean weights for untreated and treated muscles in each experimental 
group are expressed as a percentage of whole body weights of animals to normalise 
measurements to differing animal sizes (figure 22 A) (n=6).  Untreated muscles showed 
no significant change throughout the experimental time period when compared with 
the sham-operated control.  TTX nerve block produced a statistically significant 
decrease in muscle weight, which progresses following 3, 7 and 14 days of nerve block.  
When values are expressed as a percentage difference between untreated and treated 
muscles (figure 22 C) it can be seen that mean muscle weights decrease following 
treatment by 7% (+/- 1%),  29% (+/- 2%)  and 51% (+/- 1%) after 3, 7 and 14 days 
nerve block respectively.    These changes can be compared to a 13% decrease in 
muscle weight following 20Hz continuous electrical stimulation for 7 days.  This is less 
than half of the atrophy produced with TTX nerve block..  With 7 days of recovery from 
14 days TTX treatment, the muscle weight returns to only 24% less than the control.  
The level of recovery confirms that the nerve block induces muscle atrophy without 
detrimental effects on the muscle tissue as it was possible for the muscle to recover 
over the 7 days and for the effects of atrophy to be reversed to a degree. Furthermore 
the data shows that the process of atrophy and restoration of mass follow a similar 
time course. 
The level of muscle atrophy could also be determined by analysing cross sectional areas 
of fibres, measured from Haematoxylin and eosin stained muscle sections as outlined in 
2.5.2.  These are expressed as mean CSAs of the untreated and treated muscles in each 
of the experimental groups (n=6) in figure 22 B and also as a percentage difference 
between treated and untreated muscles in figure 22 D.  The effect of the nerve block on 
CSA was comparable to the effect on muscle weight.  The mean CSA decreased 
following treatment by 18%, 42% and 69% with 3, 7 and 14 days nerve block 
respectively, and with 7 days of recovery the CSA recovered to only 26% less than 
control.  When comparing panels C and D in figure 22 the patterns of change are 
remarkably similar. 
 
 
 
80 
 
 
 
 
Figure 22  Nerve Block Treatment In-Vivo Induces Progressive Decrease in 
Muscle Weight and Fibre Cross Sectional Area that Can Recover Upon Cessation of 
Block 
TA Muscle weight is expressed as a percentage of whole body weight to normalise 
measurements to differing animal sizes (A).  The mean TA weights of the 6 animals 
used in each of the experimental groups with untreated contra-lateral control (Blue) 
and treated (Red).  The difference between untreated and treated TA weights is also 
expressed as a percentage difference (C).  Differences in Fibre Cross Sectional Areas 
(CSA) between untreated and treated TA samples (B) were calculated by measuring the 
diameter of fibres from photomicrographs of haematoxylin and eosin stained muscle 
sections (10μm).  The differences are also expressed as a percentage difference (D).  
n=6, statistically significant (P<0.01 following ANOVA test) differences are indicated 
with *.  Measurements from electrically stimulated (20Hz, 1 week) samples seen in 
figure 14 and 15 have been included for comparison. Error bars indicate SEM. 
 
 
 
4.4  Discussion 
 
To achieve the aim set out in 1.6, a pilot study was designed in which muscle atrophy 
was induced via a TTX nerve cuff which was in place for 7 or 14 days.  Muscle atrophy 
was evident in all four animals in the absence of muscle damage.  This atrophy was 
progressive from 7 to 14 days.  Transcript levels of protein ubiquitin ligases known to 
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be integral to muscle atrophy increased in treated muscles compared to the contra-
lateral controls, providing evidence that our model influences atrophic transcripts 
within the muscle tissue. 
Following a successful pilot study the experimental numbers and time periods were 
increased in order to produce a more thorough profile.  The main study consisted of 
TTX muscle blocks for 3, 7 and 14 days (n=6). The study also included a TTX nerve 
block for 14 days following which the block was reversed, allowing the muscle to 
recover without detriment over the subsequent 7 days.  Progressive muscle atrophy 
was produced while the nerve block was in place, to a maximal 51% loss of muscle 
weight after 14 days.  Following 7 days of recovery the treated muscles regained weight 
to a level of 24% less than the untreated.  Measurement of CSA of muscle fibres in each 
experimental group showed concomitant changes with muscle weight, both in response 
to nerve block and during recovery upon cessation of the nerve block. 
 
4.4.1  TTX Nerve Block Induces Progressive, Recoverable Atrophy 
 
TTX nerve block for 14 days resulted in a maximal 51% loss in mass of the treated TA 
muscle compared to that in the untreated contralateral-control limb (figure 22). This 
can be compared to a smaller 39% loss in rat TA muscle following 21 days of 
denervation (Adhihetty et al., 2007) and only 25% following 14 days of hindlimb 
suspension (Stump et al., 1997).  This less severe atrophy induced by hindlimb 
suspension is due to the fact that this model does not restrict movement of the limb.  
Although the muscle is unloaded, the unrestricted movement may act to maintain some 
muscle mass.  The atrophy observed over the experimental time period of the TTX 
block was progressive with 3 and 7 days of block  reducing the weight of the muscle by 
7% and 29% respectively (figure 22).  Other studies using TTX nerve block to induce 
atrophy reported a 19% reduction in TA weight following 7 days of block (Dupont 
Salter et al., 2003), slightly less than reported here.  However, although the study by 
Dupont Salter et al used the same dosage of TTX, the TTX nerve cuff was applied on the 
sciatic nerve, rather than the common peroneal nerve.  The sciatic nerve is a larger, less 
peripheral nerve that supplies additional muscles including the Lateral gastrocnemius 
(LG), which also atrophied in their study.  This additional supply as well as the 
increased size of the nerve may have served to dilute the potency of the TTX and 
reduced the effect on the TA muscle.  
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The atrophy produced by the common peroneal TTX nerve cuff model was achieved in 
the absence of any histological signs of damage or degeneration of the muscle fibres, 
following analysis of H&E stained muscle sections (figure 21).  It was therefore possible 
to block muscle activity for 14 days, and then reverse the blockade, allowing the muscle 
to recover without detriment over the subsequent 7 days.  The muscle recovered to 
show a reduction of muscle weight of 24% (figure 22).  This represents less atrophy 
than the equivalent 7 days of TTX block, suggesting that the process of recovery may be 
faster than that of atrophy. 
 
4.4.2  Summary 
 
Although studies have used TTX nerve block to induce atrophy in skeletal muscle 
previously (Buffelli et al., 1997, Dupont Salter et al., 2003), these studies have focused 
on the fibre-type changes produced with the atrophy (Dupont Salter et al., 2003) or the 
contractile property changes (Buffelli et al., 1997).  To our knowledge, this is the first 
study to use the TTX nerve block model of atrophy with the aim of analysing the 
molecular and cellular changes involved during atrophy and in the recovery from 
atrophy.  In order to achieve this aim samples from the main nerve block study were  
analysed using microarray.  To provide a genome-wide and time-resolved profile of the 
transcriptional changes involved in inactivity atrophy and recovery.  These studies are 
described in chapter 5. 
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Chapter 5: Microarray Analysis of In Vivo Skeletal Muscle Atrophy 
Via Nerve block and Electrical Stimulation 
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5.1 Introduction 
 
Both the ‘functional' atrophy and TTX nerve block in vivo models of muscle atrophy 
undoubtedly produce a decrease in muscle weight. However, whether there is a 
universal mechanism involved in the molecular pathways leading to muscle atrophy in 
both models is presently unknown.  Identification of key players in the control of 
muscle atrophy and their response to the different models is fundamental if these 
pathways are to be delineated and therapeutic targets identified. 
Previously studies have used microarray analysis to study in vivo models of atrophy.  
Several have focused on single time points during atrophy (Bey et al., 2003, Stein et al., 
2002), while other have looked over a time course (Stevenson et al., 2003).  However 
these studies employ the hindlimb suspension model which, as previously discussed 
has several drawbacks when investigating inactivity induced atrophy including the fact 
that the limbs are allowed to move freely throughout.  Furthermore, perhaps 
surprisingly, there are no experimental reports directed towards uncovering the 
transcriptional response during the process of recovery from atrophy. 
Microarray analysis was used to compare genome-wide transcript changes following 3, 
7 and 14 days of nerve blockade, in addition to 14 days of nerve block with 7 days of 
recovery, or 7 days electrical stimulation at 20Hz.  In collaboration with Pfizer, 
microarray analysis using the Affymetrix GeneChip® Rat Genome 230 2.0 Array was 
used to measure over 30,000 transcripts and variants from over 28,000 well-
substantiated rat genes.  The aim of this analysis was to identify cellular signalling 
pathways that were integral to the process of skeletal muscle atrophy.  
 
5.2  Normalisation & Quality Control of Microarray Data 
 
Untreated and TTX treated muscle samples from the pilot study of four animals, two 
having the nerve bock in place for 7 days and two for 14 days, were initially sent for 
processing.  Following completion of the main study, only the treated muscle samples 
from each animal and a sham-operated control sample group (n=4) were subject to 
microarray analysis.  The untreated control samples from the pilot study were only 
included in the initial quality control stages of the microarray analysis and were 
excluded from subsequent analysis.  Full details of all samples subject to microarray 
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analysis can be found in table 5.  In the main TTX nerve block study outlined in 4.3 an n 
of 6 was obtained for real time PCR analysis.  Based on previous experience of 
Affymetrix data (Pfizer) an n of 4 is sufficient for microarray.  For each experimental 
group, the animals that showed the largest and smallest changes in muscle weight 
following TTX nerve block or 20Hz electrical stimulation were excluded from the 
microarray study. 
The RAW data in the form of .CEL files was read into the bioconductor package within R 
(full details of the software used for analysis can be found in 2.7.2).  Data was 
normalised via the RMA (Robust Multichip Average) method (Irizarry et al., 2003) 
which consists of three steps; a background adjustment, quantile normalization and 
finally summarization.  The quality of the arrays both before and after normalisation 
was assessed using arrayQualityMetrics within Bioconductor (5.2.1-3) and were found 
to be of sufficient quality for subsequent analysis. 
 
5.2.1  Spatial Distribution of Feature Intensities 
 
A false colour representation of the spatial distribution of feature intensities prior to 
normalisation for each array (figure 23) was used to identify spatial effects that may be 
caused by, for example, gradients in the hybridization chamber, air bubbles or printing 
problems. There were no such anomalies observed in any of the array data sets. 
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Figure 23  False Colour Representations Showing Spatial Distributions of Feature 
Intensities on Each of the 28 Arrays 
The colour scale is shown in the panel on the right, and it is proportional to the ranks of 
the probe intensities. Normally, when the features are distributed randomly on the 
arrays, one expects to see a uniform distribution; sets of control features with 
particularly high or low intensities may stand out.  No Anomalies were observed on our 
array sets. 
 
 
5.2.2  Inter Array Intensity Distributions 
 
The package arrayQualityMetrics produces boxplots of the log2 intensities of each of the 
arrays (figure 24) in order to assess the homogeneity between the arrays pre- and 
post-normalisation. 
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Figure 24  Boxplots Representing Summaries of the Signal Intensity Distributions 
for Affymetrix Gene Chips 
Each box corresponds to one array.  Values are shown pre (A) and post (B) 
normalisation. Typically, one expects the boxes to have similar positions and widths. If 
the distribution of an array is very different from the others, this may indicate an 
experimental problem. Outliers, according to the Kolmogorov-Smirnov statistic 
between each array's distribution and the distribution of the pooled data are marked 
by an asterisk (*).  Array 22, marked with an asterisk represents an array that was not 
included in subsequent analysis.  Normalisation removes batch differences between 
arrays from the main study (1-20) and the pilot arrays (21-28). 
 
 
Boxes are expected to have similar positions and widths. If the distribution of an array 
is very different from the others, this may indicate an experimental problem.  In figure 
24, arrays 1-20 represent the main TTX study while arrays 21-28 are the untreated and 
TTX treated samples from the pilot study.  It was observed that the batch effect from 
combining data from two separate experiments, which is evident in figure 24 panel A, is 
removed following normalisation (panel B).  The outlier marked with an asterisk 
represents an array that was removed from subsequent analysis as this was hybridised 
with a sample from one of the untreated contralateral control muscles of the pilot study 
group.  In later analysis the sham control group of the main TTX study was used as the 
control. 
 
5.2.3  Between Array Comparisons 
 
The ‘Between array comparison’ session within arrayQualityMetrics produces a 
heatmap of between array distances (figure 25), computed as the mean absolute 
difference of the M-value for each pair of arrays. 
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Figure 25  Between Array Comparisons  
False colour heatmap representation of between arrays distances before (A) and after 
(B) normalisation, computed as the median absolute difference of the M-value for each 
pair of arrays.  The colour scale is chosen to cover the range of distances encountered 
in the dataset. Arrays for which the sum of the distances to the others is significantly 
different are detected as outliers (marked by an asterisk). 
 
The dendrogram on this plot can help to find batch effects, as well as reveal clustering 
of the arrays according to biological effects.  Here normalisation removes the batch 
effect which can be seen in panel A where chips 1-20 (main study) show a clear 
distance from chips 21-28 (pilot study).  The outlier array (array 22), marked with an 
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asterisk, which was highlighted previously in figure 24 was removed following 
normalisation.  However since sham controls were available, as discussed in 5.2.2 this 
array was removed from further analysis. 
 
5.3  Preliminary Data Analysis Confirms Clustering of Experimental Groups 
 
Following normalisation and review by arrayQualityMetrics the dataset was put 
forward for preliminary analysis.  The untreated contralateral control samples from the 
pilot study were removed from any subsequent analysis.  This decision was made as 
one of the contralateral controls was highlighted as an outlier in 5.2 and the sham 
control group were deemed of sufficient number and quality to act as the experimental 
control.  This preliminary analysis takes an unbiased view of all the experimental 
arrays and looks for correlations within the data that can be mapped to biological 
effects. 
 
5.3.1  Chip Correlation Heatmap 
 
Expression intensities of all probe sets within an array were compared to intensities on 
all the other arrays to produce an unbiased correlation heatmap of probe set 
expression (Figure 26).  The dendogram revealed two major clusters consisting of 
samples that had undergone nerve block induced atrophy (3, 7 and 14 days) and those 
that had not (sham, recovery and 20Hz electrical stimulation).  The arrays marked with 
an asterisk and highlighted in bold, 3 days atrophy (rat 1745) and recovery (rat 1770), 
seemed to correlate less well with data for the other animals within their experimental 
groups.  However, these animals showed no outlying anomalies in muscle weight 
changes or in the arrayQualityMetrics analysis of the chips, therefore were not 
excluded from subsequent analysis. 
Overall the experimental groups seemed to correlate well; with groups that have been 
exposed to nerve blockade showing a clear difference in transcriptional profile from 
controls and recovery, as well as those that have undergone electrical stimulation. 
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Figure 26  Unbiased Correlation Heatmap of Probe Set Expression Across the 
Whole Genome for Each Array 
Colour scale moves to a darker blue as the correlation coefficient approaches 1 (perfect 
correlation).  Arrays that do not correlate with their experimental groups are marked 
with an asterisk. 
 
5.3.2  Principal Component Analysis 
 
Principal component analysis was used in order to investigate further how the 
experimental groups clustered together.  This involves a mathematical procedure that 
uses an orthogonal transformation to convert a set of observations of possibly 
correlated variables into a set of values of uncorrelated variables called principal 
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components.  Plots in figure 27 show the first two components on the x and y axis 
respectively, which together account for 98.5% of the variance in the data.   
 
 
 
Figure 27  Principal Component Analysis of Experimental Arrays 
Plot showing the first two principal components which account for 98.5% of the 
variance in the data.  B shows the same plot with experimental groups enclosed with 
coloured lines and the outlier marked with an asterisk. 
 
The arrays clustered into two distinct groups based on principal component 2, which 
corresponds to the two major hierachical clusters observed in figure 26.   The 3, 7 and 
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14 days of nerve block groups clustered together.  However, the 3 day nerve block 
group showed more variation than 7 and 14 days, with the outlier marked with an 
asterisk which was also previously observed in figure 26.  Sham control, recovery and 
20Hz electrical stimulation cluster together, as previously observed (figure 26).  
However these groups are also separated along the vertical axis, representing principal 
component 2. The 20Hz electrical stimulation group showed the widest variation along 
the x-axis (principal component 1) and formed a separate, disperse cluster. 
The findings of the principal component analysis confirmed the observations from the 
correlation heatmap in 5.3.1 that the experimental groups seemed to correlate well, 
with groups that have been exposed to nerve blockade showing a clear difference in 
transcriptional profile from controls and recovery, which clustered more closely.  Again 
the 20Hz electrical stimulation formed a distinct group from the nerve blockade groups 
as well as the control and recovery groups, which correlated closely while remaining as 
two distinct groups. 
 
5.4  Differential Expression  Analysis Reveals Atrophy to be a Dynamic Process 
 
Differential expression analysis using the limma package within bioconductor allowed 
whole genome comparisons between experimental groups.  Limma is an R package for 
the analysis of gene expression microarray data for the assessment of differential 
expression. Empirical Bayesian methods are used to provide stable results even when 
the number of arrays is small.  The package was used to compare the experimental 
groups shown in table 11 below. 
 
Comparison 
Number 
First Experimental Group in 
Comparison 
Second Experimental Group in 
Comparison 
1 3 Days Nerve Block  Sham Control  
2 7 Days Nerve Block  Sham Control 
3 14 Days Nerve Block  Sham Control 
4 20Hz Electrical Stimulation  Sham Control  
5 14 Days Block with 7 Days Recovery  Sham Control  
6 14 Days Block with 7 Days Recovery  14 Days Nerve Block  
7 20Hz Electrical Stimulation  7 Days Nerve Block  
8 14 Days Nerve Block 3 Days Nerve Block 
9 14 Days Nerve Block 7 Days Nerve Block 
Table 11  Experimental Groups Compared Within Limma 
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For each of these comparisons a table was generated which contained an average fold 
change and adjusted P value for each probe set.  The probe sets within these tables 
were ranked by P value and the most statistically significant differentially expressed 
probe sets examined.   
 
5.4.1  Number of Differentially Expressed Probe Sets Between Experimental Groups 
 
The  tables generated using the limma software in 5.4 for each of the comparisons was 
restricted to contain only probe sets whose p value was less than 0.05 and whose fold 
change was greater than 2.  The number of probe sets (genes) contained in each of the 
adjusted tables were plotted on a bar graph (figure 28). 
 
Figure 28  Number of Statistically Significant Differentially Expressed Genes Bars 
indicate the number of statistically significant (p<0.05) differentially expressed (fold 
change>2) genes when comparing two experimental groups using limma software 
package. 
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Comparing 3, 7 or 14 days of nerve block with sham controls, there were over 1500 
statistically significant differentially expressed genes in each comparison. When 
comparing 7 days of nerve block with sham controls there were 2085 statistically 
significant differentially expressed genes, equating to almost 10% of the entire 
transcriptome.  This analysis confirms that the nerve block model of skeletal muscle 
atrophy does effect the transcript levels within muscle significantly.  Interestingly, the 
recovery group was almost identical to sham control with only 85 differentially 
expressed genes, suggesting that the transcriptional profile of the muscle has almost 
completely recovered within 7 days of reversing the nerve block.  On comparison of 14 
days of nerve block with 7 days there were only 34 differentially expressed genes.  
However, when comparing 14 days with 3 days there were 791 differentially expressed 
genes.  These data suggest that the transcriptional reprogramming during atrophy is a 
dynamic process, with distinct early (3 days) and later (14 days) phases.  When 
comparing 7 days of 20Hz stimulation with 7 days of nerve block there were 1426 
statistically significant differentially expressed genes, suggesting the modes of action of 
producing atrophy in these two models is different. 
 
5.4.2  Analysis of  the Top 500 Most Statistically Significant Differentially Expressed 
Genes 
 
A table was  produced using the limma software showing the most statistically 
significant differentially expressed probe sets across all the comparisons (table 12).  In 
this analysis, Histone deacetylase 4 (Hdac4) was the most statistically significant 
differentially expressed probe set (gene) across all the comparisons.  It was noted that 
this table also contained the ubiquitin ligase Trim63, as well as the transcription factor 
myogenin. 
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Table 12  The Top 10 Most Statistically Significant Differentially Expressed Probe 
Sets Over All Comparisons 
Generated using the limma package in Bioconductor and ranked according to adjusted 
p value. 
 
 
The table of the most statistically significant differentially expressed genes across all 
the comparisons was ranked by adjusted p value and restricted to include only the top 
500 genes.  The intensity values of these 500 genes across all the arrays was analysed 
using an unsupervised hierarchical clustering method within bioconductor, which was 
plotted on a correlation heatmap (figure 29).  The intensity values on the heatmap were 
scaled for absolute expression and the degree of expression so patterns of change 
between arrays can be observed more clearly.  In all cases the replicate samples within 
each experimental group cluster together.  The dendogram shows that samples subject 
to 3, 7 and 14 days atrophy cluster together with 3 days being the least similar to 7 and 
14 days. Sham, recovery and 20Hz electrical stimulation cluster together before 
separating into distinct groups. 
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Figure 29  Unsupervised Hierarchical Clustering of Top 500 Most Statistically 
Significant Differentially Expressed Genes 
'Limma' software compared all probe sets across all experimental groups using an 
ANOVA test.  The probe sets are then ranked by adjusted P value.  The top 500 most 
statistically  significantly  probe sets are plotted on an unsupervised correlation heat 
map, which is scaled to remove absolute expression and the degree of expression. 
 
 
5.4.3  Genes Cluster Into Dynamic Groups 
 
In order to investigate further the relationship between the duration of TTX nerve 
block and the changes in transcript levels, the top 500 most statistically significant 
differentially expressed genes across all comparisons were subject to temporal 
clustering analysis within bioconductor.  A time line was established with sham control 
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becoming day 0 and recovery from nerve block becoming day 21 (14 days of nerve 
block plus 7 days without nerve block).  The 20Hz electrical stimulation group was not 
considered in this analysis.  The software analysed the number of statistically 
significant clusters of genes according to patterns of change in expression over the 
experimental time period.  This was found to be two i.e. genes that increase and genes 
that decrease upon TTX block.  However the software could also be used to separate 
the 500 genes into any number of clusters to be examined further.  Figure 47 shows 
how the genes were separated into 5 distinct temporal clusters.  This number was 
chosen as the genes formed interesting groups while still remaining large enough for 
further analysis. 
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Figure 30  The Top 500 Most Statistically Significant Differentially Expressed 
Genes Organised Into 5 Distinct Temporal Clusters 
Each Panel (A-E) shows the scaled expression of each probe set over  the experimental 
time course as a joined grey line with the median values of all the genes within each 
cluster added as a black line. 
 
The clusters consisted of genes which increase (figure 30 A) or decrease (B) in 
expression by the earliest time point and maintain this throughout the atrophy time 
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course, genes which displayed a delayed increase (C) or decrease (D) in expression that 
is established later in atrophy, and genes which showed a spike increase in expression 
in early atrophy and although still elevated fall back towards the sham control levels as 
atrophy progresses (E).  Genes in all clusters returned towards sham control levels 
during the 7 day period following removal of the nerve block (21 days).  This analysis 
shows that in the context of a transcriptional response, atrophy is a highly dynamic 
process.  The data also showed  that the expression of genes did not change in the same 
direction during muscle atrophy.  
The clusters isolated in this analysis, shown in figure 30 A-E, were mapped back onto 
the heatmap in figure 29.  The clusters are highlighted within blue boxes and each 
shows the patterns of change of that cluster of genes over the experimental time 
period.  This figure highlights a clear distinction between the 3 day block group and the 
7 day/14 day block group in the genes within clusters C, D and E.  Also, within cluster C 
there seems to be a delayed recovery of genes, with a number of genes showing a 
persistent upregulation from sham control group.  Interestingly, this cluster is also 
induced in the functional atrophy group. 
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Figure 31  Unsupervised Hierarchical Clustering of Top 500 Most Statistically 
Significant Differentially Expressed Genes With Gene Clusters Highlighted 
'Limma' software compares all genes across all experimental groups using an ANOVA 
test.  The genes are then ranked by adjusted P value.  The top 500 most statistically  
significantly genes are plotted on an unsupervised correlation heat map, which is 
scaled to remove absolute expression and the degree of expression.  The genes can be 
organised into 5 distinct clusters according to patterns of change in expression over 
time.  These clusters are highlighted within each of the blue boxes (A-E, details outlined 
in figure 30). 
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5.5  Gene Ontology Terms Analysis 
 
The Gene Ontology (GO) project (Ashburner et al., 2000) is a major bioinformatics 
initiative with the aim of standardizing the representation of gene and gene product 
attributes across species and databases.  The project provides a controlled vocabulary 
of terms for describing gene product characteristics and gene product annotation data 
from GO Consortium members, as well as tools to access and process this data. 
(GOConsortium, 2008).   
The hypergeometric test is the standard gene enrichment test applied by GoStats 
(Falcon and Gentleman, 2007) within Bioconductor.  It is used to isolate statistically 
signficantly enriched GO terms for further scrutiny.  It is a statistical test calculated for 
a set of genes, in this case each of the nine comparisons outlined in table 11 and the five 
gene clusters outlined in figure 30.  The hypergeometric test specifies whether each 
gene set is enriched for any annotations out of the 'gene universe', which  was defined 
as any genes that had an Entrez Gene ID and some GO Term annotation.  This analysis 
produced 14 tables of GO terms, one for each of the nine comparisons and one for each 
of the five temporal clusters.  Each table consisted of the GO Terms which were found 
to be statistically significantly enriched (p<0.2).  An example of one of these tables is 
shown below in table 13.  The table shows the top 10 most statistically significant 
enriched GO Terms within the comparison of 3 days of nerve block vs sham control.  
Interestingly, with the exception of number 9 'glycolysis', all the GO terms are based 
around the ubiquitin ligase system. 
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GO Term ID P value 
Exp 
Count 
Count Size Term Name 
1 GO:0051436 4.14E-05 4.7 15 61 negative regulation of 
ubiquitin-protein ligase 
activity involved in mitotic cell 
cycle 
2 GO:0010498 5.29E-05 12.7 28 165 proteasomal protein catabolic 
process 
3 GO:0051248 6.91E-05 17.7 35 230 negative regulation of protein 
metabolic process 
4 GO:0031145 7.54E-05 4.9 15 64 anaphase-promoting complex-
dependent proteasomal 
ubiquitin-dependent protein 
catabolic process 
5 GO:0051352 9.12E-05 4.9 15 65 negative regulation of ligase 
activity 
6 GO:0051437 9.12E-05 4.9 15 65 positive regulation of 
ubiquitin-protein ligase 
activity involved in mitotic cell 
cycle 
7 GO:0031398 0.000105 7.4 19 96 positive regulation of protein 
ubiquitination 
8 GO:0031397 0.000275 6.1 16 79 negative regulation of protein 
ubiquitination 
9 GO:0006096 0.000369 3.4 11 44 glycolysis 
10 GO:0051351 0.000419 5.7 15 74 positive regulation of ligase 
activity 
 
Table 13  The Top 10 Most Statistically Significant Enriched GO Terms When 
Comparing 3 Days Nerve  Block to the Sham Control 
For Each GO Term the table details the GO Term ID, the P value indicating how 
statistically significantly enriched the GO term is in this analysis, the experimental 
count (Exp Count) which shows the number of genes within the GO term that a random 
selection would reveal given the number of genes within the test, the actual number of 
enriched genes the test revealed within the GO Term (Count), the number of genes 
contained within the whole GO Term (Size) and the term name.  
 
The 14 tables were scrutinised using knowledge of the surrounding literature.  Firstly, 
GO Terms were identified that might be expected to be enriched within this 
experimental model.  These GO Terms were used to validate the model before pursuing 
novel findings. 
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5.5.1  Method Validation 
 
The tables were initially scrutinised for enriched GO terms that were most obviously 
related to skeletal muscle.  Numerous examples of such enriched GO terms were seen 
across the tables.  Two examples were chosen; GO:0007515 'Muscle Organ 
Development' (figure 32) and GO:0055001 'Muscle Cell Development' (figure 33).  The 
figures show correlation heatmaps of the statistically significant genes within the 
enriched GO Term analysed using unsupervised hierarchical clustering over the 
experimental time period.  Each row shows the expression intensity of one gene on 
each of the 24 arrays from sham control to electrical stimulation having been scaled to 
remove absolute expression and the degree of expression.  This allowed the changes in 
patterns of change to be more easily recognised. 
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Figure 32  A Correlation Heatmap of the Statistically Significant Genes Within the 
Go Term 'Muscle Organ Development' 
A correlation heatmap of the statistically significant (p<0.2) genes that are shown 
within one enriched GO (Gene Ontology) term , 'GO:0007515',  identified following a 
hypergeometric test for all GO terms on each gene set. 
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Figure 33  A Correlation Heatmap of the Statistically Significant Genes Within the 
Go Term 'Muscle Cell Development' 
A correlation heatmap of the statistically significant (p<0.2) genes that are shown 
within one enriched GO (Gene Ontology) term , 'GO:0055001',  identified following a 
hypergeometric test for all GO terms on each gene set. 
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Both Figures 32 and 33 show sets of genes that show significant patterns of change 
within GO Terms based around skeletal muscle.  The individual gene names are 
excluded from the figure as the focus is on the pattern of change within the set of genes 
rather than the changes and significance of individual genes.  
The focus of the analyses moved next to investigating enrichment within the GO Terms 
that would be expected on the basis of physiological effects following application of our 
experimental model.  The GO Term 'cellular respiration' was enriched within a number 
of the comparisons and gene clusters.  A correlation heatmap of the statistically 
significant genes within the enriched GO Term 'cellular respiration' is shown in figure 
34 panel A.  The mean intensity values for all the genes within in each experimental 
group are shown as a bar plot on figure 34 panel B.   Genes associated with cellular 
respiration showed an overall drop in expression during nerve blockade.  This is 
consistent with a fall in cellular respiration rate concomitant with decreased muscle 
activity.  A rise in respiration rates would be expected upon recovery from nerve block, 
and is indeed observed  Also in line with expectations was the rise in cellular 
respiration with the increased muscle activity associated with electrical stimulation 
(figure 34). 
Therefore initial analysis of the expression data confirmed that enriched GO terms are 
consistent with the tissue type and its physiological condition.  The next stage was to 
scrutinise the enriched GO term tables for terms that could be used in subsequent 
analysis to shed light on the process of skeletal muscle atrophy through the generation 
of new hypotheses. 
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Figure 34  Patterns of Changes in Expression Over Experimental Groups of 
Statistically Significant Genes Within the Go Term 'Cellular Respiration' 
Panel A shows a correlation heatmap of the statistically significant (p<0.2) genes that 
are shown within one enriched GO (Gene Ontology) term , 'GO:004533',  identified 
following a hypergeometric test for all GO terms on each gene set.  The mean values for 
all genes in each experimental group are displayed in panel B. 
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5.5.2  The Role of The Neuromuscular Junction in In Vivo Muscle Atrophy 
 
The GO term GO:0031594 'neuromuscular junction' was enriched following TTX nerve 
block.  As the TTX block model stops all activity at the neuromuscular junction (NMJ) 
changes of associated transcripts may be expected.  A correlation heatmap of the 
statistically significant genes within this GO Term, analysed using unsupervised 
hierarchical clustering over the experimental time period is shown in figure 35 panel A.  
The mean intensity values for all the genes within in each experimental group are 
shown as a bar plot on figure 35 panel B.  Overall, an increase in expression of the genes 
associated with the term 'neuromuscular junction' was observed during nerve 
blockade, compared to a relatively low basal level in the sham controls.  This finding 
suggested that when the nerve block was in place and the activity of the NMJs within 
the muscle was silenced, a negative feedback loop in the muscle increases the 
expression of genes associated with the NMJ.   
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Figure 35  Patterns of Changes in Expression Over Experimental Groups of 
Statistically Significant Genes Within the Go Term 'Neuromuscular Junction' 
Panel A shows a correlation heatmap of the statistically significant (p<0.2) genes that 
are shown within one enriched GO (Gene Ontology) term , 'GO:0031594',  identified 
following a hypergeometric test for all GO terms on each gene set.  The mean values for 
all genes in each experimental group are displayed in panel B. 
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The muscle specific nicotinic acetyl choline receptor (nAchR) subunit alpha 1 (Chrna1) 
was one of the genes within the enriched GO term 'neuromuscular junction', shown in 
figure 35.  This result was investigated further by isolating the expression intensities of 
the other subunits that make up the nAChRs within the NMJ.  Nicotinic receptors are 
made up of five subunits, arranged symmetrically around a central pore.  In the muscle-
type receptors, found at the neuromuscular junction, receptors are either the 
embryonic form consisting of, α1, β1, δ, and γ subunits in a 2:1:1:1 ratio, or the adult 
form composed of α1, β1, δ, and ε subunits in a 2:1:1:1 ratio.  The mean expression 
intensities in experimental groups of each of the subunits, are shown in figure 36. 
 
 
 
Figure 36  Mean Expression Intensity Levels of Nicotinic Acetyl Choline Receptor 
(nAChR) Subunits Over Experimental Groups 
Mean (n=4 per experimental group) expression intensity from arrays over the 
experimental time course of induced atrophy and recovery, with 20Hz electrical 
stimulation shown as a separate value.  All data are expressed as a log2 fold change 
relative to expression in the sham controls. 
 
All 5 subunits showed an increase in expression during nerve block.  The largest 
increases were observed in the alpha and delta subunits, which increased between 2 
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and 3 fold upon nerve blockade.  Expression levels of all the subunits fell back towards 
sham control levels upon recovery.   Only the alpha and delta subunits showed a 
substantial increase in transcript expression in response to electrical stimulation at 
20Hz. 
 
5.5.3  The Role of Cytokine Signalling in In Vivo Muscle Atrophy 
 
Next, the ontology analysis was refined further by restriction of the GO terms to those 
involved in cellular signalling.  This restriction generated further tables of enriched GO 
terms, based upon the original comparisons outlined in table 11.  The GO term 
GO:0019221 'cytokine-mediated signalling pathway' was present in several of the 
tables including 7 days of TTX block vs. sham control.  A correlation heatmap of the 
statistically significant genes within this enriched GO Term using unsupervised 
hierarchical clustering over the experimental groups  is shown in figure 37. 
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Figure 37  A Correlation Heatmap of the Statistically Significant Genes Within the 
Go Term ' Cytokine-Mediated Signalling Pathway' 
A correlation heatmap of the statistically significant (p<0.2) genes that are shown 
within one enriched GO (Gene Ontology) term , ' GO:0019221',  identified following a 
hypergeometric test for all GO terms on each gene set. 
 
The statistically significant genes whose expression changed upon nerve blockade 
(figure 37) included a number that map to the Janus Kinase (Jak)/ Signal-Transducer 
and Activator of Transcription (Stat) pathway, specifically Jak1, Jak2, Stat3 and Stat5b.  
The mean expression intensities in experimental groups of each of the Jak family 
members (Jak1, 2 and 3) are shown in figure 38. 
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Figure 38  Mean Expression Intensity Levels of Janus Kinases (Jaks) Over 
Experimental Time Period 
Mean (n=4 arrays per experimental group) expression intensity from arrays over the 
experimental time course of induced atrophy, recovery and 20Hz electrical stimulation 
as a separate value all expressed as a log2 fold change from sham control levels. 
 
Jak1 and 2 showed an increase in expression of around 2 fold during nerve blockade 
which fell back towards sham control levels upon cessation of the nerve block.  
Interestingly, this increase in Jak1/2 expression was not observed by electrical 
stimulation in the functional atrophy model. 
The mean expression intensities in experimental groups of each of the Stat family 
members (Stat 2, 3, 4, 5a, 5b and 6) are shown in figure 39. Stat2, 3 and 5b all showed 
an increase in expression during nerve block with Stat2 showing a delayed response.  
Stat3 expression levels increased by up to 3 fold with 7 days of nerve block.  Stat2 and 3 
also showed an increase in expression with 20Hz electrical stimulation. 
The transcript changes of the members of the Jak/Stat pathway observed in figures 38 
and 39 indicated that this pathway may play a role in skeletal muscle atrophy.  To our 
knowledge, this was a novel finding and merited further investigation 
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Figure 39  Mean Expression Intensity Levels of Signal-Transducer and Activator 
of Transcription (Stat) 2, 3, 4, 5a, 5b and 6 Over The Experimental Time Period 
Mean (n=4 arrays per experimental group) expression intensity from arrays over the 
experimental time course of induced atrophy, recovery and 20Hz electrical stimulation 
as a separate value all expressed as a log2 fold change from sham control levels. 
 
 
5.5.4  Modelling Atrophy Signalling Pathways From Transcriptome Profiling 
 
By integrating current knowledge of cellular signalling pathways with the results of the 
microarray analysis presented in this chapter a working hypothesis was developed for 
the regulation of the expression of key atrophy genes.  This is diagrammatically 
represented in figure 40.  The hypothesis presents the NMJ as an integral activity 
sensor that controls the transcriptional expression of key genes related to atrophy 
through the transcription factor myogenin (Myog).   
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Figure 40  Transcriptome Profiling Reveals Cellular Signalling Pathways 
Controlling Transcriptional Expression of Genes Integral to Atrophy 
A; Diagram of cellular signalling pathways centred on myogenin.  Proteins are 
represented in text boxes with movements denoted by black arrows and red lines 
indicating actions.  B; Transcriptional changes in this signalling network in response to 
atrophy stimulus measured by microarray.  Red indicates an increase in transcript 
levels for that protein.  Abbreviations - EphA4; Eph receptor A4, Jak1/2; Janus kinase 
1/2, Trim63; tripartite motif-containing 63, Stat3; signal transducer and activator of 
transcription 3, CaMKIID; calcium/calmodulin-dependent protein kinase II delta, 
Hdac4; histone deacetylase 4, Hdac5; histone deacetylase 5, Mitr; a histone deacetylase 
9 splice variant, Dach2; dachshund 2, Fbxo32; F-box protein 32, Trim63; tripartite 
motif-containing 63, Chrna1; nicotinic cholinergic receptor nicotinic (alpha polypeptide 
1), Socs3; suppressor of cytokine signaling 3. 
116 
 
The first arm of the hypothesised signalling pathway involves the regulation of Myog by 
the histone deacetylase Hdac4, which was the most statistically significant differentially 
expressed probe set across the entire dataset (see table 12).  Myog also appeared on 
this table as the 10th most statistically significant differentially expressed probe set 
across the dataset.  Tang et al showed that a calcium/calmodulin-dependent protein 
kinase (CaMKII)-dependent phosphorylation of Myog contributes to activity-dependent 
suppression of nAChR gene expression in developing rat myotubes (Tang et al., 2004).  
Calcium/calmodulin-dependent protein kinases are serine/threonine-specific protein 
kinases that are regulated by the calcium/calmodulin complex, which regulates calcium 
signal transcduction by binding calcium ions and then modifying its interactions with 
various target proteins.  The group linked intracellular calcium levels with the 
regulation of expression of nAChR subunits.  The GO term 'neuromuscular junction' 
was found to be significantly enriched (figure35) with nerve block atrophy and the 
nAChR subunits were shown to increase in expression, with marked changes in the 
alpha and delta subunit in particular (figure 36).  Studies in 2009 by the same group 
showed that the histone deacetylase Hdac4 was an intermediary stage in this signalling 
pathway (Tang et al., 2009), being phosphorylated by CaMKII, which determined its 
location within the muscle fibre.  As calcium levels drop with number of muscle 
contractions, CaMKII phosphorylates Hdac4 allowing it to move into the nucleus.  Here 
it acts to suppress the expression of a histone deacetylase 9 splice variant (Mitr) and 
dachshund 2 (Dach2), whose normal role is to suppress the transcription of Myog.  
Hence the increased expression and activity of Hdac4 increases expression of Myog.  
These findings were confirmed in a mouse model of skeletal muscle atrophy involving 
denervation (Cohen et al., 2007). 
The second arm of the signalling pathways involve the regulation of Myog via the 
Jak/Stat signalling pathway.  This pathway was highlighted as the GO term 'cytokine-
mediated signalling pathway' was found to be significantly enriched (figure 37).  
Further investigation of the Jak and Stat family members revealed that  Jak1 and 2 
(figure 38) as well as Stat2, 3 and 5b (figure 39) increased in expression following 
nerve block.  Lai et al have previously linked the ephrin type-A receptor 4 (EphA4) with 
Jak/Stat proteins as novel downstream targets (Lai et al., 2004).  Eph receptors and 
their cognate ligands, the ephrins, are important players in axon guidance and neural 
patterning during development of the nervous system and have been shown previously 
to be localised in the neuromuscular junction in adult skeletal muscle (Lai et al., 2001).  
Suppressor of cytokine signalling 3 (Socs3) is a member of the Stat-induced Stat 
inhibitor family. These are cytokine-inducible negative regulators of cytokine 
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signalling.  Socs3 mRNA expression has previously been shown to increase during 
myogenesis (Diao et al., 2009) with a concomitant increase in Stat3 phosphorylation 
and Myog expression (Spangenburg, 2005). Additionally, overexpression of Socs3 
further enhanced Myog mRNA expression (Spangenburg, 2005).  In turn, Macpherson 
et al showed in 2011, through denervation of a Myog null mouse model, that Myog can 
regulate the expression of the ubiquitin E3 ligases Fbxo32 and Trim63 (Macpherson et 
al., 2011).  Trim63 was found to be the 9th most statistically significant differentially 
expressed probe set across the dataset (table 12). 
Figure 40 panel A shows a diagrammatic representation of this combined signalling 
pathway.  Panel B shows this diagram with each of the genes that are represented on 
the Affymetrix GeneChip® Rat Genome 230 2.0 Array coloured either, representing a 
gene whose transcripts increased during nerve block.  To validate the microarray data, 
these changes in expression levels were confirmed using qRT-PCR as outlined in 5.6. 
 
5.6  Confirmation of Transcriptional Changes in the Myogenin Pathway Using qRT-PCR 
 
In order to confirm the transcript changes revealed by microarray analysis, primers 
were designed to key genes of interest and their transcript levels measured using qRT-
PCR. 
 
5.6.1  End Point RT-PCR Validation of Primer Sets for Microarray Genes 
 
Forward and reverse primers were designed in rat for the genes integral to the cellular 
pathways as previously outlined in section 3.4.  Primers for Fbxo32 and Trim63 were 
as previously described (see section 3.4).  RT-PCR followed by 2% agarose gel 
electrophoresis (outlined in 2.6.6) confirmed that all primer pairs amplified a PCR 
product of the correct size at an optimum annealing temperature of 61 °C (figure 41 A).  
An RT- template was tested with each primer set to ensure there was no amplification 
from genomic DNA (figure 41 B).  No genomic DNA contamination was found to 
interfere with amplification for any of the primer sets. 
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Figure 41  Specificity of Rat-Specific Primer Sets For Transcripts in Interest 
Identified by Microarray 
End-point RT-PCR Followed by 2% agarose gel electrophoresis shows single bands of 
the correct size for each of the primer sets (A). An RT- template was tested with each 
primer set to ensure there was no amplification from genomic DNA (B).  Each gel was 
run with a molecular weight hyperladder, whose band positions for 100-400 base pairs 
(bp) are shown next to each. 
 
5.6.2  Determination of Primer Efficiency in qRT-PCR 
 
The efficiency of the primer sets was tested using the method described in 3.4.3.   The 
efficiency of each primer set is shown in table 14 was determined that the efficiency of 
all the primer sets was between 90 and 110% as recommended for use in qRT-PCR by 
BioRad, with the exception of Dach2.  This efficiency reading could be explained by the 
extremely low levels of transcript,  as evidenced by a weak band following end-point 
RT-PCR and agarose gel electrophoresis (figure 41).  In subsequent analysis, Dach2 
transcript levels were not able to be analysed using qRT-PCR.   
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Table 14  Efficiency of Product Amplification During qRT-PCR for Each Primer Set  
2-fold serial dilutions of a template cDNA (from control, untreated tissue) were used to 
generate a standard curve for each primer set.  Amplification efficiency was calculated 
from the gradient of the linear regressions line of these curves.  For subsequent 
analysis an optimum efficiency of between 90% and 110% was required and achieved 
with the exception of Dach2. 
 
 
5.6.3  Comparative Transcript Changes Determined by Microarray and qRT-PCR 
analyses 
 
The transcript levels for the genes involved in cellular pathway outlined in figure 40 
were measured using qRT-PCR.  The results, shown in figures 42, 43 and 44, are 
displayed using the 2-ΔΔCT method, where differences between the mean of the 
reference genes CT values and the target gene CT value in each muscle sample was 
quantified individually, then the difference between the untreated and treated samples 
was calculated as a fold-change.  In each of the figures the transcript levels measured 
using qRT-PCR (n=6) are displayed alongside the mean expression intensity values 
which were extrapolated from the microarray data (n=4). 
Figure 42 shows that transcript levels measured using both analytical methods were 
very similar for Hdac4 and Hdac5 with each experimental treatment.  Hdac4 expression 
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increased with nerve blockade and remained at an increased level throughout the 
nerve block, returning to sham control levels upon recovery.  Although the activity of 
Hdac4 has been reported to be controlled by phosphorylation (Tang et al., 2009), the 
increase in transcript level by 13.6-fold (+/- 4.5) with 14 days of nerve block will likely 
contribute to an increase in activity.  In contrast, Hdac5 transcript levels remain 
relatively unchanged following nerve block by TTX treatment. These data therefore 
confirm the expression level changes seen following the microarray analysis.  However, 
for the other arm of the cellular pathways outlined in 5.5.4 involving Stat3, qRT-PCR 
did not completely validate the microarray data.  Stat3 expression levels increased 
when analysed using qRT-PCR in response to nerve block, however this increase 
seemed relatively small when compared to changes measured using microarray (figure 
42, panel F).  It should be noted that the changes in transcript levels measured using 
microarray are less quantifiable than those measured using qRT-PCR and should be 
used to look for patterns of change rather than absolute levels of expression.  Morey et 
al investigated the correlation between qRT-PCR and microarray results (Morey et al., 
2006) concluding that even though each method has pitfalls,  the use of qRT-PCR to 
validate microarray was sound and the correlation was statistically significant.  In the 
case of the Stat3 the primers used in qRT-PCR were designed to include the exon 
complementary to the probe sets on the microarray and were validated using end point 
PCR and sequenced.  The seemingly different levels in change of transcriptional 
expression following TTX nerve block were down to the analytical methods adopted. 
 
121 
 
 
Figure 42  Comparison of Gene Transcript Levels Represented by Microarray 
Expression Intensity and Quantitative Reverse Transcription PCR (qRT-PCR) of 
Hdac4, Hdac5 & Stat3 
Mean microarray expression intensity (n=4) of Hdac4; histone deacetylase 4 (A), 
Hdac5; histone deacetylase 5 (C) and Stat3; signal transducer and activator of 
transcription 3 (E) over the experimental groups including atrophy, recovery from 
atrophy and 20Hz electrical stimulation.  These are compared with transcript levels of 
Hdac4 (B), Hdac5 (D) and Stat3 (E) in the same experimental groups measured using 
qRT-PCR and normalised to the mean of two housekeeping genes (Rn18s and Polr2a).  
Levels are expressed as fold changes from contralateral untreated control TA to treated 
TA sample levels (n=6).  Error bars indicate SEM. 
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Further downstream in the signalling pathway (figure 43) the two forms of analysis 
recorded very similar transcript profiles for Socs3 and Myog.  This confirmed that 
Socs3 transcript levels remained unchanged in response to nerve block treatment or 
electrical stimulation.  However, Myog transcript levels show a marked increase in 
expression following nerve block, with expression peaking sharply 3 days after TTX 
treatment at a 34.1-fold (+/- 13.8) higher level in treated compared to untreated 
muscle.  This was observed with both analysis methods. The effectors of Hdac4, Mitr 
and Dach2, which act as Myog supressors were harder to measure.  Dach2 was not 
available on the Affymetrix microarray plus the transcript levels were at too low a level 
to measure using qRT-PCR.  Data for Mitr was also not available from the microarray 
analysis due to the absence of probe sets for the gene on the Affymetrix GeneChip® Rat 
Genome 230 2.0 Array.  However, qRT-PCR analysis revealed a sharp 2.8-fold  (+/- 
0.1)decrease in transcript levels at 3 days of nerve block.  This decrease in expression 
was present throughout nerve block and upon cessation of the nerve block transcript 
levels were found to return to control levels.  This decrease in Mitr would be consistent 
with the role in the pathway outlined in figure 40.  Here the increased activity of Hdac4 
reduces the transcription of Mitr, a supressor of Myog, which in turn increases the 
transcription of Myog. 
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Figure 43  Comparison of Gene Transcript Levels Represented by Microarray 
Expression Intensity and Quantitative Reverse Transcription PCR (qRT-PCR) of 
Mitr, Socs3 & Myog 
Mean microarray expression intensity (n=4 arrays for each experimental group) of 
Socs3; suppressor of cytokine signalling 3 (B) and Myogenin (D) over the experimental 
time period including atrophy, recovery from atrophy and 20Hz electrical stimulation.  
These are compared with transcript levels of Socs3 (C) and Myogenin (E) in the same 
experimental groups measured using qRT-PCR and normalised to two housekeeping 
genes (Rn18s and Polr2a).  Levels are expressed as fold changes from contralateral 
untreated control TA to treated TA sample levels (n=6).  Transcript levels observed 
using RT-PCR of Mitr; a histone deacetylase 9 splice variant, are shown in A, a probe set 
from this gene was not present in the microarray.  Error bars indicate SEM. 
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Figure 44 shows the transcript levels of the Myog target genes Chrna1, Fbxo32 and 
Trim63, as analysed using microarray and qRT-PCR.  The two methods of analysis 
showed similar changes in transcript levels, as well as the pattern of changes with 
treatment.  Expression of Chrna1 increases markedly following nerve block, with qRT-
PCR showing a 43.4-fold (+/- 18.4) increase in expression after 3 days rising to a 133.5-
fold (+/- 15.8) and a 177.5-fold (+/-83.8) increase by 7 and 14 days respectively.  
Expression levels of Chrna1 measured using microarray show an increase in expression 
after 3 days of nerve block which is maintained at 7 and 14 days.  This slight difference 
in pattern is due to the limited dynamic range of this detection method.  The expression 
of Fbxo32 also increased following nerve block with a peak 4.0-fold (+/- 1.0) induction 
of the transcript 3 days after instigation of the nerve block.  The expression levels were 
increased throughout the period of blockade, returning to sham control levels upon 
cessation of the nerve block.  Both analysis methods confirmed that increases in 
Fbxo32 expression were most marked in the early period of nerve block.  This pattern 
is also present in the expression of Trim63.  Trim63 showed a peak increase in 
expression at 3 days of nerve block with a 5.1-fold (+/- 1.1) increase in transcript.  The 
degree of increased expression with nerve block was less marked in the later period of 
atrophy and returned to sham control levels upon cessation of the block. 
As shown in figures 42, 43 and 44, 20Hz electrical stimulation produced relatively 
small changes in the expression of these transcripts compared to nerve block 
treatment. 
Figures 42, 43 and 44 show that transcript levels measured using qRT-PCR confirmed 
changes observed using microarray analysis.  This strengthened the hypothesis set out 
in figure 40 that the NMJ acts as a sensor within the muscle fibre, acts through Hdac4 
and the Jak/Stat signalling pathway to alter the transcriptional expression of Myog and 
ultimately it target genes, which are integral to muscle atrophy. 
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Figure 44  Comparison of Gene Transcript Levels Represented by Microarray 
Expression Intensity and Quantitative Reverse Transcription PCR (qRT-PCR) of 
Chrna1, Fbxo32 & Trim63 
Mean microarray expression intensity (n=4 arrays for each experimental group) of 
Chrna1; nicotinic cholinergic receptor nicotinic (alpha polypeptide 1) (A), Fbxo32; F-
box protein 32 (C) and Trim63; tripartite motif-containing 63 (E) over the 
experimental time period including atrophy, recovery from atrophy and 20Hz electrical 
stimulation.  These are compared with transcript levels of Chrna1 (B), Fbxo32 (D) and 
Trim63 (F) in the same experimental groups measured using qRT-PCR and normalised 
to two housekeeping genes (Rn18s and Polr2a).  Levels are expressed as fold changes 
from contralateral untreated control TA to treated TA sample levels (n=6).  Error bars 
indicate SEM. 
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5.7  Discussion 
 
Microarray analysis was used to compare genome-wide transcript changes following 3, 
7 and 14 days of nerve blockade, in addition to 14 days of nerve block with 7 days of 
recovery, or 7 days electrical stimulation at 20Hz.  Raw array data was assessed for 
quality using arrayQualityMetrics and normalised using the RMA method.  Data was 
further analysed using Bioconductor within R. 
 
5.7.1  Preliminary Analysis Reveals Nerve Block Atrophy to be a Dynamic Process with 
Transcript Levels Recovering Upon Cessation of Block 
 
Unbiased correlation of probe set expression across the whole genome distinguishes 
the nerve block atrophy groups from the electrical stimulation, recovery and sham 
control groups (figure 26).  We can infer from this that atrophy produced using a nerve 
block does transcriptionally program skeletal muscle.  Upon cessation of the block the 
transcriptional profile of the recovery group after only 7 days was strikingly more 
similar to that of the control than to the nerve block group.  Further separation of the 
recovery and control groups is evident from the dendogram.  This relatedness within 
each group was confirmed by using principal component analysis (figure 27).  With this 
analytical approach the recovery and sham samples from distinct groups that are 
closely related and separate from the nerve block groups.  Here we can also see that the 
transcriptional response over the different periods of nerve block is stratified.  Samples 
subjected to 7 days or 14 days nerve block form distinct groups whereas the 3 day 
group showed greater variation but remained distinct from the sham and recovery 
groups.  The differences between the groups were quantified using differential 
expression analysis (figure 28).  Nerve block atrophy induced over 1500 genes to be 
significantly (p<0.05) differentially expressed (fold change>2) when compared to a 
sham control group.  7 days of nerve block induced 2085 genes to be differentially 
expressed, which is nearly 10% of the entire genome.  This is compared to less than 5% 
of probe sets analysed by Stevenson et al, where hindlimb suspension was analysed by 
microarray (Stevenson et al., 2003).  It was also observed that when comparing 
recovery and sham control groups there were only 85 significantly differentially 
expressed genes.  Considering the analysis included transcript levels of nearly 30,000 
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genes the recovery and sham control groups can be considered near identical on this 
basis. 
This analysis also revealed that there are different phases of the transcriptional change 
that occurs in response nerve block.  When 14 days of atrophy was compared with the 
3 day group there were 791 differentially expressed genes.  However when 14 days 
was compared to 7 days only 34 were differentially expressed.  These data suggests 
that there may be early (3 days) and established (7-14 days) phases of transcriptional 
change during nerve block atrophy.  Temporal changes in gene transcripts with 
continued atrophy stimulus have been observed previously in hindlimb suspension 
model  (Stevenson et al., 2003) but nothing has been previously reported with total 
inactivity due to nerve block.  This dynamic response to nerve block was investigated 
further by separating the top 500 most statistically significant differentially expressed 
genes into clusters dependant on their patterns of change over the experimental time 
period (figure 30).  The clusters consisted of genes which increase or decrease in 
expression throughout atrophy, genes which displayed a delayed increase or decrease 
in expression which is established later in atrophy, and genes which showed a spike 
increase in expression during early atrophy which is still elevated but closer to sham 
control levels in later atrophy(Fig 30).  Almost all genes moved towards sham control 
levels upon recovery (21 days). 
 
5.7.2  Microarray Analysis Distinguishes In Vivo Models of Atrophy 
 
Global analysis of microarray data begins to distinguish the transcriptional response 
during nerve block atrophy, or an atrophic electrical stimulation pattern.  Using both 
unbiased correlation heatmaps of probe set expression across the whole genome 
(figure 26) and principal component analysis (figure 27) it is clear that the changes in 
gene expression following these two treatments are markedly different.  Indeed, when 
using differential expression analysis to compare electrical stimulation with 7 days of 
nerve block there were 1426 statistically significant (P<0.05) differentially expressed 
(fold change>2) genes (figure 28).  Using Gene Ontology (GO) term analysis the 
differences between the two models were explored further.  When looking at the GO 
term 'cellular respiration' (figure 34) nerve block and electrical stimulation had 
opposite effects on transcript levels of the majority of the genes within this GO term.  
Almost all of the 51 genes which were significantly differentially expressed within this 
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GO term showed a reduction in expression with nerve block compared to an increase in 
expression intensity with electrical stimulation.  There were also marked differences in 
the genes associated with the signalling pathways controlling Myog after nerve block 
atrophy or electrical stimulation, including myogenin itself (34-fold increase with nerve 
block measured using qRT-PCR, no significant change with electrical stimulation; figure 
43) and Chrna1 (177-fold increase with nerve block using qRT-PCR, no significant 
change with electrical stimulation; figure 43).  These results suggest that the atrophy 
produced via electrical stimulation does not utilise Myog induction, but potentially 
exploits another pathway which ultimately produces a reduction in muscle size. 
 
5.7.3  Myogenin May Play a Key Role in Nerve Block Atrophy 
 
GO term analysis along with current knowledge of molecular and signalling pathways 
in the literature was used to generate a working hypothesis (See 5.5.3 for full details).  
The cellular pathway consists of two arms which originate within the neuromuscular 
junction and converge on the transcription factor Myog, which in turn controls the 
transcriptional expression of genes involved in neuromuscular junction formation and 
proteolysis.  The first arm of the signalling pathway involves the regulation of Myog 
through the histone deacetylase Hdac4.  The second arm of the signalling pathways 
involve the regulation of Myog via the Jak/Stat signalling pathway (see figure 40).  The 
transcriptional changes, analysed from the microarray data (figure 40 panel B), were 
then confirmed using qRT-PCR (5.6.3). 
qRT-PCR data generally correlated well with the transcriptional changes (observed by 
microarray analysis), following nerve block. The main exception was Stat3, which 
showed a smaller degree of increase in transcript levels during the nerve block when 
measured using qRT-PCR (figure 42) compared to the fluorescence levels measured 
using microarray analysis.  All suitable steps had been taken to ensure the specificity of 
the primers used in qRT-PCR and this slight difference in levels of transcript induction 
recorded by the two methods of analysis was probably due to the limited quantification 
of fluorescence in microarray analysis.  Socs3 transcript levels did not show any 
increase following nerve block following analysis by microarray or qRT-PCR.  Thus the 
hypothesis that Socs3 links Stat3 activity with Myog expression (Caldow et al., 2011) 
was not confirmed in our analysis of the Socs3 transcript changes.  However in this 
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study Caldow et al overexpressed Socs3 using adenovirus in primary myoblast cultures 
taken from human muscle tissue.  These cells were not cultured in atrophy inducing 
differentiation media and this study simply showed a concomitant overexpression of 
Myog as a result of Socs3 overexpression.  However, our observation from the nerve 
block model that Socs3 transcript levels remain unchanged during atrophy does not 
rule out the possibility that Socs3 could be regulated at a level other than transcription, 
and so still impact on the expression of Myog. 
qRT-PCR validation for the transcripts of other genes of interest did however reflect the 
changes seen in microarray analysis.  Myog transcript levels were observed to increase 
markedly following nerve block, with a 34-fold increase after 3 days of block (figure 
43).  This confirms previous studies (Macpherson et al., 2011, Moresi et al., 2010, Tang 
and Goldman, 2006, Tang et al., 2009) that have implied that Myog has a role in skeletal 
muscle atrophy.  The possible control of Myog expression through the Hdac pathway 
was also observed following analysis using qRT-PCR.  The transcript levels of Hdac4 
increased through nerve block to a peak induction of almost 14-fold over control 
following 14 days of block.  This was expected, as previous studies have shown that 
Hdacs are activated with denervation in vivo (Cohen et al., 2007, Moresi et al., 2010, 
Tang et al., 2009) and in vitro (Tang and Goldman, 2006).  qRT-PCR also provided some 
further evidence for the Hdac4 pathway that was not evident in the original microarray 
data set. Importantly, the repressor of Myog expression Mitr was shown to be 
downregulated following nerve block (figure 43); this was not seen by microarray 
analysis, as there was no probe set on the genechip. This suggests that Hdac activity is 
indeed linked to Myog expression through Mitr as seen in other studies (Tang and 
Goldman, 2006, Tang et al., 2009).  The levels of Hdac5 were not increased during 
nerve block (figure 42).  Although previous studies have shown that it is the 
phosphorylation state that determines the activity of the Hdacs (Tang et al., 2009), the 
relative differences in transcript changes in Hdac4 and Hdac5 indicate that during 
nerve block atrophy Hdac4 expression is more dynamic, perhaps suggesting that it may 
play a more important role than Hdac5.  This would need to be confirmed with further 
analysis of the phosphorylation state of both Hdac4 and Hdac5, and their localisation 
within the muscle fibre. 
Several potential targets of Myog including Chrna1, the nAChR subunit, and the E3 
ubiquitin ligases, Fbxo32 and Trim63 all increased in expression during nerve block 
induced atrophy when measured using microarray analysis and qRT-PCR (figure 44).  
The levels of Chrna1 increased by 178-fold (+/- 84) following 14 days of nerve block.  
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This massive fold change is due to fact that Chrna1 levels are very low in control 
muscle.  However the induction of this gene is marked.  This suggests that new NMJ 
formation is not active in mature muscle.  However, in response to silencing of the 
neuronal input, the muscle begins to produce new NMJs and hence increase the 
sensitivity of the muscle to nerve impulses.  Both Fbxo32 and Trim63 transcript levels 
show a peak in expression at the early phases of atrophy (4- and 5-fold respectively 
following 3 days block, figure 44).  Although still elevated after 14 days of nerve block 
(2- and 2.5-fold respectively), their expression is diminished compared to that seen in 
the earlier phases.  Upregulation of these E3 ubiquitin ligases is thus a rapid response 
to atrophy stimuli.  
 
5.7.4  Summary 
Microarray analysis has shown that the two in vivo models of atrophy utilise different 
cellular pathways in order to reduce muscle size.  TTX nerve block produces atrophy as 
a dynamic process, in which the transcriptome measured using microarray analysis 
moves towards the control state after 7 days of recovery.  Following validation using 
qRT-PCR, it was observed that Myog may play a central role in nerve block atrophy.  Its 
transcription levels may be regulated through the Hdac and Jak/Stat pathways, 
controlled through the NMJ.  Myog ultimately controls the transcription levels of genes 
integral to the process of muscle atrophy. 
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Chapter 6: Chemical Inhibition of In Vitro Muscle Atrophy and 
Comparisons With The In Vivo Models 
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6.1  Chapter Introduction 
 
Microarray analysis of an in vivo atrophy model reliant on blocking muscle innervation 
using TTX (chapter 5) supported a cellular mechanism centred on regulating the 
expression of Myog through Hdac4 and/or Jak/Stat3.  The two convergent pathways 
are detailed in section 5.5.4 and are represented in figure 45 panel A.  In order to 
investigate the role of these same cellular pathways in other models of muscle atrophy 
the impact of chemical inhibitors targeted to each pathway in cultured C2C12 
myotubes would be assessed. 
The first arm of the pathway relies on an inducible nuclear translocation of 
phosphorylated Hdac4/5 into the nucleus, where it represses transcription of Dach2 
and Mitr, two negative regulators of Myog.  MC1568, a class II specific Hdac inhibitor 
(Mai et al., 2005) would inhibit the activity of Hdac4, allowing Dach2 and Mitr to 
suppress the transcription of Myog (as shown diagrammatically in figure 45 panel B).  
Previously, studies have used MC1568 in myotubes to study differentiation (Nebbioso 
et al., 2009), but none have studied its effect on atrophy induction.  The Class I specific 
Hdac inhibitor MGCD0103 (Fournel et al., 2008) was used as this would not inhibit 
Hdac4 (Fournel et al., 2008).  If, in the absence of a NMJ, a similar key cellular 
mechanism exists whereby Myog expression is controlled by a class II Hdac (Hdac4), 
the pathway should be blocked by MC1568 but unaffected by the addition of a Class I 
Hdac inhibitor.  Previously trichostatin A (TSA) has been used to demonstrate a link 
between the Hdac pathway and Myog in vitro (Tang et al., 2009) and in vivo (Bricceno 
et al., 2012, Tang and Goldman, 2006).  However TSA is a broad spectrum inhibitor that 
targets both Class I and Class II Hdacs.  The use of specific Class I or Class II Hdac 
inhibitors would give greater insight into the specific Hdacs involved in the atrophy of 
cultured myotubes.  
The second arm of the pathway initiates with phosphorylated Stat3 moving into the 
nucleus and activating transcription of Socs3 which in turn activates transcription of 
Myog (figure 45 panel C).  S3I-201, inhibits Stat3 DNA-binding activity and diminishes 
Stat3 phosphorylation (Siddiquee et al., 2007).  This would prevent the transcriptional 
upregulation of Socs3 and so the transcription of Myog.  Stat3 inhibitors have not, to 
our knowledge, been previously tested in either in vivo or in vitro studies of skeletal 
muscle atrophy. 
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Through the utilisation of class II Hdac and Stat3 inhibitors the aim of this study was to 
selectively interfere with each of the pathways upstream of their convergence on Myog.  
Ultimately these chemical interventions may inhibit the atrophy process generated by 
glucose deprivation in cultured C2C12 myotubes, which may translate to other models 
of skeletal muscle atrophy. 
 
 
Figure 45  Chemical Inhibition of Cellular Pathways Regulating Myogenin and Its 
Targets 
A; Two branches of the signalling pathway proposed from the in vivo TTX study to 
control the levels of transcription of myogenin and ultimately genes associated with 
atrophy.  Possible Effects of the Hdac class II inhibitor MC1568 (B) and the Stat3 
inhibitors S3I-201 (C) on myotubes undergoing glucose starvation.  Abbreviations can 
be found in figure 40. 
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6.2  Atrophy Measurement Following Glucose Starvation of Myotubes 
 
C2C12 mouse myoblasts were cultured to induce myotube formation as outlined in 
2.1.1.  6 plates were treated by replacing the culture media for 24 hours with DMEM 
supplemented with 2% HS (Normal Media Control) and 6 were treated with DMEM, no 
glucose supplemented with 2% HS (Glucose Free Media) to give a total of 12 plates in 
the study.  This experimental group was replicated a further 4 times,  producing 48 
plates in total.  In each of these experimental groups there was an addition of a 
chemical inhibitor; histone deacetylase (Hdac) Class I inhibitor MGCD0103 (Selleck) at 
10µM, the Hdac class II inhibitor MC1568 (Selleck) at 10µM, or the Signal Transducer 
and Activator of Transcription (Stat3) inhibitor S3I-201 (Selleck) at 50µM, as well as a 
combination of MC1568 and S3I-201 at the same concentrations.  The optimal 
concentrations of the inhibitors were determined by a cell viability test on cultured 
C2C12 myotubes, using a CellTiter 96® AQueous Non-Radioactive Cell Proliferation 
Assay (Promega) as per the manufacturer's instructions (2.1.3). 
In the main study, the degree of atrophy was measured by changes in myotube cross 
sectional area (CSA).  The transcriptional changes in the genes integral to the working 
hypothesis were measured by qRT-PCR following treatment in order to further analyse 
the effects of the chemical inhibitors. 
 
6.2.1  Phase Contrast Microscopy of Chemically Treated Myotubes Shows Healthy 
Cultures 
 
Phase contrast microscopy was used as described in 3.2.1 to confirm intact myotubes 
with little evidence of apoptosis following any of the treatments (Figure 46). 
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Figure 46  Phase Contrast Microscopy Showing Viable Cultured C2C12 Myotubes 
Before and After Each Treatment With Each Chemical Inhibitor 
Photographs were taken before and after treatment for each of the 48 plates of cultured 
C2C12 myotubes, a representative example from each group is shown.  Plates were 
treated for 24 hours with normal media and 10µM MC1568 (A), with glucose deficient 
media and 10µM MC1568 (B), normal media and 10µM MGCD0103 (C), glucose 
deficient media and 10µM MGCD0103 (D), normal media and 50µM S3I-201 (E), 
glucose deficient media and 50µM S3I-201 (F), normal media with 10µM MC1568 and 
50µM S3I-201 (G) and with glucose deficient media and 10µM MC1568 and 50µM S3I-
201 (H).  All myotubes remained intact with little evidence of apoptosis of damage. 
 
 
6.2.2  The Effects of Chemical Inhibition on Atrophy Induced by Glucose Starvation 
 
In order to measure the degree of in vitro atrophy attributable to each chemical 
treatment, the CSA of the myotubes in culture were measured before and after 
treatment, and comparisons were made.  The full method is outlined in 2.1.3.  Figure 47 
shows the effects of each chemical treatment on the degree of atrophy due to glucose 
starvation observed in cultured myotubes as well as the effects in myotubes cultured in 
normal media. 
136 
 
 
 
Figure 47  The Response of Myotube Cross Sectional Area (CSA) to Glucose 
Starvation and Inhibition of the Hdac and Jak/Stat3 Pathway 
C2C12 myotubes were cultured for 24 hours in media containing glucose (blue) or no 
glucose (red), with MC1568, MGCD0103 and S3I-201 as indicated below each bar.  CSAs 
were calculated by measuring the diameter of myotubes from photomicrographs.  Bars 
indicate mean (n=6) changes in CSA following treatment and statistically significant 
(p<0.05) changes are indicated by an asterisk.  Error bars indicate SEM. 
 
24 hours growth in normal media containing glucose and no additional chemicals gave 
no significant increase in mean CSA.  Incubation in glucose-free media produced a 
56.36% (+/- 2.01) decrease in mean CSA compared to the same culture at time zero 
(Figure 47), which was shown to be statistically significant following an ANOVA test 
(p<0.05). 
Myotubes cultured in normal media supplemented with the Hdac Class II inhibitor 
MC1568 at 10µM showed a non significant (p=0.072) 16.12% (+/- 9.15) decrease in 
CSA following treatment.  However, on combining glucose starvation with 10μM 
MC1568, the myotube CSA still decreased significantly but now only by 42.23% (+/- 
3.74).  Thus the degree of atrophy produced by glucose starvation, as measured by 
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myotube CSA, was significantly inhibited by 14.13% by the addition of MC1568 (p= 
0.008, following an ANOVA test).  This is in line with the predications set out in 6.1 
figure 45, if Hdac4 plays a role in atrophy in this in vitro starvation atrophy model. 
Myotubes treated with normal media supplemented with the Stat3 inhibitor S3I-201 at 
50µM showed no significant difference in changes in CSA following treatment when 
compared with normal media alone (p= 0.939).  However, when myotubes were 
glucose starved with the addition of S3I-201, the CSA decreased by only 21.76% (+/- 
5.71), compared to 56.36% without chemical inhibition.  This difference was found to 
be significant following statistical testing (p= 0.00007), showing that Stat3 also plays a 
role in starvation atrophy. 
When myotubes were treated with a combination of S3I-201 and MC1568 in normal 
media there was no significant change in CSA following treatment (3.66% increase +/- 
7.06).  However, on glucose starvation this combination treatment produced a 
significant (p=0.001) decrease in CSA of myotubes of 24.51% (+/- 5.15).  This decrease 
in CSA was not significantly different from the change in CSA observed with S3I-201 
alone (p=0.671), suggesting that Stat3 signalling might play a more dominant role than 
Hdac4 in starvation atrophy. 
The addition of the class I Hdac inhibitor MGCD0103 to myotubes was intended as a 
control for the specifity of class II Hdacs in atrophy.  However MGCD0103 at 10µM in 
normal media surprisingly produced a significant increase in myotube diameter of 
25.19% (+/- 6.73).  Even more noteably, on glucose starvation the degree of atrophy 
was markedly reduced in the presence of MGCD0103, which showed only a non 
significant (p=0.557) 2.93% (+/- 6.93) decrease in CSA.  Thus chemical inhibition by 
MGCD0103 effectively blocked atrophy due to glucose starvation.  This was in contrast 
to the expected effects of the chemical proposed in 6.1. 
 
6.3  Transcriptional Changes of Cellular Pathway Genes 
 
In order to investigate the effects of glucose starvation, as well as chemical inhibition of 
the Class I or Class II Hdacs and the Jak/Stat3 pathway, on cultured myotubes the 
transcriptional changes in genes integral to the cellular pathways outlined in figure 45 
were measured using qRT-PCR. 
138 
 
6.3.1  End Point RT-PCR Validation of Murine Primer Pairs 
 
As C2C12 myoblasts are murine in origin, new mouse specific RT-PCR primers were 
designed for the genes integral to the cellular pathways outlined in figure 45 as 
outlined in section 3.4.  These included Hdac4, Hdac5, Stat3, Mitr, Socs3, Myogenin and 
Chrna1.  Primers for Fbxo32 and Trim63 were designed previously (see section 3.4).  
RT-PCR followed by 2% agarose gel electrophoresis (outlined in 2.6.6) confirmed that 
all primer pairs amplified a PCR product of the correct size at an optimum annealing 
temperature of 61 °C (figure 48 A).  An RT- template was tested with each primer pair 
to ensure there was no amplification from genomic DNA (figure 48 B).  No genomic 
DNA contamination was found to interfere with amplification for any of the primer 
pairs. 
 
 
Figure 48  Specificity of Murine PCR Primer Pairs For Microarray Genes 
End-point RT-PCR Followed by 2% agarose gel electrophoresis shows single bands of 
the correct size for each of the primer Pairs (A).  An RT- template was tested with each 
primer pair to ensure there was no amplification from genomic DNA (B).  Each gel was 
run with a molecular weight hyperladder, whose band positions for 100-400 base pairs 
(bp) are shown next to each. 
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6.3.2  Determination of Primer Efficiency in qRT-PCR 
 
The amplification efficiency of all primer pairs for microarray genes was assessed using 
qRT-PCR as previously outlined in 3.4.3.  The standard curves generated for each of the 
primer pairs can be found in appendix 7.  It was determined that the efficiency of all the 
primer pairs was between 90 and 110% as recommended for use in qRT-PCR by 
BioRad, with the exception of  Dach2.  This efficiency reading could be explained by the 
extremely low levels of transcript, making it difficult to detect.  This very low level can 
also be observed in figure 41, where a weak band was evident following end-point RT-
PCR and agarose gel electrophoresis.  In subsequent analysis, it was not possible to 
determine Dach2 transcript levels using qRT-PCR.  The efficiency of each primer pair is 
shown in table 15. 
 
 
Table 15  Efficiency of Amplification During qRT-PCR for Each Primer Pair  
2-fold serial dilutions of a template cDNA (from control, untreated tissue) were used to 
generate a standard curve for each primer pair.  Amplification efficiency was calculated 
from the gradient of the linear regression line of these curves.  For subsequent analysis 
an optimum efficiency of between 90 and 110% was required, and was achieved with 
the exception of Dach2. 
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6.3.3  Overview of Transcriptional Changes 
 
The transcript levels of each of the target genes were measured using qRT-PCR.  The 
results were analysed by the 2-ΔCT method, where differences between the mean of the 
reference genes CT values and the target gene CT value in each sample was quantified 
individually.  Figure 49 shows the transcript levels of each of the genes in each of the 
experimental treatment groups, in order to highlight the differences in abundance of 
transcripts.  Evidently, Chrna1 and Myog transcript levels are relatively more abundant 
than the other transcripts under both normal growth conditions and glucose starvation. 
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Figure 49  Mean Transcript Levels of Genes of Interest following Each Treatment 
In Vitro 
C2C12 myotubes were cultured for 24 hours in media containing glucose, MC1568, 
MGCD0103 or S3I-201 as indicated below each set of transcripts.  mRNA transcript 
levels were measured using qRT-PCR and normalised to the mean of two housekeeping 
genes (Rn18s and Polr2a) (n=6). 
 
 
Further analysis used the 2-ΔΔCT method, where the difference between the transcript 
levels of each of the genes was calculated as a fold change in the treated group, 
compared to treatment with normal media containing no chemical inhibitors.  The 
results from this analysis are shown in Figure 50, where the fold changes of each of the 
genes are displayed following each treatment. The fold change of these transcripts was 
highly divergent and thus the response these transcripts was further analysed by 
considering each of the chemical inhibitors and their effects separately (section 6.3.5, 
6.3.6 and 6.3.7).   
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Figure 50  Mean Changes in Transcript Levels Following Treatment In Vitro 
Treatment of cultured C2C12 myotubes included 24 hours of media containing glucose, 
MC1568, MGCD0103 and S3I-201, as indicated below each set of transcripts.  Mean fold 
changes in transcript levels following treatment from normal media were measured 
using qRT-PCR and normalised to two housekeeping genes (Rn18s and Polr2a) (n=6).  
Error bars indicate SEM. 
 
 
6.3.4  Does Glucose Starvation in Myotubes Utilise Hdac4 or Stat3 Regulation of 
Myogenin? 
 
Gene expression on glucose starvation of myotubes might be expected to decrease the 
Myog suppressor Mitr, leading to an increase in expression of Myog and of its potential 
targets Fbxo32, Trim63 and Chrna1.  However, when the transcript levels of these 
genes were analysed following glucose starvation these predicted changes were not 
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observed (figure 50).  In fact, Mitr expression actually increased following glucose 
starvation with a concomitant decrease in the levels of Myog.  There was however an 
increase in Fbxo32 levels, but  no significant change in Trim63 or Chrna1 levels.  These 
results suggest that Myog expression levels may not play a role in the myotube 
starvation model of atrophy, in contrast to the results found following TTX nerve block 
in vivo. The difference in the response of Myog in the in vivo and in vitro models may be 
related to the absence of the NMJ in the latter. Thus, it may still be possible to 
determine a role for Myog in the in vitro model of muscle atrophy with the use of 
chemical inhibitors which act on genes further downstream of the NMJ. 
 
6.3.5  The Class II Hdac Inhibitor MC1568 Significantly Reduces Atrophy in Myotubes 
Cultured in Glucose-Free Media 
 
When considering the effect of MC1568 on glucose starvation we compared the 
transcript changes following glucose starvation, with and without MC1568 (figure 51). 
 
 
 
Figure 51  The Transcriptional Response of Myotubes Following Glucose 
Starvation with and without MC1568 
Mean transcript levels were measured using qRT-PCR and normalised to the mean of 
two housekeeping genes (Rn18s and Polr2a).  Transcript levels are represented as a 
fold change from myotubes treated with normal media, without chemical inhibition.  
Statistically significant (p<0.05) differences in changes in transcript levels following an 
ANOVA test are marked with *(n=6).  Error bars indicate SEM. 
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There were significant increases in several genes in the presence of MC1568.  Hdac4 
transcript levels significantly increased after the addition of MC1568.  This may be the 
result of a positive feedback mechanism following the inhibition of Class II Hdac 
activity.  The significant increase in both Stat3 and Socs3 may suggest that the two arms 
of the cellular signalling pathways are linked.  For example, the increase in the 
expression of Stat3 and Socs3 may be a compensatory mechanism in response to the 
decreased activity of the Hdac pathway.   However, Myog levels remain unchanged with 
the addition of MC1568, suggesting that whilst the Hdac and Jak/Stat3 pathways may 
be affected by chemical inhibition in myotubes, there may be other downstream targets 
that are involved in the control of atrophy without the involvement of Myog.  
Furthermore, the transcript levels of the E3 ligases, targets of Myog, do not change as 
predicted. Levels of Trim63 remain unchanged following MC1568 treatment and 
Fbxo32 levels increase.  As MC1568 has been shown to reduce the degree of atrophy 
following glucose starvation in myotubes,  a decrease in the levels of these E3 ligases 
would be expected.  However, the failure to suppress Trim63 and Fbxo32 transcript 
levels suggests they are not integral to the atrophy process induced by glucose 
starvation in myotubes, and that there is potentially an alternative mechanism 
governing atrophy that does not utilise the Myog pathway. 
 
 
6.3.6  The Class I Hdac Inhibitor MGCD0103 Inhibits Atrophy Through Altered 
Myogenin Expression 
 
Surprisingly, the most striking effects of chemical inhibition were for MGCD0103 which 
strongly inhibited glucose starvation atrophy, and demonstrated a hypertrophic affect 
under normal growth conditions (Figure 47).  These changes in myotube size were 
accompanied by significant changes in some transcript levels, most notably the Myog, 
Trim63 and Chrna1 transcripts, which all decreased on addition of MGCD0103 (Figures 
49 and 50).   
Changes in Myog, Trim63 and Chrna1 have been considered earlier, where significant 
increases in these genes were observed in the TTX in vivo model of atrophy (Figures 43 
and 44). Thus, a central role for Myog and its targets has been highlighted in both in 
vivo and in vitro models of atrophy. More detailed comparisons between these two 
models and the response of Myog and its targets are discussed further here. 
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Figure 52 shows the relative transcript levels of myogenin in control muscle tissue and 
C2C12 myotube cultures that have been grown in normal media to make comparisons 
between the two models at the transcript level.  
 
 
Figure 52  Myogenin Transcript Levels in In Vivo and In Vitro Models of Atrophy 
Mean transcript levels were measured using qRT-PCR and normalised to the mean of 
two housekeeping genes (Rn18s and Polr2a).  Levels were calculated using the 2-ΔCT 
method to show the relative abundance of each transcript (n=6).  Error bars indicate 
SEM. 
 
 
Lower relative basal transcript levels of Myog were observed in the in vivo sham 
control group (0.034 +/- 0.002) when compared with the in vitro normal media control 
group (0.656 +/- 0.024). This represents an 18-fold (+/- 2.61) higher transcript level of 
Myog in the in vitro control group.  This difference was not unexpected as Myog is 
known to be involved in the differentiation of muscle cells (Hasty et al., 1993).  Thus a 
higher expression of Myog in vitro is likely to be indicative of the developmental stage 
of the myotubes in comparison with fully differentiated muscle tissue in vivo. The 
potential consequences of this difference were explored further, to investigate whether 
basal transcript levels of Myog have any effect on the response of Myog during atrophy.  
Changes in myotube or fibre CSA were measured to determine the degree of muscle 
atrophy, and correlated with changes in Myog expression, to investiage further the 
importance of basal Myog expression. 
 
Figure 53 shows the correlation between Myog transcript levels and the CSA of muscle 
fibres in vivo (panel A) and myotubes in vitro (panel B) across all the treatment groups. 
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Figure 53  The Relationship Between Myogenin Transcript Levels and CSA  in 
Muscle (A) and Myotubes (B) 
Transcript levels were measured using qRT-PCR and normalised to the mean of two 
housekeeping genes (Rn18s and Polr2a) and are shown on the x axis of each graph.  
CSAs (y axis) were calculated by measuring the diameter of myotubes/muscle fibres 
from photomicrographs using ImageJ and scaled using a graticule. 
 
It was observed that as Myog transcript levels increase from a relatively low basal 
control level in vivo (A) there is a delayed concomitant decrease in CSA.  Following 3 
days of nerve block Myog levels generally increase without a significant change in CSA.  
By day 7 of the nerve block the levels of Myog remain elevated with a decrease in the 
fibre CSA. This is further exacerbated at day 14 of the nerve block, where Myog levels 
remain elevated and a further decrease in CSA is observed.  The delay in changes in CSA 
compared with changes in Myog transcript expression levels is logical since changes in 
transcript levels are part of the early response mechanisms which eventually lead to 
changes in muscle structure and function.  
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The in vitro model of atrophy revealed a pattern of negative correlation between Myog 
transcript levels and myotube CSA only when the myotubes were treated with 
inhibitors or subjected to glucose starvation (figure 53). Under normal growth 
conditions (which was taken as a control) the Myog/CSA correlation appears as an 
outlying group. 
The relationship between Myog and its transcriptional targets, which significantly 
altered during chemical inhibition by MGCD0103, was then considered.  Interestingly, 
both Trim63, a ubiquitin ligase, and Chrna1 transcript levels were found to decrease 
with a decrease in Myog (figure 50). However, the ubiquitin ligase Fbxo32 did not 
change, despite evidence that it is a downstream target of Myog (Moresi et al., 2010). 
Figure 54 shows the correlations between Myog transcript levels and the levels of each 
ubiquitin ligase, Trim63 and Fbxo32, both in vitro and in vivo across all experimental 
groups, to compare the relationship between Myog transcript levels and expression of 
these target genes. 
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Figure 54  The Relationship Between Transcript Levels of Myog and The 
Ubiquitin Ligases Trim63 and Fbxo32 Both In Vitro and In Vivo 
Correlations between Myog and Trim63 (A) and Myog and Fbxo32 (B) were analysed in 
both the in vitro and in vivo models of atrophy. Transcript levels were measured using 
qRT-PCR and normalised to the mean of two housekeeping genes (Rn18s and Polr2a). 
Correlations are determined by the coefficient of determination (R2).   
 
A strong positive correlation (R2=0.9) can be seen between Myog and Trim63 
transcript levels in vitro, which is evident to a lesser extent in vivo (R2=0.7907). In 
contrast. Myog transcript levels showed no correlation with Fbxo32 transcript levels in 
vitro, although in vivo some degree of correlation was evident (R2 0.6064).  Thus the 
data suggests a relationship between Myog and Trim63 transcription.  However, 
Fbxo32 may be subject to control by other upstream effectors, particularly in the in 
vitro setting.  
Figure 55 shows the relationship between myogenin transcript levels and transcript 
levels of Chrna1 in vitro and in vivo. 
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Figure 55  The Relationship Between Transcript Levels of Myog and Chrna1 In 
Vitro and In Vivo  
Correlations between  Myog and Chrna1 Transcript levels in vitro (A) and in vivo (B) 
were measured using qRT-PCR and normalised to the mean of two housekeeping genes 
(Rn18s and Polr2a).  Correlation is determined by the coefficient of determination (R2).  
 
A very strong correlation between Myog and Chrna1 transcript levels is evident in vivo 
with an R² value of 0.999, with a weaker relationship apparent in vitro (R20.5566). The 
difference between the correlation in the in vitro and in vivo models may be related to 
the absence of the NMJ in cultured myotubes and the role of Chrn1 as an AchR subunit 
in the NMJ. 
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The chemical inhibition of in vitro muscle atrophy with MGCD0103, characterised by a 
lesser reduction in myotube CSA, was a surprising result.  The addition of MGCD0103 to 
myotubes cultured under conditions of glucose starvation appears to affect the basal 
levels of Myog transcript, which is relatively high in the in vitro model when compared 
with the in vivo model. A concomitant decrease in Trim63 and Chrna1, downstream 
targets of Myog, was also evident. Further scrutiny of the data revealed strong 
correlations between Myog and Trim63 transcript levels, as well as Myog and Chrna1, 
in both in vitro and in vivo models of atrophy. However, the correlation between Myog 
and another of its downstream targets, Fbxo32, was absent in the in vitro model, 
suggesting that Myog may act only on specific downstream targets in different 
conditions of muscle atrophy, or that Fbxo32 is controlled by upstream effectors other 
than Myog in cultured myotubes.  
 
6.3.7 Comparisons of The Effects of S3I-201 on Atrophy and Combination Therapy with 
MC1568 
 
The addition of S3I-201 to myotubes incubated in glucose free media resulted in the 
decrease of myotube CSA by 21.76% (+/- 5.71), compared to a decrease of 56.36% in 
response to glucose starvation alone (figure 47).  When the transcripts were analysed 
(figure 56) there were significant decreases in Trim63 and Myog expression in the 
presence of S3I-201, and increases in Stat3 and Hdac4 expression. The Reduction in the 
level of atrophy in response to S31-201 indicates an important role for the Jak/Stat3 
pathway in the control of myotube size, and the decrease in the expression of Myog and 
its downstream target Trim63 suggests that the Jak/Stat3 pathway is indeed regulating 
Myog expression in this model. Interestingly, an increase in Stat3 was observed, 
potentially indicative of a positive feedback mechanism in response to a severe 
decrease in Stat3 activity. Furthermore, the increase in Hdac4  may be the result of a 
compensatory mechanism to permit control of muscle size via a pathway that does not 
require Stat3 activation.  The data shown in Figure 51, where increases in Stat3 were 
observed following inhibition of the Hdac pathway by MC1568, also support 
compensatory cross talk between the two arms of the pathway. 
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Figure 56 Fold Transcript Level Changes in Myotubes Following Glucose 
Starvation with and without S3I-201 
Mean transcript levels were measured using qRT-PCR and normalised to the mean of 
two housekeeping genes (Rn18s and Polr2a).  Statistically significant (p<0.05) 
differences in changes in transcript levels following an ANOVA test are marked with * 
(n=6). Error bars indicate SEM. 
 
The rescue in CSA caused by S31-201 combined with MC1568 and glucose starvation 
was not significantly different to that seen with S3I-201 alone (p=0.671).  Decreases in 
Trim63 and Myog were observed in myotubes cultured in glucose free media with the 
addition of S31-201, when compared to those cultured in normal media with S31-201 
(figure 56). The addition of MC1568 to both normal and glucose free cultures, in 
combination with S31-201, did not appear to effect the changes in these transcripts any 
further (figure 57).  This was unsurprising result since an earlier study showed that the 
addition of MC1568 alone did not change the expression of either of these genes 
(Figure 51). Thus it would appear that the Hdac Class II inhibitor has no effect on the 
transcription of these genes, irrespective of whether the Stat3 pathway is inhibited. 
An increase in Hdac4 expression was observed following the addition of S31-201 in 
myotubes cultured in glucose free media compared with normal media. Intriguingly 
though, the response of Hdac4 to a combined therapy of S31-201 and MC1568 in 
myotubes cultured in glucose free media, was a significant decrease in transcript 
compared with that when cultured in normal media . The response of Hdac4 to the 
combined therapy further illustrates the complexity of the pathways that may interlink 
to control Myog expression and ultimately muscle size. 
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Figure 57  Mean Transcript Levels Following Treatment With S3I-201, and a 
combination of S31-201 and MC1568, Cultured in Normal and Glucose Free Media 
Mean transcript levels were measured using qRT-PCR and normalised to the mean of 
two housekeeping genes (Rn18s and Polr2a). Transcript levels are shown as mean fold 
changes compared to myotubes cultured in normal media.  Significant differences 
(p<0.05) in fold changes following an ANOVA test are marked with * (n=6). Error bars 
indicate SEM. 
 
 
6.3.8  The Differential transcriptional response to In Vitro Glucose Starvation and In 
Vivo Nerve Block  
 
The transcript levels following glucose starvation in vitro and after 14 days of nerve 
block in vivo were considered in order to compare the two models of muscle atrophy.  
The transcript levels are shown as fold changes following each of the treatments (figure 
58). 
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Figure 58  Comparison of Transcript Changes with Glucose Starvation In Vitro and 
Muscle Block In Vivo  
Transcript levels were measured using qRT-PCR and normalised to the mean of two 
housekeeping genes (Rn18s and Polr2a).  Transcript levels are represented as fold 
changes, glucose starved from normal media treated myotubes and 14 days atrophy 
from the untreated contraleteral control.  The transcripts are shown in 3 panels (A-C) 
to allow for differences in scale of change (n=6). Error bars indicate SEM. 
 
 Comparisons between changes in key transcripts in the in vitro and in vivo models of 
atrophy have highlighted the differential responses between the two. Increases in Stat3 
and Hdac 4 were observed in the in vivo nerve block study, whilst myotubes cultured in 
vitro in glucose-free conditions showed no change in Hdac4 and a very small decrease 
in Stat3. Similarly, increases in Myog transcript and its downstream targets Trim63 and 
Chrna1 were also observed in the in vivo model but not in the in vitro model. Thus it 
would appear that the Myog dependent pathway is involved in muscle atrophy in fully 
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differentiated tissue in vivo, but perhaps an alternative pathway exists in vitro, where 
different transcripts are required to induce changes in myotube size.  
Interestingly, the ubiquitin ligases Trim63 and Fbxo32 appear to respond differently in 
different conditions of atrophy at the transcript level.  Whilst Trim63 seems to be more 
involved in the in vivo nerve block model of atrophy, Fbxo32 showed a greater 
response in the in vitro glucose starvation model. The data therefore indicates that 
while Myog may contribute to the control of the expression of these ubiquitin ligases, 
there may well be other upstream effectors which are involved in different conditions 
of atrophy.  
 
6.4  Discussion 
 
Myotube cultures incubated in normal differentiation media or in media lacking 
glucose in order to induce atrophy were used to investigate the response of chemical 
inhibitors of Hdac class I and II and Stat3.  The Hdac Class II inhibitor MC1568 was used 
in order to target the Hdac arm of the Myog transcriptional network.  It has been 
suggested that the Class II Hdacs that are involved with the regulation of Myog 
expression in muscle atrophy (Moresi et al., 2010).  If this is true then the Class II 
inhibitor has the potential to have an effect on the degree of atrophy (figure 45 panel 
B).  The class I Hdac inhibitor MGCD0103 was chosen as a control under the premis 
that this may not have an effect on Myog expression during atrophy.  Lastly the Stat3 
inhibitor S3I-201 was chosen to investigate the role of Stat3 in muscle atrophy.  If Stat3 
is playing a major role in atrophy then S31-201 would be expected to reduce the 
expression of Myog and ultimately inhibit the atrophy process (figure 45 panel C). 
 
6.4.1  A Potential Role for Class I or II Hdacs in Control of Myotube Size 
 
The class II Hdac inhbitor MC1568 significantly blunted atrophy in myotubes cultured 
in glucose free media by 14%.  This confirms the role of Hdac Class II proteins in 
muscle atrophy, (figure 47) which have been observed in previous studies (Moresi et 
al., 2010).  This result was interesting in light of the fact that Hdac4 was previously 
described as a transcriptional sensor located at the NMJ, whilst myotubes in culture do 
not have NMJs. However, subsequent analyses of transcriptional changes suggest a 
more complex role for the class II Hdacs.  Figure 51 analysed transcript changes 
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following glucose starvation dependent on the Hdac Class II inhibitor MC1568.   The 
chemical inhibition of the Class II Hdacs might be expected to reduce the expression of 
Myog through the transcriptional induction of its suppressor Mitr.  However, the 
addition of MC1568 produced no significant changes in Myog or Mitr transcript levels, 
or the targets of Myog; Trim63 and Chrna1. Additionally, Fbxo32 levels actually 
increased with the addition of MC1568.  The expression of Hdac4 increased suggesting 
a positive feedback mechanism to produce more Hdac4 to compensate for the 
inhibition of existing Hdac4.  The addition of MC1568 to myotubes cultured in normal 
media, produced a 16.12% (+/- 9.15) decrease in CSA. Whilst this was found to be non-
significant (p=0.072), the analysis of the data may be abnormally skewed.  For five 
experimental replicates a decrease in CSA of between 38% and 13% was observed, but 
one replicate instead showed an increase in CSA of 25% following treatment.  
Interestingly, the inhibition of Hdac4/5 in this replicate did effect Myog transcript 
levels, with a decrease in expression and a concomitant  increase in its repressor Mitr 
and its  hypothesised target Trim63 (figure 50).  There is the possibility that human 
error may account for this discrepancy on the basis that the rest of the data followed a 
similar pattern of response.  Further repetitions of these experiments are required to 
determine the reproducibility and frequency of outlier samples.  
In contrast to the other Myog target genes, MC1568 produced a significant increase in 
Fbxo32, which may go some way to explain the atrophy this inhibitor caused even 
without concomitant glucose starvation.  So how can inhibition by MC1568 produce 
opposing effects under different culture conditions?  MC1568 blunts the atrophy 
produced by glucose starvation but in normal cells produces atrophy.  This implies a 
dual role for the Hdac Class II proteins in normal and atrophy inducing states.  This 
could be exacerbated by the fact that in our model, the myotubes are still 
differentiating, even when they are cultured in normal media in the presence of 
glucose.  To date, the effects of class II Hdac specific inhibition in vivo have not yet been 
investigated, to look for differences between differentiating muscle and fully 
differentiated tissue. It should be noted whilst MC1568 has been shown to specifically 
inhibit Class II Hdacs in other studies (Cenik et al., 2011, Munkacsi et al., 2011), and the 
results show that it undoubtedly has an effect on the myotube cultures, there is no 
direct evidence in this assay that Class II Hdacs specificity is certain.  This is also true 
for the use of the Class I Hdac inhibitor MGCD0103. 
The most surprising result of our in vitro study came from the addition of MGD0103 to 
myotubes cultured in both normal and glucose free conditions. The addition of 
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MGCD0103 produced marked changes in myotube size and transcriptional output.  
Addition to myotubes cultured in normal media produced a significant increase in 
myotube diameter by 25% and in myotubes cultured in glucose-free conditions showed 
no significant decrease in CSA.  Thus MGCD0103 effectively blocked atrophy caused by 
glucose starvation.  When the transcript changes were analysed, the changes in Myog 
were marked and are discussed below in 6.4.2. 
 
6.4.2  Further Evidence for The Role of Myog in Muscle Atrophy 
 
Data produced from the nerve block study (discussed in 5.7.3) indicate that an increase 
in Myog expression may play a central role in this in vivo model of atrophy. This is in 
line with other in vivo studies (Moresi et al., 2010, Tang et al., 2009).  We have also 
shown a less significant role for Myog in glucose starvation induced atrophy in vitro, 
with no significant increase in expression of most targets (6.3.4).  However, chemical 
inhibition of the Class I Hdacs essentially blocked glucose-starvation induced atrophy.  
This was accompanied by a 14-fold (+/- 0.005, p< 0.0001) decrease in Myog transcript 
levels when compared to myotubes cultured in normal media (figure 50).  When 
myotubes were cultured in normal media, the addition of MGCD0103 alone induced 
hypertrophy and a 19-fold (+/- 0.003, p< 0.0001) decrease in expression level of Myog 
(figure 50).  This indicates a link between Myog transcript level and myotube size, and 
thus a potential role for Myog in the control of myotube size in culture.  
One plausible explanation for the differential response of Myog across the different 
atrophy models may be related to its role in myotube development. The in vitro model 
of atrophy is based on immature, differentiating myotubes and thus the role of Myog in 
these conditions may lean towards the control of differentiation. Alternatively, the in 
vivo model employs fully differentiated muscle, and thus Myog may be recruited to help 
regulate muscle size under different physiological conditions. Figure 52 shows a 
comparison between Myog expression in control samples in vitro and in vivo, 
highlighting the differential responses. The addition of MGCD0103 to C2C12 myotube 
cultures may alter the role of Myog even in differentiating muscle cells. This idea was 
investigated further in figure 53.  Here, comparisons were made between Myog 
transcript levels and fibre CSA in vivo, and myotube CSA in vitro, across all treatment 
groups. The in vivo data showed that an increased level of Myog transcript is associated 
with in a decrease in fibre CSA (figure 53 A), with a delayed response in the 3 day block 
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group.  However, in vitro, a relationship between increased Myog levels and decreased 
myofibre CSA was evident, but only with either the addition of a chemical inhibitor or 
in glucose free culture conditions. The data appears to strengthen the theory that Myog 
is recruited into its role in regulating myotubes under conditions of glucose starvation 
or in response to chemical inhibition.   
The mechanisms underlying the role of Myog in regulating muscle size are yet to be 
fully elucidated. Previous studies have shown that Myog regulates the expression of the 
E3 ubiquitin ligases Fbxo32 and Trim63 (Moresi et al., 2010, Tang et al., 2009).  
However, the data shown in figure 54 suggests that the regulation of both E3s may not 
be the sole responsibility of Myog.  Whilst comparisons of Myog transcript levels with 
Trim63 and Fbxo32 transcript levels does not provide direct evidence (figure 54), it 
does highlight a stronger relationship between Myog and Trim63 than between Myog 
and Fbxo32.  Further evidence comes from the data showing that during glucose 
starvation of myotubes, Myog transcript levels are not significantly changed (figure 50) 
but Fbxo32 transcript levels increase.  One possible explanation for this could be that 
the E3 ubiquitin ligase is under the control of Foxo transcription factors in this model.  
Although the transcript levels of Foxo1 showed no significant change with any of the in 
vitro treatments (data not shown), it is the phosphorylation state of the protein that is 
known to dictate its activity (Van Der Heide et al., 2004), and thus it is still possible that 
Foxo activation effects Fbxo32 transcription. Further investigation into the 
phosphorylation state and cellular location of Foxo1 during these treatments would be 
required in order to make links between Foxo1 and Fbxo32.   
The use of Hdac inhibitors in muscle atrophy has so far focused upon their effects on 
Myog, without consideration of their effects on Foxo.  One study using human lung 
cancer cell lines has shown a link between Class I Hdacs, but not Class II Hdacs, in the 
regulation of Foxo1 (Yang et al., 2009). This may help to explain the relatively small 
effect of the Hdac Class II inhibitor in our models, but when considering the large effect 
of the Hdac Class I inhibitor, further investigation is required to make sense of the 
potential role for Foxo1. Studies using the broad-spectrum Hdac inhbitor Trichostatin A 
(TSA) in both in vivo (Bricceno et al., 2012) and in vitro models (Tang et al., 2009) have 
focused on its effects on the Class II Hdacs in blunting atrophy.  However, TSA inhibits 
all Classes of Hdacs, making it difficult to isolate which are involved in the atrophy 
process. 
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6.4.3  Does the Jak/Stat pathway play a role in Atrophy? 
 
The addition of the Stat3 inhibitor S3I-201 to myotubes cultured under glucose free 
conditions blunted the atrophy produced from a 56% to a 22% reduction in myotube 
CSA.  The predicted changes in transcript levels in line with a role for Myog included a 
decrease in Socs3 and Myog and a subsequent decrease in Trim63, Fbxo32 and Chrna1.  
Although the addition of S3I-201 did significantly reduce the expression of Myog and 
Trim63 (figure 56) there was no significant reduction in the expression of Fbxo32 or 
Chrna1. In fact, Fbxo32 transcript levels increased, although this was not statistically 
significant.  This further reinforces the idea that in the myotube model of glucose 
starvation-induced atrophy, Myog is more strongly linked to Trim63 than Fbxo32.  
Socs3 expression did not significantly change with the addition of S3I-201.  This 
suggests that if Stat3 does regulate Myog, as our data implies, then it does not do so 
through the action of Socs3.  The addition of S3I-201 also increased the expression of 
Stat3 and Hdac4.  Stat3 induction could be the result of a feedback mechanism within 
the cell in an attempt to compensate for the blocked activity of Stat3. A similar response 
was seen with the Hdac Class II inhibitor, when inducing Hdac4 expression (figure 51).   
Blocking Stat3 activity may also feedback to the Hdac4 pathway, as seen in an induction 
of Hdac4 expression.   
Further investigations are required in order to clarify these theories and confirm that 
the Stat3 inhibitor is effectively blocking the activity of Stat3 in our model, and that this 
functionally induces activity of the Hdac4 pathway by analysis of Hdac4 protein levels,  
phosphorylation state and sub-cellular localisation.  However, inhibition by S3I-201 did 
significantly blunt atrophy and it's mode of action requires further investigation.  Stat 
inhibitors have not been evaluated in muscle atrophy previously and when comparing 
their effects with the Class II Hdac inhibitors they seem to be more effective in 
modulating the atrophy pathway.  This is illustrated in figure 57, showing that 
transcript changes, along with changes in CSA (figure 47) are not significantly affected 
with the addition of the class II Hdac inhibitor in combination with the Stat3 inhibitor. 
 
6.4.4  Myotube Starvation & Nerve Block Atrophy Utilise Different Cellular Pathways 
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We have already discussed the differences between the in vitro glucose starvation and 
in vivo electrical stimulation models of atrophy in 3.5.3,  as well as the differences 
between both in vivo models of atrophy: 20Hz electrical stimulation and nerve block in 
5.7.2 (available comparisons are made in table 16). 
 
Gene 
Gene Transcriptional Changes in Each Atrophy Model 
Glucose 
Starvation 
Functional 
Atrophy 
TTX Nerve Block 
Hdac4 - ↑ ↑ 
Hdac5 - - - 
Mitr ↑ - ↓ 
Stat3 - - - 
Socs3 ↑ - - 
Myog - ↑ ↑ 
Chrna1 - ↑ ↑ 
Fbxo32 ↑ ↑ ↑ 
Trim63 - - ↑ 
Table 16  Gene Transcriptional Changes Across Atrophy Models 
↑; Upregulation of gene transcript levels, ↓; downregulation, -; no significant change 
 
 
Finally, comparisons must be made between the glucose starvation model and nerve 
block atrophy.  6.3.8 outlines the differences in transcriptional changes following the 
two treatments.  There are significant differences in 5 out of the 9 genes analysed   
including a marked 17-fold increase following nerve block and no significant change 
following glucose starvation.  Thus whilst all 3 models of atrophy (glucose starvation in 
vitro, nerve block and electrical stimulation in vivo) undoubtedly produce a reduction 
in muscle or myotube size, the evidence here indicates that the cellular pathways 
utilised may differ between different models. Consequently, considering the model 
used when investigating skeletal muscle atrophy is of great importance.  
 
6.4.5  Summary 
 
The novel discovery that the chemical inhibition of the class I hdacs effectively blocked 
the atrophy caused by glucose starvation in myotubes is an exciting finding. Whilst 
cellular pathways involving Hdac4/5 or Stat3 converging on Myog to regulate its 
transcription have been implicated in several studies previously, the data from the in 
vitro, glucose starvation model of muscle atrophy strengthens the hypothesis that these 
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two pathways cross talk at several levels.  Most importantly, the role of Class I Hdacs in 
muscle atrophy has not been considered previously. Furthermore, the data suggest that 
whilst Myog and its downstream targets may play an important role in the control of 
muscle size, this is not the only mechanism by which muscle atrophy is regulated. 
Comparisons of the in vitro myotube glucose starvation and in vivo TTX nerve block 
models of atrophy highlighted differences in the transcriptional, suggestive of a more 
complex, multi-dimensional regulation of muscle mass under different physiological 
conditions. 
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Chapter 7: Thesis Conclusions and Further Work 
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A number of conditions lead to skeletal muscle atrophy, including disease states such as 
cancer cachexia, age-related sarcopenia and muscle disuse. The latter can also 
contribute in a secondary manner to muscle atrophy, primarily in response to the 
impact on mobility of many of these debilitating disorders. Whilst there is a large body 
of research directed towards muscle atrophy, the complexity of the signalling pathways 
involved in the regulation of muscle mass have resulted in large gaps in the 
understanding of these pathways. One contributing factor may be the fact that there are 
numerous events that can initiate muscle atrophy, and that regulation of protein 
synthesis may be unique in each case. A more in-depth knowledge of the cellular and 
molecular mechanisms that govern muscle size is vital in identifying therapeutic 
targets to prevent muscle breakdown and encourage muscle growth. 
An important role for the transcription factors Myog and Foxo in muscle atrophy has 
been highlighted in several studies through their regulation of the E3 ubiquitin ligases 
Trim63 and Fbxo32. Both E3 ligases have been shown to be upregulated in several 
models of muscle atrophy and consequently have been used as markers of muscle 
breakdown (Clarke et al., 2007). In contrast to the control of Foxo activity, which 
involves phosphorylation and cellular localisation, control of Myog occurs through 
transcriptional expression. Consequently, our study of the transcriptional response to 
muscle atrophy has involved analyses of Myog and a number of its downstream targets 
linked to muscle atrophy.  
Comparisons of in vitro models of muscle atrophy, using glucose starvation or 
dexamethasone treatment of myotubes, with an in vivo model of ‘functional atrophy’ 
showed remarkably different responses in terms of transcriptional regulation. Target 
genes of Foxo transcription factors were selected and a transcriptional profile was 
analysed in response to each of the models of atrophy. The data from our comparative 
study suggested that each model of atrophy potentially has a unique transcriptional 
profile and highlighted the need for a more physiologically relevant in vivo model in 
order to identify the transcriptional pathways involved in muscle disuse atrophy. Data 
obtained from a more clinically accurate muscle disuse model could have a greater 
potential to provide information which would lead to a therapeutic target for the 
prevention of muscle atrophy.       
We developed an in vivo model of muscle atrophy, utilising TTX to block nerve activity 
and provide a model of complete muscle disuse. The model permitted a time course 
analysis of muscle disuse with the option of recovery.  Progressive muscle atrophy was 
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observed in response to TTX nerve block over a 14 day period, without damage to the 
muscle tissue.  Removal of the nerve block resulted in partial recovery, characterised 
by an increase in muscle mass. Interestingly, our study indicates that the time scale for 
muscle atrophy is similar, if not the same as, the time scale of muscle recovery from 
atrophy.  
Comparative microarray analysis of both the ‘functional atrophy’ and TTX nerve block 
in vivo models showed remarkable differences in the transcriptional profile of the two 
models. This is unsurprising in light of previous studies in which comparisons of 
transcriptional profiles have suggested a unique regulation of protein loss in response 
to the different events initiating the atrophy pathway (Kandarian and Jackman, 2006). 
The importance of studying the time course of transcriptional changes in response to 
muscle disuse was highlighted by the temporal changes in gene transcripts over a 14 
day period.  ‘Early responders’ were identified following 3 days of muscle disuse, whilst 
after 7-14 days gene transcripts involved in the ‘established’ phase of muscle atrophy 
were highlighted. Many studies have previously focused on a single time point when 
considering the transcriptional response to muscle atrophy, potentially overlooking the 
response of key genes involved in the initiation of signalling pathways leading to 
muscle protein breakdown (Bey et al., 2003, Stein et al., 2002).   
Data from the microarray analysis supported data available in the current literature 
and was used to link together two potential cellular pathways controlling the 
expression of Myog, originating within the NMJ and acting as a sensor for changed 
muscle activity. The intermediaries of this pathway, which consisted of two branches, 
could be targeted to potentially interfere with the process of muscle atrophy.  
Subsequently, we designed an in vitro study which involved inhibition of the two arms 
of the pathway, the class II Hdacs, Hdac4/5 and Jak/Stat3, which are thought to 
converge on the regulation of Myog.  Our findings indicated a role for these pathways in 
the control of Myog expression in conditions of glucose starvation in myotubes, where 
addition of the chemical inhibitors of the class II Hdacs, MC1568, and Stat3, S3I-201, 
showed a reduction in the degree of atrophy produced in the absence of chemical 
inhibition. However, the response to chemical inhibition of the class I Hdacs with 
MGCD0103 was the most surprising and interesting result. The class I Hdac inhibitor 
was selected as a control, under the premise that it would selectively block class I Hdac 
activity and thus it would not affect either of the arms of the cellular pathway. 
Treatment of myotubes cultured in glucose-free media with MGCD0103 showed a 
significant reduction in the atrophy evident without chemical inhibition, to produce a 
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non-significant reduction in myotube CSA, effectively blocking atrophy.  Furthermore, 
Myog transcript levels were shown to dramatically decrease in this in vitro model, 
highlighting a potential link between Myog transcript and atrophy. Whilst this is a 
preliminary study that must be repeated in order to verify the data, the results provide 
an exciting new avenue of potential research. Future studies should confirm the 
specificity of the class I Hdac inhibitor to determine selective blocking of class I, and not 
class II, Hdac activity. Once the in vitro model has been validated and established, the 
chemical inhibition of class I Hdacs must be considered in an in vivo model, to see if the 
mode of action and subsequent response of the muscle translates in physiologically 
relevant conditions. The potential role for class I Hdacs in the prevention of muscle 
atrophy is a novel finding that has not been reported in the literature to date.  
Finally, comparisons were made between the transcriptional output from the in vitro 
glucose starvation model of atrophy and our in vivo TTX nerve block model to 
determine whether our model showed a similar transcriptional response to the in vitro 
model. Our findings showed distinct differences between the two models in terms of 
the response of Myog and its downstream targets at the transcript level, reinforcing the 
theory that the particular cause of muscle atrophy in a given model dictates the 
response of the muscle by initiating a distinct and unique signalling pathway. Whilst 
Myog and its key targets genes involved in muscle size regulation appear to play a 
central role in many models of muscle atrophy, the data produced for this thesis 
highlights a role for alternative signalling pathways that do not utilise Myog. Foxo 
transcription factors have been implicated as another key regulator of muscle atrophy 
and further investigation into the response and regulation of Foxo in different atrophy 
models could help to further elucidate their role.  
The data produced in this cross-model study of muscle atrophy has highlighted the 
need for care when interpreting the cellular changes that by various routes produce the 
end result of loss in protein content. Such complex interactions need multivariate or 
systems analysis to understand fully, but the data contained in this thesis is exactly the 
type of multi-dimensional data across the genome and across the time course of muscle 
adaptation that will be required for a complete analysis of the remarkable adaptive 
capacity of muscle cells. 
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APPENDIX 1 
Details of All Experimental Procedures 
Rat 
No. 
Animal 
Weight 
(g) 
Treatment 
Untreated 
TA Weight 
(µg) 
Treated 
TA Weight 
(µg) 
% 
Change 
in TA 
Reason For Omission 
1673 404 
14 Days 
Atrophy 
740 372 -49.7  
1674 373 694 368 -47.0  
1675 445 686 347 -49.4  
1676 394 729 364 -50.1  
1677 434 819 365 -55.4  
1678 393 772 366 -52.6  
1679 396 
7 Days 
Atrophy 
742 735 -0.9 Failed Block 
1680 409 737 513 -30.4  
1681 392 772 575 -25.5  
1682 407 
Sham Control 
742 469 -36.8 Nerve Damage 
1683 409 728 543 -25.4 Nerve Damage 
1684 414 743 722 -2.8 Failed Block 
1685 395 629 590 -6.2 Failed Block 
1686 410 815 562 -31.0 Nerve Damage 
1687 416 731 715 -2.2 Failed Block 
1688 411 
7 Days 
Atrophy 
810 529 -34.7  
1689 442 847 547 -35.4  
1690 400 842 829 -1.5 Failed Block 
1712 385 
Sham Control 
650 459 -29.4 Nerve Damage 
1721 291 857 861 0.5  
1722 473 946 956 1.1  
1723 458 887 850 -4.2  
1724 477 875 879 0.5  
1725 466 890 919 3.3  
1742 438 
7 Days 
Atrophy 
754 580 -23.1  
1743 444 818 794 -2.9 Failed Block 
1744 428 889 644 -27.6  
1745 460 
3 Days 
Atrophy 
870 805 -7.5  
1746 485 888 830 -6.5  
1747 401 781 723 -7.4  
1748 429 776 802 3.4 Failed Block 
1749 464 759 783 3.2 Failed Block 
1750 449 792 701 -11.5  
1751 457 836 798 -4.5  
1752 460 851 813 -4.5  
1753 548 Sham Control 902 897 -0.6  
1758 413 
20Hz 
Stimulation 7 
Days 
712 589 -17.3  
1759 425 658 578 -12.2  
1760 416 771 652 -15.4  
1761 387 711 604 -15.0  
1762 367 704 679 -3.6  
1763 391 664 582 -12.3  
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1764 412 
14 Days 
Atrophy with 
7 Days 
Recovery 
748 476 -36.4  
1765 410 707 351 -50.4 Block Did Not Cease 
1766 396 842 800 -5.0 Failed Block 
1767 445 899 334 -62.8 Block Did Not Cease 
1768 421 771 634 -17.8  
1769 384 808 639 -20.9  
1770 392 802 645 -19.6  
1771 402 741 320 -56.8 Block Did Not Cease 
1772 419 759 481 -36.6  
1773 413 767 648 -15.5  
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APPENDIX 2 
 
Subbing Slides 
Manufacturers; 
Slides: Twin frost, BDH premium 406/0184/02 
Gelatine: Bovine type B Sigma G-9328 
 
Solutions 
0.1% w/v gelatine 
0.01% chromium potassium sulphate 
Double-distilled water 
 
Protocol 
1.  Slides were cleaned in 100% alcohol and left to dry for approximately 30 minutes 
2.  Slides were then dipped in subbing solution and left to dry overnight 
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APPENDIX 3 
 
H&E Solutions and protocol 
Solutions 
Erhlich's Haematoxylin 
0.65% w/v haematoxylin 
33.25% ethanol 
32.25% glycerine 
32.25% double-distilled water 
3.23% acetic acid 
4.52% aluminium potassium sulphate 
 
Protocol 
1. Dissolve haematoxylin in alcohol and add remainder of ingredients 
2.  Leave the stain to ripen in a container with a loose lid.  The solution must be kept in 
a warm place for a minimum of 4 months to mature. 
 
Eosin 
1% Eosin  
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APPENDIX 4 
 
Electrophoresis Gels 
 
 
 
 
Agarose Gel (1.5%) Electrophoresis of RNA From Each Muscle Sample Showing 
Consistently Good Quality & Yield 
Gel Confirms yield and quality of RNA as represented by clear 18- and 28-S bands.  Each 
of the 36 animals (1721-1763) has both an untreated contralateral control TA sample 
(C) and a treated TA sample (T). 
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Agarose Gel (1.5%) Electrophoresis of RNA From Each Myotube Sample Showing 
Consistently Good Quality & Yield 
Gel Confirms yield and quality of RNA as represented by clear 18- and 28-S bands.  Each 
Group (Normal Media, Glucose Starved etc.) has 6 samples running 1-6 from left to 
right. 
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APPENDIX 5 
 
Details of Nanodrop Readings 
 
Myotubes A 
 
Sample 
number 
Treatment 260nm 280nm Ratio 
conc 
µg/ml 
1 
Normal Media 
84.256 43.171 1.95 39.41 
2 36.164 17.622 2.05 47.29 
3 44.123 21.776 2.03 32.94 
4 37.326 17.866 2.09 17.79 
5 58.380 28.476 2.05 38.72 
6 36.594 17.633 2.08 35.60 
7 
Glucose Starved 
61.982 30.601 2.03 87.38 
8 69.016 34.424 2.00 89.51 
9 65.284 32.548 2.01 97.76 
10 58.994 29.197 2.02 106.24 
11 18.826 9.285 2.03 126.73 
12 23.521 11.623 2.02 86.35 
13 
Dexamethasone 
Treated 
59.785 29.127 2.05 77.42 
14 69.028 33.889 2.04 28.54 
15 72.730 35.904 2.03 89.60 
16 70.039 34.449 2.03 81.92 
17 92.864 48.125 1.93 122.59 
18 104.181 58.323 1.79 131.95 
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Myotubes B 
 
Sample 
number 
Treatment 260nm 280nm Ratio conc µg/ml 
1 
MC1568 
Normal 
Media 
23.946 11.967 2.00 1197.31 
2 55.320 27.749 1.99 2766.01 
3 63.344 31.962 1.98 3167.20 
4 81.664 42.200 1.94 4083.18 
5 23.863 11.911 2.00 1193.13 
6 27.957 13.942 2.01 1397.87 
7 
MC1568 
Glucose 
Starved 
37.917 18.720 2.03 1895.86 
8 33.582 16.617 2.02 1679.10 
9 81.161 41.707 1.95 4058.04 
10 26.151 13.079 2.00 1307.56 
11 21.158 10.544 2.01 1057.89 
12 23.779 11.868 2.00 1188.94 
13 
MGCD0103 
Normal 
Media 
62.813 31.418 2.00 3140.65 
14 35.868 17.755 2.02 1793.40 
15 25.662 12.665 2.03 1283.08 
16 31.293 15.418 2.03 1564.65 
17 23.715 11.627 2.04 1185.75 
18 25.196 12.357 2.04 1259.82 
19 
MGCD0103 
Glucose 
Starved 
21.331 10.501 2.03 1066.53 
20 44.519 21.941 2.03 2225.96 
21 28.532 14.024 2.03 1426.60 
22 22.149 10.936 2.03 1107.46 
23 20.682 10.113 2.05 1034.08 
24 29.361 14.382 2.04 1468.05 
25 
S3I-201 
Normal 
Media 
19.360 9.739 1.99 968.00 
26 48.539 24.439 1.99 2426.96 
27 55.935 28.137 1.99 2796.73 
28 23.041 11.556 1.99 1152.03 
29 37.391 18.613 2.01 1869.57 
30 34.342 17.099 2.01 1717.12 
31 
S3I-201 
Glucose 
Starved 
11.705 6.092 1.92 585.24 
32 24.398 12.257 1.99 1219.91 
33 38.145 19.120 1.99 1907.24 
34 19.463 9.865 1.97 973.15 
35 105.068 62.547 1.68 5253.40 
36 27.298 13.600 2.01 1364.91 
37 
MC1568 + 
S3I-201 
Normal 
Media 
23.369 11.739 1.99 1168.45 
38 23.006 11.555 1.99 1150.32 
39 23.447 11.715 2.00 1172.33 
40 30.024 15.045 2.00 1501.18 
41 22.561 11.205 2.01 1128.05 
42 23.688 11.846 2.00 1184.42 
43 
MC1568 + 
S3I-201 
Glucose 
Starved 
22.327 11.154 2.00 1116.35 
44 24.992 12.479 2.00 1249.61 
45 22.426 11.195 2.00 1121.28 
46 23.422 11.668 2.01 1171.11 
47 22.016 10.870 2.03 1100.82 
48 24.836 12.404 2.00 1241.78 
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Muscle Samples 
 
Animal 
Number & 
Limb Side 
Treatment 260nm 280nm Ratio conc µg/ml 
1721RL 
Sham 
Control 
12.955 6.271 2.07 647.77 
1721RR 6.936 3.442 2.02 346.81 
1722RL 14.889 7.045 2.11 744.46 
1722RR 11.789 5.928 1.99 589.47 
1723RL 13.906 6.961 2.00 695.28 
1723RR 18.397 9.178 2.00 919.83 
1724RL 16.565 8.239 2.01 828.27 
1724RR 19.337 9.729 1.99 966.84 
1725RL 24.017 12.390 1.94 1200.85 
1725RR 27.027 13.289 2.03 1351.35 
1753RL 17.449 8.781 1.99 872.43 
1753RR 17.231 8.591 2.01 861.57 
1745RL 
3 Days 
Atrophy 
11.894 5.846 2.03 594.69 
1745RR 19.981 9.478 2.11 999.03 
1746RL 18.334 9.056 2.02 916.70 
1746RR 16.770 8.450 1.98 838.48 
1747RL 23.051 11.338 2.03 1152.54 
1747RR 23.420 11.696 2.00 1171.00 
1750RL 19.278 9.570 2.01 963.90 
1750RR 33.313 16.396 2.03 1665.66 
1751RL 13.673 6.984 1.96 683.64 
1751RR 19.511 9.768 2.00 975.54 
1752RL 15.649 7.787 2.01 782.45 
1752RR 15.616 7.771 2.01 780.82 
1680RL 
7 Days 
Atrophy 
37.312 17.972 2.08 1865.62 
1680RR 11.960 5.968 2.00 597.98 
1681RL 21.245 10.439 2.04 1062.24 
1681RR 17.473 8.575 2.04 873.64 
1688RL 21.064 10.604 1.99 1053.21 
1688RR 41.540 20.330 2.04 2077.02 
1689RL 25.507 12.752 2.00 1275.33 
1689RR 20.742 10.340 2.01 1037.12 
1742RL 20.305 10.090 2.01 1015.23 
1742RR 13.843 6.888 2.01 692.16 
1744RL 18.476 9.260 2.00 923.78 
1721RL 12.955 6.271 2.07 647.77 
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Animal 
Number & 
Limb Side 
Treatment 260nm 280nm Ratio conc µg/ml 
1744RR 
14 Days 
Atrophy 
16.430 8.255 1.99 821.48 
1673RL 13.429 6.525 2.06 671.45 
1673RR 27.050 12.846 2.11 1352.48 
1674RL 15.103 7.562 2.00 755.15 
1674RR 16.553 8.051 2.06 827.64 
1675RL 29.779 14.926 2.00 1488.93 
1675RR 18.255 9.083 2.01 912.76 
1676RL 20.946 10.482 2.00 1047.29 
1676RR 34.923 17.219 2.03 1746.17 
1677RL 22.172 11.261 1.97 1108.60 
1677RR 24.212 11.952 2.03 1210.58 
1678RL 21.661 10.945 1.98 1083.03 
1678RR 
14 Days 
Atrophy 
with 7 Days 
Recovery 
23.564 11.638 2.02 1178.18 
1764RL 15.605 7.426 2.10 780.23 
1764RR 21.398 10.501 2.04 1069.89 
1768RL 16.488 8.480 1.94 824.42 
1768RR 21.398 10.501 2.04 1069.89 
1769RL 19.764 9.843 2.01 988.19 
1769RR 18.115 9.094 1.99 905.73 
1770RL 18.255 9.083 2.01 912.76 
1770RR 20.972 10.397 2.02 1048.58 
1772RL 24.040 12.007 2.00 1202.01 
1772RR 20.972 10.397 2.02 1048.58 
1773RL 17.231 8.591 2.01 861.57 
1773RR 
20Hz 
Stimulation 
for 7 Days 
26.863 13.371 2.01 1343.14 
1758RL 21.357 10.289 2.08 1067.84 
1758RR 15.605 7.426 2.10 780.23 
1759RL 17.751 8.779 2.02 887.53 
1759RR 17.009 8.407 2.02 850.46 
1760RL 27.632 13.743 2.01 1381.60 
1760RR 19.991 9.951 2.01 999.53 
1761RL 31.000 15.367 2.02 1550.01 
1761RR 17.647 8.793 2.01 882.35 
1762RL 58.724 29.497 1.99 2936.18 
1762RR 7.282 3.737 1.95 364.11 
1763RL 26.863 13.371 2.01 1343.14 
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APPENDIX 6 
 
Sequencing Results 
 
Mouse Rn18s 
 
 
 
Mouse Polr2a 
 
 
 
Mouse G6pc3 
 
 
 
Mouse Pdk4 
 
 
 
 
 
 
 
185 
 
Mouse Lpl 
 
 
 
Mouse Bcl2l11 
 
 
 
Mouse Tgfb2 
 
 
 
Mouse Sod2 
 
 
 
 
 
 
186 
 
Mouse Ccnd2 
 
 
 
Mouse Ccnb1 
 
 
 
Mouse Plk1 
 
 
 
Mouse Cdkn1b 
 
 
187 
 
Mouse Fbxo32 
 
 
 
Mouse Myog 
 
 
 
Mouse Stat3 
 
 
 
Mouse Hdac4 
 
 
 
 
 
 
 
 
188 
 
Mouse Hdac5 
 
 
 
Mouse Mitr 
 
 
 
Mouse Dach2 
 
 
 
Mouse Chrna1 
 
 
189 
 
Rat Rn18s 
 
 
 
Rat G6pc3 
 
 
 
Rat Pdk4 
 
 
 
Rat Bcl2l11 
 
 
 
 
 
 
 
 
 
 
190 
 
Rat Tgfb2 
 
 
 
Rat Sod2 
 
 
 
Rat Ccnd2 
 
 
 
Rat Ccnb1 
 
 
 
 
191 
 
Rat Plk1 
 
 
 
Rat Cdkn1b 
 
 
 
Rat Trim63 
 
 
 
Rat Fbxo32 
 
 
 
 
 
 
192 
 
Rat Myog 
 
 
 
Rat Stat3 
 
 
 
Rat Hdac4 
 
 
 
Rat Hdac5 
 
 
 
 
 
 
 
 
193 
 
Rat Mitr 
 
 
 
Rat Chrna1 
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APPENDIX 7 
 
Primer Efficiency Curves 
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APPENDIX 8 
 
Validation of SYBR green reaction by melt curve analysis 
 
Melt curve analyses of the products formed using each primer set.  The melt curve is a 
plot of the total fluorescence as a function of the temperature.  The y-axis, represented 
by -d (RFU)/dT, is the rate of change of fluorescence in the reaction and a significant 
change in fluorescene accompanies teh melting of the double-stranded PCR products.  
Thus a plot of -d (RFU)/dT vs. temperature displays the change in fluorescence as a 
distinct peak. 
 
 
Mouse Rn18s 
 
 
Mouse Polr2a 
 
 
Mouse G6pc3 
 
 
 
 
Mouse Pdk4 
 
 
Mouse Lpl 
 
 
Mouse Bcl2l11 
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Mouse Tgfb2 
 
 
Mouse Sod2 
 
 
Mouse Ccnd2 
 
 
Mouse Ccnb1 
 
 
 
 
 
 
Mouse Plk1 
 
 
Mouse Cdkn1b 
 
 
Mouse Trim63 
 
 
Mouse Fbxo32 
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Mouse Myog 
 
 
Mouse Stat3 
 
 
Mouse Hdac4 
 
 
Mouse Hdac5 
 
 
 
 
 
 
Mouse Mitr 
 
 
Mouse Chrna1 
 
 
Mouse Socs3 
 
 
Rat Rn18s 
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Rat Polr2a 
 
 
Rat G6pc3 
 
 
Rat Pdk4 
 
 
Rat Lpl 
 
 
 
 
 
 
Rat Bcl2l11 
 
 
Rat Tgfb2 
 
 
Rat Sod2 
 
 
Rat Ccnd2 
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Rat Ccnb1 
 
 
Rat Plk1 
 
 
Rat Cdkn1b 
 
 
Rat Trim63 
 
 
 
 
 
 
Rat Fbxo32 
 
 
Rat Myog 
 
 
Rat Stat3 
 
 
Rat Hdac4 
 
 
 
 
 
 
202 
 
Rat Hdac5 
 
 
Rat Mitr 
 
 
 
Rat Chrna1 
 
 
Rat Socs3 
 
 
 
  
